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ABSTRACT 
The glycoprotein CD36 is expressed in the plasma membrane (PM) of many cell types 
that surround or contact arteries, including macrophages, myocytes, and endothelial cells. 
CD36 binds oxidized low-density lipoprotein (oxLDL), which promotes atherosclerosis, 
and fatty acids (FA), which promotes their cellular uptake. To gain insights into the 
molecular mechanisms of uptake, HEK293 cells expressing CD36 were studied by cell 
biological and fluorescence methods. To test our hypothesis that the PM is not an 
impermeable barrier to FA and that FA move into cells by diffusion via their uncharged 
form, we first applied biophysical fluorescence spectroscopy to directly measure 
transmembrane FA movement and membrane fluidity. Expression of CD36 in HEK293 
cells did not increase either transport across the PM or the fluidity of the PM compared to 
HEK293 cells without CD36; however, CD36 enhanced intracellular FA esterification. 
Furthermore, the widely used “inhibitors” of FA transport did not alter either the rapid 
FA transmembrane diffusion in HEK293 cells or diffusion in control experiments with 
protein-free phospholipid bilayers. To gain new insights into the physiological relevance 
of FA binding to CD36, we applied surface plasmon resonance (SPR) to quantify FA and 
oxLDL binding to the ectodomain of CD36. Structurally distinct FA [saturated, 
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monounsaturated (cis and trans), polyunsaturated, ω-3, ω-6, and oxidized FA] were 
pulsed in a solubilized form (bound to methyl-β-cyclodextrin) across SPR channels, 
generating real-time association and dissociation binding curves. With the exception of 
the oxidized FA hydroxyoctadecadienoic acid (HODE), all FA tested bound to CD36 
with rapid association and dissociation kinetics similar to human serum albumin.  In 
addition, FA increased oxLDL binding to CD36. To investigate whether FA affect CD36-
mediated oxLDL uptake in live cells, we monitored fluorescent oxLDL (Dii-oxLDL) 
uptake using confocal microscopy. Addition of exogenous FA to serum-free media 
enhanced dose-dependent oxLDL uptake. Exceptions were ω-3 FA, which bound to 
CD36, and HODE, which did not bind to CD36, demonstrating FA structure-specific 
effects on a major function of CD36 and a new mechanistic link between atherosclerosis 
and high levels of FA in obese and Type-II diabetic individuals. 
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CHAPTER ONE: INTRODUCTION 
1.1. Fatty Acids, Cholesterol, and Low-Density Lipoprotein 
1.1.1. Structures, Forms, and Functions of Fatty Acids and Cholesterol 
Fatty acids (FA) are defined by the International Union of Pure and Applied 
Chemistry (IUPAC) as “any one of the aliphatic monocarboxylic acids derived from or 
contained in esterified form in an animal or vegetable fat, oil, or wax” [1].  Naturally 
occurring FA commonly have a chain length of 4-28 carbons (usually unbranched and 
even-numbered), which may be saturated or unsaturated and often are broadly categorized 
into four main groups: short-chain FA (SCFA), medium-chain FA (MCFA), long-chain FA 
(LCFA), and very long chain FA (VLCFA).   
In addition to commonly used (traditional) FA nomenclature and/or IUPAC 
nomenclature, the FA carbon-chain-length can be designated by a number followed by a 
colon punctuation mark and then the number of double bonds beginning from the 
carboxylic acid carbon. Next, the number preceded by either an ω- (or n-) refers to the 
position of the first double bond starting from the carbon at the FA tail end, opposite of the 
carboxylic acid (Figure 1).  
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The first number, 20, is counted from the 
carboxylic acid carbon (blue) while the 
last number is from the opposite side (red). 
 
 
 
Each of the four FA chain-length groups have specific specifications and 
physiological relevance. SCFA are FA with aliphatic tails of < 6 carbons [2], beginning 
with the simplest carboxylic acid, formic acid (methanoic acid [1:0]) named from its early 
isolation from ant venom [3].  Another example is butyric acid (4:0), characterized by its 
unpleasant odor.  Butyric acid is found in milk, human vomit and sweat, and has been 
shown to inhibit certain types of cancerous cells [4].   
MCFA are FA with aliphatic tails of 6-12 carbons [5].  Readily metabolized 
medium-chain triglycerides (MCTs) are composed of a glycerol backbone and three FA, 
at least two of which are MCFA.  MCT’s have been studies extensively and are important 
components of parenteral nutrition formulations [6]. MCT’s have recently been under 
scrutiny due to the increased elevation of high-density lipoprotein (HDL) as triglyceride 
(TG) chain-length decreases along with new findings on the significance of a balanced 
ratio of HDL to low-density lipoprotein (LDL) [7, 8].   
LCFA are FA with aliphatic tails of 13 – 22 carbons [9], while VLCFA have > 22 
carbons.  LCFA are our main interest since this is most common FA group within the 
human diet and since LCFA are a major nutrient for human cells.  Interest in LCFA has 
Figure 1. Fatty acid numerical 
representation and abbreviation 
illustration 
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also been enhanced by controversies over whether they to require a protein transporter for 
cellular uptake [10].  Additionally, many LCFA have been implicated in worsening cardiac 
systolic function and cardiovascular disease (CVD), type 2 diabetes, ischemic stroke, and 
obesity [11-14].  Obesity is of particular significance since excess storage of TG represents 
a major source of elevated plasma LCFA that can cause systemic physiological effects, 
such as oxidative stress and inflammation, on a range of different cell and tissue types.   
On the other hand, some LCFA such as DHA (22:6 ω-3) have been shown to 
promote beneficial health in areas including decrease oxidized LDL (oxLDL) uptake in 
both endothelial and macrophage cells [15, 16], and increased DHA decreases overall 
inflammation, neuroinflammation, macular degeneration, and various neurodegenerative 
diseases [17].  These particular affects by DHA within the brain are not surprising since 
DHA accounts for 30-40% of the total FA found in human brain cell membranes [18].   
Two other LCFA found to be beneficial to human health are both of the known “essential” 
FA (referring to FA required for biological processes but that the human body cannot 
synthesize): alpha-linolenic acid (18:3 n-3) and linoleic acid (18:2 n-6).  Alpha-linolenic 
acid has been found to moderately lower risk of CVD [19], while conjugated linoleic acid 
(CLA) is now sold as a supplement (Tonalin®) to boost well-documented health benefits 
associated with taking supplements of CLA [20].  
Physiologically, various FA are a major component of cholesteryl esters, 
phosphatidic acids (phospholipids and phosphoglycerides), glycerides (mono-, di-, 
triglycerides and esters), glycolipids (glycogylcerolipids, glycosphingolipids, psychosines, 
and sulfolipids), and eicosanoids (leukotrienes and prostaglandins). Of this assortment of 
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FA containing compounds, by far the most prevalent in the human body are the 
phospholipids (PL), TG, and the cholesteryl esters (CE), in that order (Figure 2).   
  
 
 
(A) Phospholipids are predominantly composed of LCFA of different chain lengths and saturations (green 
and red), a diester of ethylene glycol (black), a phosphate group (cyan), and a variable headgroup (-R).  (B) 
Triglyceride is also mainly composed of LCFA of varying chain lengths and saturations (blue, green, and 
red), with an ester of glycerol (black).  (C) Cholesteryl esters are esters of cholesterol usually with LCFA of 
varying chain lengths and saturations (red) on a cholesterol molecule (black), positioned on the hydroxyl 
group bonded to the number 3 carbon of cholesterol. 
 
While FA carbon chain lengths vary significantly, LCFA are the main constituent 
of triglyceride FA tails [21], phospholipid FA tails [22] and cholesterol ester FA tails [23]. 
In fact, even including FA composition percent changes resulting from diverse diets 
between Italy, Finland, and the USA, phosphatidylcholine (PC) compared between these 
three countries is mainly comprised of palmitic acid (PA [16:0]; 31.1 +/- 3.4%), stearic 
acid (SA [18:0]; 14.3 +/- 0.4%), oleic acid (OA [18:1]; 16.1 +/- 2.2%), and linoleic acid 
(LA [18:2]; 23.1 +/- 2.2%), giving a total of ~84.6% of the total FA from only these four 
LCFA types.  Additionally, the remaining ~15.4% of FA in PL were also LCFA in this 
study.   
Figure 2. Chemical structures of the most prevalent sources of physiological FA-containing 
compounds in humans: PL, TG, and CE 
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In the same study, CE from blood plasma was found to be comprised mainly of PA 
(13.7 +/- 2.9 %), OA (28.5 +/- 9.6%), and LA (44.0 +/- 12.2), with very little SA (1.3 +/- 
0.4 %). Hence, with CE, the total FA was ~86.2% from only PA, OA, and LA [23].   
The FA composition of TG droplets remains similar in many cases but varies 
depending on droplet size as well as cell type [24].  Specifically, while all TG droplet sizes 
mostly contain PA and OA, a few TG droplet sizes exhibit a high percentage of 
eicosapentaenoic acid (EPA [20:5 ω-3]) in liver, ranging from 1.6% to  25.6% depending 
on droplet size [21].  Except for EPA, the FA composition of TG remains consistent, for 
example, even the sebum from facial sebaceous glands in persons with or without acne 
have similar TG fatty acid compositions [25]. 
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(A) Selected physical properties and lipid compositions of human VLDL, LDL, and HDL. (B) Fatty acid 
compositions (wt% of the total) in human VLDL, LDL, and HDL along with the main lipids TG, CE, and 
PL.  Table modified from [26]. 
 
All lipoproteins are comprised of FA-containing PL, CE, and TG (Table 1), and 
smaller quantities of free fatty acid (FFA).  In early studies investigating the FFA in total 
(mixed) human lipoprotein fractions, the resulting relative percent composition of the FFA 
were similar to PL, CE, and TG, where 23.7 +/- 0.7% were PA, 16.9 +/- 3.8% were SA, 
and 45.4 +/- 4.4 were OA [27].  This early study (1964) noted that the absolute amounts of 
each FFA within lipoproteins was not determined because the buffer to extract lipoprotein 
from plasma tended to promote FFA leaving human serum albumin (HSA) with subsequent 
transfer to lipoproteins. 
Table 1. Lipoprotein lipids 
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In more recent studies of lipoproteins, the activated dimer form of lipoprotein lipase 
(LPL) has been found on LDL and is able to hydrolyze TG thus creating additional FFA 
on/in LDL [28].  A different study highlighted the physiological magnitude of this finding, 
showing that LDL containing more FFA is prone to greater oxidation, increasing the 
atherogenicity of FFA-loaded LDL [29].  Furthermore, in an analysis of the absolute 
amounts of FFA in the LDL, a 10-fold increase in the mean LDL FFA 
(0.66 ± 0.40 0.02 mg/mg versus 0.06 ± 0.02 mg/mg LDL protein, p < 0.01) was observed 
in LDL from diabetic subjects compared to controls, even while there was no difference in 
either TG or PL fatty acids between these groups [29]. 
Along with direct FFA transport through the bloodstream via lipoproteins, human 
serum albumin (HSA) is an even more principle and primary FFA transporter.   In fact, 
lipoproteins have been shown to significantly compete with HSA for FFA only when the 
molar ratio of FFA to HSA exceeds 4 [30]. This standard type of analysis was supported 
by a novel NMR study with C-13 labeled FFA added to serum [31]. Furthermore, HSA is 
the most abundant protein in the circulatory system (3.5 – 5.0 g/dL) with its principle 
function being FFA transport [32].  
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Figure 3. Spacefill structure of human serum albumin protein with bound fatty acids 
 
July 2002 JLR cover photo, of the structure of HSA with C18:0 (left panel) and C26:0 modeled into “the 
presumed highest affinity binding sites for LCFA” (right panel).  It is noted by the authors that “binding 
sites 1-5 are labeled in the right panel; C18:0 is present in site 3 but not visible.  The three domains (I-III) 
and the two subdomains of each domain (A,B) of HSA are labeled in the left panel.  The methylene tail 
(yellow) of C26:0 protrudes into the water in four of the sites, and site 3 is not large enough to 
accommodate the C26:0”.  Image modified from [33]. 
 
 
Our lab has characterized various types of FA binding to BSA (Figure 3) using 
two-dimensional nuclear magnetic resonance (NMR) spectroscopy and more recently has 
resolved 9 binding sites for OA by 13C NMR spectroscopy [33-35].  Earlier studies with 
classical methods of measuring affinities have characterized the KD’s of several FA types 
binding to HSA (Table 2).  Overall, FA appears to bind HSA with differing affinities 
dependent upon FA type as well as how many FA are already bound to HSA. To this end, 
Krenzel et al. from the Hamilton group have published data showing that the number of 
observed HSA FA binding sites decreased with increasing FA chain length, from 9 sites 
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for C18:2 [34], 4-5 for C20:0, 3-4 sites for C22:0, 2 for C24:0, and only one binding site 
for C26:0 [33].  These studies included competition experiments which suggested that the 
HSA highest affinity sites for VLCFA are low affinity sites for LCFA.   
 
KD’s (KD = Kd/Ka) for various FA binding to HSA, including the variability of the KD for each of 5 binding 
sites.  Experiments were done at 37°C in physiological buffers.  Table modified from [36]. 
 
 
Early studies have shown that HSA undergoes several structural changes over a 
range of pH’s [37], which could also have an impact on FA binding. Cooperative binding 
has been observed mainly after the first FA is bound [36], although a range of different FA 
types have not been investigated regarding HSA cooperativity and allosteric modulation; 
modulation which is marked in the cases of various drugs binding to HSA (even leading to 
the assertion that HSA acts similar to a multimeric protein) [38].   
While most FA is mainly transported throughout the bloodstream by albumin, FA 
have a measurable solubility in water, especially highly unsaturated FA.  Even fully 
saturated FA, however, are somewhat soluble at 37°C in water, with C12:0 soluble up to 
345µM (24°C = 290µM), C16:0 up to 35µM, and C18:0 up to 13µM [39].  One additional 
Table 2. KD’s of 9 fatty acids and 5 human serum albumin binding sites 
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caveat, however, regarding FA solubility is that common laboratory material surfaces such 
as various plastics (pipette tip materials, etc.), glasses, and metals have been shown to 
bind/adsorb water-solubilized OA from 10% and up to 95% (depending on material type) 
unless BSA was present, in which case these binding effects were negated with a high 
BSA: OA molar ratio [40].  Therefore, solubility of FFA in any experiment may be 
confounded by artifacts and this possibility is always a consideration in FFA studies. 
When FFA reaches a cell, rapid partitioning occurs mainly between albumin and 
the lipid bilayer as well as between proteins within the PM of the cell that bind FA (e.g. 
CD36) [41].  Exchange of the FA occurs through the soluble form, which desorbs rapidly 
from both albumin and membranes [42].  The membrane dynamics (i.e. fluidity) of the PM 
lipid bilayer predominantly depends on the lipid composition of the PL, which remains 
largely stable (see above), as well as the amounts of FFA and cholesterol present and/or 
fluxing in and out of the PM, which can rapidly be altered.  Furthermore, the amount of 
FFA and the degree of FFA saturation can rapidly change the PM fluidity.  This will be 
discussed further below with laurdan and in Chapter 4. 
While much of the biophysics of FFA depend on bond saturation and length as 
discussed above and in other chapters, oxidized and trans FA are also found within the 
human diet and can drastically alter biological processes.  Firstly, unsaturated FA that is 
isomerized during the process of hydrogenation, whether in commercial food plants or in 
the rumen of an animal, can become a mixture of geometric cis and trans positional isomers 
(Figure 4) [43].  Highly commercially processed foods are the predominant source of 
human-consumed trans FA, and among trans FA, elaidic acid (EA) is the most prevalent 
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(~70%) [44, 45].  Moreover, this common industrially generated trans FA, EA, has been 
clearly implicated in the pathogenesis of CVD, while trans FA from dairy products (e.g. 
vaccenic acid [18:1]) have been found to be significantly less deleterious [45].  The adverse 
effects of EA include altered glucose tolerance and a positive correlation with type 2 
diabetes [46], induction of β-cells to secrete insulin even under low glucose levels [47], 
and other mechanisms that lead to inflammation and overall CVD [45]. 
 
 
The cis and trans positional isomers of a generic monounsaturated fatty acid (left) and the specific example 
of the common 18:1 fatty acids in cis and trans configurations (oleic and elaidic acids, respectively) to 
illustrate the geometric kink or straight fatty acid tail conformations, respectively.  
 
 
Another physiologically common FA modification is oxidation to hydroxylated 
forms.  HODE (either 9-hydroxy-10,12-octadecadienoic acid or 13-hydroxy-9,11-
octadecadienoic acid) has been shown to be the most common oxidized FA in humans [48].  
This is not surprising, since HODE is derived from the common lipid LA.  HODEs have 
Figure 4. Cis and Trans isomers of fatty acids 
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also been shown to be the most abundant oxidative product in plaques [49].  Isomers of 
HODE can be formed by an enzymatic process involving either lipoxygenase (LOX; 
resulting in the formation of 13-HODE) or cyclooxygenase (COX; which can form 9-
HODE and/or 13-HODE) [50].  HODE is also produced in a nonenzymatic process from 
LDL’s upon lipid peroxidation [51].  And while the receptors for oxidized lipids, especially 
HODEs, are the subject of continued debate, PPARγ and GPR132 are both reported to be 
receptors [48, 52, 53]. GPR132, in particular, has been identified as a receptor for numerous 
forms of oxidized FA, with 9-HODE being the most potent ligand, mediating a 
proinflammatory response [54].  HODEs also have been reported to cause a proapoptotic 
response in numerous cell types [55, 56]. 
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(A) Crystal structure model of PPARγ with the two molecules of 9-HODE bound and (B) crystal structure 
model of PPARγ with one molecule of 13-HODE bound. (C) The chemical structures of 9- and 13-HODE 
and linoleic acid (LA) added for comparison. Image derived and modified from [57]. 
 
 
Cholesterol can also become oxidized.  This oxidation can have adverse effects on 
biomembranes and plasma lipoproteins, with the primary cholesterol oxidation products 
being cholesterol hydroperoxides (especially 5α-hydroperoxide) [58].   
Figure 5. Oxidized fatty acids 9-HODE and 13-HODE structures and binding to PPARγ 
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In studies where oxidized FA and oxidized cholesterol were fed to humans, only 
cholesterol hydroperoxides were detected in lipoprotein fractions after 8hr (oxidized FA 
was cleared by 8hr) [59].  This same study used rabbits to show that oxidized cholesterol 
can accelerate atherosclerosis and increase fatty streak lesions in the aorta by 100%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Oxidized cholesterol structures 
Cholesterol oxidation products resulting from singlet oxygen.  Physiologically, the most common product is 
5α-cholesterol hydroperoxides. 
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Over 400 scientific review articles contain the term “oxidized cholesterol” in the 
abstract or title, so this oxidized biochemical has numerous facets and implications within 
diverse diseases.  Oxidized cholesterol has particularly adverse effects within vascular and 
neurodegenerative diseases [60], impaired bile acid synthesis [61], and numerous aspects 
and pathways of inflammation [62].  Very little, however, have been done with oxidized 
cholesterol and caveolae genes (i.e. Cav-1, Cavin-1, Cavin-2, etc.); to our knowledge, only 
one study showing oxidized cholesterol within caveolae (uncoupling platelet-derived 
growth factor receptors from tyrosine kinase substrates) has been reported [63].  And 
although FA are our primary interest, the effect of cholesterol, oxidized cholesterol, and 
cholesterol together with FA, are all likely to be interconnected, especially within the PM. 
LDL has a long history within CVD research and its role in initiating and accelerating the 
development of atherosclerosis has been well recognized for decades [64]. Compared to 
other lipoproteins (Table 1), LDL has become established as the lipoprotein associated 
with the greatest adverse health impact leading to CVD, at least in part due to the ability 
of LDL to become oxidized more readily than other lipoproteins [65].  OxLDL can have 
numerous oxidized components.  Predominantly, these components are oxidized FFA 
(discussed above), oxidized cholesterol (discussed above), and oxidized phospholipids. 
Oxidized phospholipids are said to be “recognized by soluble and cell-associated receptors 
of innate immunity, including scavenger receptors, natural (germ line-encoded) antibodies, 
and C-reactive protein, thus directing removal of senescent and apoptotic cells or oxidized 
lipoproteins” [66]. The chemical structures widely vary to include truncated oxidized 
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phospholipids, isoprostanes, isolevuglandins, isothromboxanes, and other molecules 
(Figure 7). 
 
Free radical-induced oxidation of phospholipids may result in an array of variable products, as shown. Image 
derived and modified from [67]. 
 
 
OxLDL has clearly been shown to initiate inflammatory pathways and other 
pathologies in numerous molecular studies [68].  While the broader LDL oxidative 
hypothesis of atherosclerosis is still debated (Figure 8), which assigns oxLDL a crucial 
Figure 7. Physiologically common oxidized phospholipid classes and structures 
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role in atherosclerosis initiation and progression, available data even present a likely 
validation of this hypothesis currently.  In fact, in the review article titled “The role of 
oxidized low-density lipoproteins in atherosclerosis: the myths and the facts,” Maoilino et 
al. illustrate the considerable body of work done on this area [69], beginning with in vivo 
studies supporting the oxLDL role in atherosclerosis.  The article then discusses 14 clinical 
“cohort studies demonstrating an association between oxLDL measurement and 
cardiovascular events” and 12 clinical cohort studies demonstrating no associations.  The 
authors also present randomized controlled trials both demonstrating a beneficial effect of 
antioxidant therapy and other trials demonstrating no effect of antioxidant therapy.  After 
an in depth analysis, the conclusion of the review is that “available data seem to validate 
the oxidative modification hypothesis of atherosclerosis” [69]. 
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Oxidized LDL plays a central role in initiating arterial plaque according to the oxidative hypothesis of 
atherosclerosis.  Figure derived and modified from [69]. 
 
Even by the early 1980’s, extensive studies on the formation and physiological 
removal of LDL had been done [70].  From continued research, lipoprotein formation and 
metabolic pathways have been further refined (Figure 9) and include LDL removal by the 
LDL receptor (LDLr) and also the removal of oxLDL by CD36 with contributions from 
SR-B1. 
 
 
Figure 8. Putative pathway of oxLDL in the atherogenic process according to the oxidative hypothesis of 
atherosclerosis 
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Including liver biogenesis, re-uptake, and interconnected pathways of lipoproteins, the LDL begins in the 
liver (via VLDL or nascent PreB HDL) or in the intestine (via chylomicrons).  The simplified extent of these 
pathways are illustrated, including oxLDL macrophage uptake by CD36.  Note: CD36 is also expressed in 
many other cell types, such as endothelial cells.  Figure derived and modified from [71]. 
 
For simplification, lipoprotein metabolism has been categorized into two 
interconnected cascades: apoB-containing lipoproteins (e.g. LDL) and apoA-I–containing 
lipoproteins (e.g. HDL) [71]. Our main focus is the apoB cascade, which includes the 
VLDL-IDL-LDL pathway and the chylomicron/chylomicron remnant pathway. Even 
though the “canonical” pathway of LDL uptake is via the LDLr, oxLDL is our main focus 
and other receptors besides LDLr – including CD36 – are involved in the uptake of oxLDL 
(see Chapter 2 for an overall description of the “scavenger receptors” classes, which share 
the defining feature of binding to modified forms of LDL).   
Figure 9. Lipoprotein emergence and clearance pathways 
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Figure 10. Structural elements of LDL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A)–(D) Model of human LDL based on cryo EM, showing a variety of views including “*” to indicate the 
proposed location of the β-propeller of the LDLr, and the superposition of the outer shell density of two 
reconstructed models (B and C). (D) is said to be: “the probability (P = 0, low; = 1, high) of helical (red, Pα) 
and β-strand (blue, Pβ) regions in apo B-100 based on sequence prediction suggests a five domain model 
designated as α2, α3, β1, β2 and βα1” (from [72]). 
(E) A simplified schematic of a consensus model for LDL, including component labels. Figure derived and 
modified from [73]. 
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While various groups have proposed a binding site for LDL to the LDLr (asterisk 
in Figure 10), the docking site on oxLDL to scavenger receptors such as CD36 remains 
uncharacterized.  Since PL, cholesterol, and FFA within LDL can all become oxidized, one 
specific binding site on oxLDL may not exist and individual oxidized products on LDL 
may bind CD36. These important aspects will be further considered in Chapter 5. 
 
1.2. Hypotheses of Fatty Acid Transport across the Plasma Membrane 
1.2.1. Simple Diffusion Model 
Early studies in by Kamp et al. from the Hamilton group using SUVs have 
demonstrated that pH gradients across PL membranes can be generated by fast flip-flop of 
un-ionized FA [74].  In additional follow-up studies, fatty acid flip-flop in various PL 
bilayers was found to be extremely fast even with LCFA (Table 3). 
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     FA Short Formula Vesicle Type Flip-Flop 
t1/2 upper limit 
Octanoic acid 8:0 SUV 1 sec 
Lauric acid 12:0 SUV, LUV 10, 25 msec 
Myristic acid 14:0 SUV, LUV 10, 25 msec 
Palmitic acid 16:0 SUV, LUV 10, 35 msec 
Margaric acid 17:0 SUV 350 msec 
Stearic acid 18:0 SUV, LUV 10, 25 msec 
Oleic acid 18:1 (cis) SUV, LUV 10, 35 msec 
Elaidic acid 18:1 (trans) SUV 1 sec 
Linoleic acid 18:2 (cis, cis) SUV, LUV 1 sec 
Linolelaidic acid 18:2 (trans, trans) SUV 1 sec 
Parinaric acid 18:4  SUV 1 sec 
Eicosanoic acid 20:0 SUV 1 sec 
Arachindonic acid 20:4  SUV, LUV 1 sec 
Pentaenoic acid 20:5 SUV, LUV 1 sec 
Docosanoic acid 22:0 SUV 1 sec 
Docosapentaenoic acid 22:5 SUV, LUV 1 sec 
Docosahexaenoic acid 22:6 SUV, LUV 1 sec 
Tetracosanoic acid 24:0 SUV 1 sec 
Hexacosanoic acid 26:0 SUV 1 sec 
13-HODE 18:2 SUV, LUV 1 sec 
15-HETE 20:4 SUV, LUV 1 sec 
Table 3. Summary of fatty acid flip-flop rates in model membranes 
Many common fatty acid flip-flop across phospholipid bilayers within msec and all tested fatty acid flip-flop 
< 1s.  Table derived and modified from [75]. 
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The rate of FA flip-flop through the PM of adipocytes [76] and HepG2 cells [77], 
as well as Hela and HEK293 cells expressing CD36 and/or other caveolae proteins will be 
further discussed in Chapter 4.  Nevertheless, because of a body of evidence showing that 
proteins affect overall FA uptake into cells, controversy remains whether chemical (or 
enzymatic) inhibitors can alter this process via PM protein modifications; so much 
controversy, in fact, a recent ATVB article was titled “Commentary on Fatty Acid Wars: 
The Diffusionists Versus the Translocations” [78].  This commentary supported the general 
notion of rapid FA flip-flop through membranes and encouraged a search for new 
mechanisms related to CD36 enhancement of intracellular metabolism (which enhances 
FA “uptake” but not PM “transport”, as discussed further in Chapter 4). 
 “Uptake” of FFAs is “the net disappearance of FFA from plasma or from an in 
vitro incubation medium into cells”, as we previously noted in a review [42].  In that same 
review, we also summarized the distinct steps that are involved, as follows: 
(1) dissociation of FFA from albumin or a plasma lipoprotein;  
(2) adsorption and association to the outer leaflet of the plasma 
membrane; (3) movement across the plasma membrane;  
(4) dissociation from the inner leaflet to enter the cytosol;  
(5) diffusion, either as a monomer or bound to FABP, through the 
cytosol to sites of binding and utilization (mitochondria, 
peroxisomes, endoplasmic reticulum); and  
(6) metabolism  
 
These steps are further investigated and illustrated in Chapter 4.  This Chapter will also 
discuss the metabolic implications of the FFA flip-flop model. 
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1.2.2. Protein Facilitated Transport Model 
In certain cases, protein-mediated transport at the PM occurs.  For example, with 
glucose (e.g. GLUT4 transporter [79]), with ions (e.g. plasma membrane Ca2+ ATPase 
[PMCA] transporter [80]), with proteins (e.g. secretin transporters [81]), with monoamines 
(e.g. dopamine transporter [DAT] [82]), and other various compounds. Despite the rapid 
flip-flop of FFA seen in protein-free vesicles and even in live cells, some researchers 
continue to argue that one or more protein transporters are required for rapid entry of FFA 
into cells.  In fact, as recent as 2010, the requirement for protein transporters for FFA to 
cross the PM is essentially being cited as dogma by some groups: “However, in recent 
years there has been a fundamental shift in understanding, and it is now generally 
recognized that fatty acids cross the cell membrane via a protein-mediated mechanism” 
(emphasis mine) [83]. 
To investigate protein-mediated FA uptake many studies have utilized radio-
labeled FFA but without recognition of the pitfalls of this approach.  Various studies 
interpret an increase in FFA uptake when CD36 is expressed, using radioactive-labeled 
FFA, as a CD36 “transporter” effect [84].  In agreement, we find that CD36 indeed 
enhances FFA uptake, not as a transporter, however, but through increasing the rate of 
intracellular esterification and not transport across the PM (Chapter 4).  Since addition of 
radio-labeled FFA requires a quenching step, usually minutes after FFA is added, these 
assays are missing real-time data and may omit the contributions of metabolism. 
Other studies utilize albumin to deliver FFA to cells to investigate uptake rates [10].  
Krenzel et al. from the Hamilton group have described 9 different FFA binding sites within 
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HSA, with varying affinities [34], making albumin a FFA competitor.  Furthermore, 
Brunaldi et al. from the Hamilton group have demonstrated that FFA are rapidly (< secs) 
delivered to and extracted from membranes by methyl-beta-cyclodextrin (MβCD) [85].  In 
addition, this study showed that FFA delivery into SUVs with MβCD closely resembles 
ethanol delivery of FFA.  And although the presence of albumin restricts the net delivery 
of FFA to membranes (partitioning), it does not affect the kinetics of delivery. 
 Another common method to study FA uptake is fluorescence-labeled FFA (e.g. 
BODIPY-FA).  Studies frequently use FA labeled with these large, synthetic, organic dyes, 
and uptake is measured by methods such as flow cytometric analyses [84].  In this case, 
the dye compounds are likely to alter membrane bilayer flip-flop of the FFA that is 
covalently attached, leading to altered uptake rates or uptake that may indeed require 
protein transporters such as the scavenger receptor CD36. 
 Finally, enzymes and various chemical inhibitors appear to disrupt FFA protein-
mediated transport.  This topic will also be further discussed in Chapter 4, along with the 
metabolic perturbations and/or the drastic pH alterations that arise when these enzymes 
and chemicals are added. 
 
1.3. Evaluating Membrane Fluidity and Order: Comparing Techniques and Probes 
1.3.1. An Overview of the Techniques used to Characterize Membrane Order 
CD36 and/or FFA may alter PM fluidity and possible changes in fluidity may alter 
FFA uptake. Many techniques have been developed to investigate a variety of aspects 
related to membrane order and fluidity.  The most common of these methods, summarized 
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in Figure 11, include using fluidity-sensitive fluorescence probes, NMR techniques, 
isolating the membranes or regions within the membranes, employing atomic force 
microscopy (and various other microscopy methods), or even adopting a variety of mass 
spectrometry techniques.  These methods are all useful both to characterize membrane 
order within membrane microdomains (e.g. lipid rafts) and/or whole membranes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strong and weak points of the most common methods used for characterization of lipid rafts. Figure derived 
and modified from [86].  These same methods are useful not only to characterize lipid rafts but membrane 
fluidity and order overall. 
 
Figure 11. The most common methods used for lipid raft and membrane fluidity 
characterization 
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1.3.2. A Summary of the Techniques used to Analyze Fluorescence Probes 
Of all the techniques used to investigate membrane fluidity changes, fluorescence 
probes have the singular advantage of application within live cells.  We therefore chose the 
fluorescence methodology to study fluidity within our CD36-expressing HEK293 and 
HeLa cell systems. 
Early fluorescence techniques predominantly utilized fluorimetry, especially in 
vesicles (small unilamellar vesicles [SUVs], giant unilamellar vesicles [GUVs], etc.), 
isolated membranes, and then live cells [87].  These methods are still useful and widely 
used and are included in our group’s ongoing investigations.   
Most recently, numerous microscopy methods using fluorescence probes have been 
developed and adapted to study membrane fluidity, including three-dimensional confocal 
microscopy, total internal reflection fluorescence (TIRF) microscopy, fluorescence 
recovery after photobleaching (FRAP), subpixel localization of particle position (SPT), 
fluorescence correlation spectroscopy (FCS),  image correlation spectroscopy (ICS), and 
atomic force microscopy (AFM) [88].  One of the advantages with microscopy analysis of 
membrane fluidity is the use of multiple probes together (Figure 12) as well as developing 
probes that intrinsically change properties based on membrane environment changes.  
Microscopy has also led to a deeper understanding of the striking phase differences within 
single membranes (heterogeneity), as illustrated in Figure 12.  Therefore, in our fluidity 
studies, we utilized both microscopy as well as fluorimetry. 
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Early confocal fluorescence microscopy of a GUV of 
DPPC/DLPC (4:1) containing BODIPY-PC and C20:0-
DiI (1:1,000 dye: total lipids).  Figure derived and 
modified from [89]. 
 
 
 
 
 
1.3.3. An Overview of Membrane Phases and Fluorescence Probes 
Numerous fluorescence probes have been designed and specifically characterized 
to measure a variety of aspects of membrane order.  All fluorescence probes have certain 
limitations or unique specifications to consider and all are unavoidably foreign additions 
to a membrane.  Most probes work extremely well in model lipid membranes, while only 
a few function as predicted/expected within live cells [86]. 
The fluorescence probes designed to investigate fluidity changes have been recently 
organized into three main classes and are defined as follows: 
The first class includes probes that specifically label lipid components of 
the membrane, such as gangliosides (for example GM1) or cholesterol. 
Probes that rely on the selective partitioning of the dyes to either Lo or Ld 
phases are grouped into the second class. Finally, probably the most recent 
class of probes corresponds to environment sensitive probes that can 
directly distinguish Lo and Ld phases due to differences in their intrinsic 
properties [86]. 
 
Figure 12. GUV microdomains seen using 
fluorescence probes 
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Various select examples from the three generalized classes of fluorescent 
membrane probes (sub classified) are represented in Table 4.  Probes that specifically label 
lipid components of the membrane (class #1, above) would include TF-Chol, NBD-DOPE, 
and 5-BODIPY-PC.  Class #2 probes rely on selective partitioning of the dyes into either 
liquid ordered (Lo) or liquid disordered (Ld) phases and would also include NBD-DOPE 
(Ld specific partitioning), DSPE-PEG-KK114 (Lo specific partitioning), or naphthopyrene 
(Lo specific partitioning). Class #3 probes, defined as environmentally-sensitive probes 
that can directly distinguish Lo and Ld phases due to differences in their intrinsic 
properties, include FCVJ and laurdan. 
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Representative probes from three general classes, sub-classified, and specificity to Lo, Ld, or both Lo and Ld 
phases in GUVs. Table derived and modified from [86]. 
 
 
Representative Probes  
Sub Classified 
Partitioning in GUVs 
Cholesterol Derivatives 
Cholestatrienol 
NBD-Chol  
TF-Chol 
 
Lo [90] 
Ld [90] 
Both (Lo + Ld) [91] 
PE Head Group Labeled 
DSPE-PEG-KK114 
NBD-DOPE 
NBD-DPPE 
 
Lo [92] 
Ld [90] 
Both (Lo + Ld)  [90] 
PC Acyl Chain Labeled 
N/A 
5-BODIPY-PC 
N/A 
 
Lo 
Ld [90] 
Both (Lo + Ld) 
SM Acyl Chain Labeled 
N/A 
5-BODIPY-SM 
12-BODIPY-SM 
 
Lo 
Ld [91] 
Both (Lo + Ld)  [91] 
SM Head Group Labeled 
N/A 
SM-Atto647N 
N/A 
 
Lo 
Ld [91] 
Both (Lo + Ld) 
LCH Dyes 
LcTMA-DPH 
DiD-C18 
DiI-C18 
 
Lo [93] 
Ld [91] 
Both (Lo + Ld)  [90] 
PAH Dyes 
Naphthopyrene 
N/A 
Perylene 
 
Lo [90] 
Ld  
Both (Lo + Ld) [90] 
Solvochromatic Probes 
N/A 
N/A 
Laurdan 
 
Lo 
Ld 
Both (Lo + Ld)  [94] 
Molecular Rotors 
N/A 
N/A 
FCVJ 
 
Lo 
Ld  
Both (Lo + Ld)  [95] 
GM1 Derivatives 
BODIPY-GM1 
N/A 
5-BODIPY-GM1 
 
Lo[96] 
Ld  
Both (Lo + Ld)  [91] 
Table 4.  Representative fluorescence probes sub-classified and partitioning properties of each probe 
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For our investigations of Lo and Ld phases in cells, we chose the class #3 probe 
laurdan.  Class #2 partitioning probes have been shown to be powerful tools for model 
membranes, but their applications in live cells are less clear because the partitioning 
between Lo and Ld phases depends strongly on the nature of lipids constituting these 
phases [86].  This problem with class #2 probes compounds problems with an already 
complex data analysis. From class #3 probes (environmentally-sensitive probes that can 
directly distinguish Lo and Ld phases due to differences in their intrinsic properties), the 
solvochromatic probes sub-class (Figure 13) are among the oldest and most established 
membrane probes, though their applications for lipid raft research took shape only in the 
recent years [86, 97]. More details about class #3 probes will be discussed below 
specifically in reference to laurdan.  
Solvochromatic probes localized in either Lo (green, 3) and Ld (red, 3) phases (the same probe), which results 
in different emission spectra due to changes in environment.  Examples of commonly used solvochromatic 
probe chemical structures and names are shown on the right.  Membrane cartoon and chemical structures 
adapted from [86]. 
 
 
Figure 13. Cartoon illustrating the principles of solvochromatic probes 
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1.4. A Review of the Fluorescence Probe Laurdan 
1.4.1. Laurdan Introduction 
Over 40 fluorescence probes have been used to examine membrane properties, 
membrane domains, and membrane order [86].  Laurdan is one of the most established 
probes for studying overall membrane fluidity and is rapidly expanding into new modes of 
use, from whole living zebrafish embryos down to single cell microdomain deconvolutions 
[94, 97, 98].  
Following the synthesis and chemical characterization of prodan (6-propionyl-2-
dimethylaminonaphthalene) in 1979, which contained only a three fatty acid (FA) carbon 
tail (propionyl-) [99], laurdan (6-dodecanoyl-2-dimethylaminonaphthalene) was 
developed soon after (1981), with a twelve carbon FA tail (dodecanoyl-) that maintains a 
more consistent membrane orientation and generally resides lower within the bilayer [100] 
(Figure 14). Whereas prodan can probe the surface of a membrane, laurdan can probe both 
interfacial region and the lipid bilayer close to the surface and is thus more versatile.  
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Figure 14. Laurdan and prodan bilayer locations 
 
 
 
 
 
 
 
 
 
 
Chemical structures of the phospholipid, dioleoyl phosphatidyl choline (DOPC) and laurdan and prodan, 
depicting their approximate bilayer locations, image modified from [101].  The phospholipid bilayer of live 
cells is normally 30-40 Å thick [102]. 
 
While laurdan is essentially incompatible with standard widefield and confocal 
fluorescence microscopy due to low photostability, two-photon microscopy was 
demonstrated and endorsed for use with laurdan beginning in 1996 [103].  Since then, two-
photon microscopy has grown into one of the predominant techniques used to examine 
membrane organization with the laurdan probe, together with long-standing fluorescence 
spectroscopy (fluorimetry) techniques.  However, inconsistencies have become widespread 
in (i) describing membrane phase separated domains (gel, liquid crystalline, liquid ordered 
[Lo], liquid disordered [Ld], etc.), (ii) reporting membrane organization versus 
fluidity/order, and (iii) analyzing laurdan data from both two-photon microscopy and 
fluorescence spectroscopy.  These will be discussed and clarified.  Furthermore, specific 
suggestions will be offered to amend disparities. 
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1.4.2. Diverse Applications 
Laurdan presents many merits for investigating membrane fluidity and has been 
used within an extensive range of membrane types: vesicles, supported bilayers, cells, 
organelles, and hybrid membrane systems. Applications include spectroscopic studies and 
microscopy imaging of phase separated domains as listed in Table 5. 
 
Liposomal Vesicles Small Unilamellar Vesicles (SUVs) [104] 
Large Unilamellar Vesicles (LUVs) [105] 
Giant Unilamellar Vesicles (GUVs) [94]  
Vesicles Comprised Entirely of FA [106, 107] 
Cell Lines BY-2 tobacco cells [108], human macrophages and fibroblasts [109], 
MEF cells [110], MDCK and CV-1 cells [111], melanophore cells 
[112], neutrophils [113], OK kidney cells [114], oligodentrocytes 
[115], glioblastoma cells [116], T. marmorata cells [117], human 
spermatozoa cells [118], human endothelial cells [119], seven 
additional mammalian cell lines [120], assorted bacterial cells such as 
G. stearothermophilus [121] and E. coli [122], NIH3T3 cells [123], 
HeLa cells [97], HEK293 cells [97, 124] 
Other Membrane Types Native Pulmonary Surfactant [94, 125]  
Brain Cortex Membranes [126]  
Liver Microsomes [127]  
Giant Plasma Membrane Vesicles (GPMVs) [128] 
 
Table 5. Fluidity studies using either spectroscopy or microscopy 
Fluidity studies using laurdan have been diverse.  The uses of laurdan have included various liposomal 
vesicles, cell lines, and other membrane types. 
 
Furthermore, recent advances in microscopy have enabled membrane rafts in live 
cells containing laurdan to be resolved [109, 129], although data analysis was reported to 
be complicated by the rapid internalization of this dye [130].  In part due to the laurdan dye 
internalization (diffusion into the cell), on the other hand, laurdan is now even being used 
to image membrane lipid order in whole, living vertebrate organisms.  This includes 
various tissues of live zebrafish embryos in three dimensions including hindbrain, retina, 
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kidney, gut, and muscle [131].  These innovative applications of the laurdan probe will 
likely stimulate further developments in the near future. 
Early Lo and Ld Complications–The first characterizations of laurdan for detecting 
phospholipid membrane dynamics were performed in 1990. Herein, the concept of 
“generalized polarization” (GP) was introduced, which utilized the peak emission spectra 
wavelengths from the two pure lipid phases, gel (440nm) and liquid crystalline (490nm) 
[132].   
A complication arose, beginning around 2001, when the classical fluid mosaic 
model of the membrane (including “gel” and “liquid crystalline” phase descriptions) was 
replaced by the view that the membrane was a complex combination of liquid ordered (Lo) 
and disordered (Ld) phases (reviewed here [86]).  The Lo and Ld phases were defined as 
saturated and unsaturated membrane lipids, respectively, together with cholesterol.  And 
while laurdan was among the first probes introduced for imaging Lo and Ld phases in 
model membranes [133], certain growing pains came with revising the long-standing fluid 
mosaic model.  As a consequence, some publications using laurdan to investigate 
membrane fluidity continue to include gel/crystalline (Lβ and Lα, respectively) phase 
descriptions [114], or even a conglomeration of Lo, Ld, Lβ, and Lα together [134].  Since 
typical studies using laurdan involve physiologically relevant conditions (liquid disordered 
or ordered; without freezing or boiling), Lo and Ld should therefore solely be used in 
membrane phase descriptions involving laurdan (Figure 15A). 
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(A) Schematic of an unsaturated Ld bilayer compared to a saturated Lo bilayer (image modified from [135]). 
(B) Structures of the ground and excited states of laurdan, where hν indicate the excitation. (C) Molecular 
model illustrating a representative “polarization-like state” of laurdan due to a weak interaction of the 
dimethylamino group of laurdan with the ester groups of DOPC.  This interaction is strengthened by laurdan 
rising higher within the membrane (Ld phase) or interacting with certain other lipids such as sphingolipids 
(image modified from [136]). 
 
 
 
1.4.3. Organization and Order 
With these advances in imaging heterogeneity, a further clarification must be noted 
between membrane organization and fluidity/order. Historically, the term “fluidity” was 
Figure 15. Altering the laurdan excited state 
  
37 
 
used exclusively to describe biophysical membrane properties but “order” was later added 
(~1989) to precisely specify membrane organized domains [137].  With the revamped 
representation of membrane phases (liquid disordered and ordered), fluidity and order are 
now generally used synonymously [86] and organization (in place of “order”) is currently 
being used to describe the organized domains (e.g. domains seen using laurdan with two-
photon microscopy). While fluidity/order refer to overall Ld/Lo membrane phase ratios (as 
seen using fluorescence spectroscopy, for example), membrane organization refers to 
changes in phase location, density, and/or composition (in the case of introduced, 
membrane-embedded, substances) within the larger membrane context.  Lipid 
organization, then, would be more readily observed from above a surface (X– or Y– plane) 
corresponding to lateral lipid packing, whereas lipid order or fluidity would normally be 
seen by a sample cross-section (Z– plane) or a full fluorimetry emission spectra.  A 
publication by Guo et al. from the Hamilton group illustrates the new terminology in an 
application to lipid bilayers [138]. Another example of a recent application of the terms 
“organization” versus “fluidity/order” comes from an examination of oleic acid doses on 
membranes.  This oleic acid study found that concentrations up to 100µM had little effect 
on membrane fluidity but, at the same time, these concentrations inducted important 
changes in membrane lipid organization [139].  We recommend that similar precision is 
used with these terms, in ongoing and future laurdan research.  
1.4.4. Environment Sensing 
Laurdan is a solvochromatic probe that reports on environmental changes (e.g. 
membrane fluidity alterations) through manifold properties. One way this occurs is through 
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a progressive (non-binary) enhancement of laurdan charge separation within increasingly 
polar environments, which increases the dimethylamino dipole moment.  Laurdan 
therefore, has more than one excited state: a locally excited state intrinsic to the fluorophore 
and an internal charge transfer state created by the larger dipole moment [97] (Figure 15B).   
In addition to dipole-variable sensing of surroundings, a well-defined and unique 
property of the laurdan probe is its sensitivity to hydration levels [140].  Even while it is 
not fluorescent in a purely aqueous environment [141], laurdan shifts emission spectra 
when present in more or less hydrated membrane environments due to H-bonding.  This 
shift is significant, with several studies demonstrating that the water density at the location 
of laurdan is approximately 8 times higher in the Ld phase compared with the Lo phase 
[142, 143] (Figure 15C).  In the Ld phase, comprised mostly of unsaturated phospholipid 
FA tails (containing more “kinks”), greater water penetration is permitted into the glycerol 
region of the bilayer surface and, as a consequence, the fluorescence spectra of laurdan 
exhibit a pronounced directional shift (a blueshift, in the case of the Ld phase, Figure 15A 
and Figure 16A). Importantly, these membrane-phase-dependent emission shifts have 
been reported as independent of the nature of the glycerophospholipid polar head group 
[144]. 
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(A) Schematic of two separate laurdan fluorescence emission spectra (blue and red lines), illustrating a blue 
shift or a red shift which occur within Ld or Lo phases, respectively. Below are the visible spectrum 
wavelengths and corresponding wavelength colors (image modified from [145]), as well as the generic 
ratiometric exGP equation. (B) Laurdan ratiometric (GP) microscopy image of a GUV 
(SM/DOPC/cholesterol mixture) containing laurdan, with arrows illustrating Ld and Lo phases and including 
a standard colorimetric GP-LUT bar (image modified from [94]).  (C) The (i) first published laurdan 2-photon 
microscopy image of live MEF cells (image modified from [103]), compared to a (ii) recent 2-photon 
microscopy image of live HEK293 cells and (iii) a live, 5-d-old zebrafish embryo muscle tissue (10µM scale 
bars) containing laurdan (image used with permission from Nature [97]). 
 
 
Miscellaneous accompanying properties further demonstrate why laurdan is a 
popular and prominent probe for use in membrane dynamics studies. Laurdan has been 
Figure 16. Laurdan phases, equation, and advances 
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found to maintain no preferential orientation within Ld membranes, but is present in a 
constrained vertical orientation in Lo membranes, further boosting emission shift changes 
already present  from hydration and/or polar-environment dipole separations  [146] 
(detailed orientation characterizations also here [147]).  Moreover, while the C-laurdan 
analogue gives higher fluorescence quantum yields within the Lo phase [86] and prodan 
preferentially partitions to the Lo phase of a membrane, laurdan partitions equally between 
Lo and Ld [148] and gives comparable quantum yields in both phases [149].  Hence, among 
membrane localized fluorescence probes, laurdan sustains minimal negative characteristics 
while multiplying and enhancing environmental change-detection through several 
characteristics: polarity-dependent charge separation, the strength of available H-bonding 
interactions, hydration sensitivity, and lateral molecular constraint/freedom [150, 151]. 
Redshift, Blueshift–In early characterizations of laurdan (described above), 
environment-dependent fluorescence emission spectra shifts were quantified using those 
values (440/490nm) that represented the peak positions reached in the two pure lipid phases 
(Ld and Lo phases, previously referred to as the gel and liquid crystalline phases) [120, 
132].  Included in these characterizations, traditional terminology was borrowed from 
physics to describe the direction of a laurdan spectrum shift as a redshift, indicating an 
increase in a peak spectrum wavelength (when comparing two conditions), or a blueshift, 
indicating a decrease in wavelength.  This led to the excitation generalized polarization 
(exGP) equation: exGP = IB – IR / IB + IR where I = intensity, B = blue (440nm), and R = 
red (490nm) (Figure 16A).   
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The exGP equation has become nearly ubiquitous for quantifying and comparing 
laurdan spectra replicates and differing experimental conditions.  However, GPRed is 
intuitively confusing since the 490nm wavelength is tangibly green within the visible 
spectrum. Subsequently, a few recent studies use GPGreen rather than GPRed (as in: exGP = 
IB – IG / IB + IG) [142] even while the majority of current publications continue to use GPRed.  
This semantic confusion is understandable because (i) redshift terminology is imprecise 
albeit historical, and (ii) the laurdan shift is not actually within the red wavelengths, but 
rather toward the red direction, since red is at the far end of the ROYGBIV visible spectrum 
(~700nm).  Compounding the disorientation, GPBlue (from “blueshift”) is always used 
(rather than “GPViolet”, which would be at the opposite end of the visible spectrum from 
red), and the GPBlue 440nm value coincidentally is authentically blue within the visible 
light spectrum (Figure 16A).  Therefore, in this case, the exact visible spectrum color is 
used (blue) rather than the true direction of the visible spectrum color shift (violet). 
Despite the logical validity of using GPGreen to describe the laurdan emission Lo 
phase shift, the redshift/blueshift and corresponding GPRed/GPBlue should continue to be 
used since the vast majority of literature up to and including current work (and this thesis 
work) continues to use GPRed/GPBlue. Additionally, the redshift/blueshift terms have 
expanded within physics and biophysics to include wavelengths far outside the visible 
spectra (such as gamma rays [152] or microwaves [153] etc.), which indicates that these 
terms will continue to be used to describe directional shifts.  Finally, colorimetric look-up 
tables (LUTs) are often inserted into laurdan two-photon microscopy images and represent 
increased membrane order (up to red) and decreased order (down to blue) based on the 
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corresponding GP values and ranging from –1.0 to +1.0 (Figure 16B). Even while these 
LUTs are assigned arbitrary representative colors and not actual representations of the 
visible spectrum, red has been chosen to represent the +1.0 end, while blue has been 
assigned to the –1.0 end of the standard GP LUT.  If the Lo phase was described as a green 
shift, these modified LUTs would likely foster greater confusion rather than clarity. 
1.4.5. Generalized Polarization Discrepancies 
Since the redshift and blueshift GP equation terms have been inconsistent within 
the literature, it is not surprising that wide variability exists in numerical fluorescence 
spectroscopy exGP values as well as in two-photon microscopy emission input values 
(where dual emission ranges are manually selected in the microscopy software representing 
Ld and Lo phases). 
For example, two-photon microscopy uses the ratiometric equation: GP = IB – IR / 
IB + IR, and some groups use the values IB = 400-460nm and  IR = 470-530nm [97], others 
use IB = 410-490nm and IR = 503-553nm [119]; others IB = 420-460nm and IR = 470-510nm 
[128]; or IB = 415-455nm and IR = 490-530nm [112]; or IB = 395-455nm and IR = 470-
550nm [113]; or IB = 460-480nm and IR = 540-550nm [123]; or IB = 430-440nm and IR = 
480-500nm [114]; or IB = 410-470nm and IR = 500-536nm [115].  This variability between 
publications leads to variability within results between groups and difficulty comparing 
them, even when the same cell types or model membranes are used. 
Furthermore, other aspects of laurdan two-photon data analysis can lack congruity.  
This is normally subtler and less problematic than GP range values, since many different 
membranes are investigated and specific modes of analysis are required.  Most studies use 
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their version of the GP equation to analyze the data and either choose a specific region to 
quantify (e.g. within a cell [119]) or manually outline and distinguish between the inner 
and outer regions (the PM versus the intracellular space, for example [97]).  Using a free 
custom-written macro with Image J software (NIH, Bethesda), this process can be 
standardized, simplified, and fast, using the following GP values: IB = 400-460nm and  IR 
= 470-530nm [97].  Since these values are also the most widely published for laurdan and 
two-photon microscopy, these are recommended for use in order to standardize this field 
of study. 
In fluorimetry spectroscopy studies using laurdan, again significant variation exists 
with exGP values (even while IB and IR are single numerical values and not a range of 
values, as in two-photon microscopy). Using the standard equation: exGP = IB – IR / IB + 
IR, many studies use the original IB = 440 and IR = 490 [104, 105, 107, 111, 121, 122, 126, 
154-156]; others use IB = 435 and IR = 490 [127]; or IB = 435 and IR = 480 [157]; or IB = 
430 and IR = 500 [106]; or IB = 430 and IR = 480 [118]; or IB = 434 and IR = 490 [117]; or 
IB = 430 and IR = 490 [108].  Additional procedures to analyze laurdan emission spectra 
have been developed that rely on the log-normal asymmetric function rather than Gaussian 
distributions [142], and either these new tools should be used, or the original 440/490 
values exactly, to maintain consistency and comparison among laurdan spectroscopic 
studies. 
1.4.6. Summary and Conclusions 
Added to cells, model membranes, or even live organisms, the single probe laurdan 
has been shown to (i) distinguish Lo and Ld organized domains, (ii) sense PM phospholipid 
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bilayer fluidity, and (iii) sense intracellular fluidity, all with relatively easy experimental 
methods, fast response times, and high spatial resolutions.  While many fluorescence 
probes work extremely well in model lipid membranes, only a few function as 
predicted/expected within live cells [86].  Laurdan is an example that does work. This 
introduction delineates the deviation within membrane phase terminology (and 
recommends Ld/Lo), membrane phase descriptions (and recommends fluidity/order versus 
organization), GP equation terms (and recommends redshift/blueshift [IB and IR] terms), 
exGP fluorimetry values (and recommends IB = 440 and IR = 490), and GP two-photon 
range values (and recommends IB = 400-460nm and IR = 470-530nm).  These propositions 
might not only contribute to the expanding field of study using laurdan, but may benefit 
the growing library of laurdan analogues (2,6 substituted naphthalene derivatives) such as 
C-laurdan, patman, prodan, acdan, danca, and acrylodan, that often adapt laurdan data 
analysis strategies and equations [97, 112, 144]. 
 
1.5. The Association of Fatty Acid and Cholesterol with Caveolae 
1.5.1. An Overview of the Caveolin Proteins 
Simard et al. from the Hamilton group have previously studied caveolin protein in 
FA biophysics with an emphasis on PM fluidity [158]. The caveolin gene family has three 
members: CAV1, CAV2, and CAV3.  The three caveolin proteins (caveolin-1 [Cav-1], 
caveolin-2 [Cav-2], and caveolin-3 [Cav-3]) have unique tissue distributions and they are 
said to “all concentrate signal transducers within distinct regions of the PM” [159]. 
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Cav-3 is almost exclusively expressed in muscle tissue in humans (full Affymetrix 
U133A expression-array data: [160]).  This protein has many similar functions to Cav-1 
and Cav-2, even forming sodium-permeant Cav-3 channels that can functionally replace 
Nav1 sodium channels in species where they are lacking, such as Caenorhabditis elegans 
[161].  However, most known pathologies associated with Cav-3 loss relate to specific 
muscle disorders [162]. 
Cav-2 is expressed in mostly the same tissues as Cav-1, except less tissue types 
(full Affymetrix U133A expression-array data: [160]).  Not only do Cav-1 and Cav-2 co-
localize and form stable hetero-oligomeric complexes, they are located next to each other 
at 7q31.1 on human chromosome (unlike Cav-3, which is located on different 
chromosomes) [163].  Due to the current consensus that Cav-2 and Cav-1 are likely 
redundant or complementary [164], our focus is Cav-1. 
By approximately a factor of 10, Cav-1 is investigated in publications more than 
Cav-2 and Cav-3 combined.  It is a was the earliest caveolin protein discovered, initially 
named Vesicular Integral-membrane Protein of 21 kD (VIP21) [165, 166], after which 
quickly came the discovery of M-caveolin (muscle-caveolin; Cav-3) [167] and then Cav-
2, identified via sequencing [168]. Soon after the discovery of Cav-1, it was determined 
that Cav-1 expression could lead to caveolae formation [169].  Later, however, the critical 
importance of the cavin protein family was recognized in this process, which will be 
introduced below and in Chapter 6. 
Caveolae and Cav-1 are predominantly located at the PM, although Cav-1 has been 
identified to play a functional role within the mitochondria and endoplasmic reticulum 
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[170].  In fact, without Cav-1, free cholesterol has been shown to accumulate in 
mitochondrial membranes, reducing efficiency of the respiratory chain and antioxidant 
defense [171].  PM localized Cav-1 embeds in the cytosolic leaflet, where most Cav-1 
binding proteins have been found to interact with the amino-terminal membrane-
attachment domain, also called the caveolin scaffolding domain (CSD) (Figure 17).  Cav-
1 has been shown to interact with heterotrimeric G proteins [172], Src tyrosine kinases 
(Src, Lyn) and H-Ras [173], TGF-β receptor 1 [174], endothelial NOS [175], androgen 
receptor [176], amyloid precursor protein [177], gap junction protein, alpha 1 [178], 
epidermal growth factor receptor (EGFR) [179], endothelin receptor type B [180], beta-
type platelet-derived growth factor receptor A and B (PDGFRA/B) [181], estrogen receptor 
alpha (ERα) [182], Bruton's tyrosine kinase [183] and many other proteins.  These diverse 
protein interactions can also be dependent upon or disrupted by Cav-1 interactions with 
lipids, which will be discussed below. Because of these protein and lipid binding properties 
and their requirement for physiological functions, mutations in Cav-1 can result in 
lipodystrophy, cell transformation and cancers, cardiovascular diseases, atherosclerosis, 
diabetes, and pulmonary fibrosis [171].  
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(A) The predicted topology of Cav-1 in the PM. Caveolin-1 monomers are shown forming a dimer for 
simplicity, but it is noted that “about 14-16 monomers normally self-associate to form a single caveolin 
homo-oligomer (the caveolar assembly unit, akin to the clathrin triskelion)”. (B) The domains present in Cav-
1.  Images derived and modified from [184].  
 
 
Numerous studies have shown that acylation of protein plays a crucial role in 
targeting to caveolae, especially palmitoylation and myristoylation [185, 186]. Caveolae 
have also been shown to be highly enriched in saturated FFAs.  From caveolae preparations 
from 5x107 cells, for example, 0.83μg of oleic acid, 0.61μg of stearic acid, and 0.48μg of 
palmitic acid were found [185].  Moreover, in this same study, Cav-1 was found to be 
acylated by palmitic acid and stearic acid, but not by myristic acid. 
Figure 17. Primary structure and topology of Cav-1 
  
48 
 
Cholesterol binds to the Cav-1 TM domain and binding this has been postulated to 
lead to lipid raft formation (Figure 17) [187].  In addition to this direct interaction, high-
cholesterol fed Cav-1(-/-) mice also showed a reduction in free cholesterol and were 
enriched in esterified cholesterol (in addition to complete elimination of caveolae, except 
in cardiac and skeletal muscle) [188].  This indicates cholesterol is sequestered in the PM 
by Cav-1. 
Simard et al. from the Hamilton group have also found that Cav-1 sequesters FA in 
the PM (on the cytoplasmic leaflet), protecting cells from lipotoxicity [158].  In this same 
study, it was noted that Cav-1 augmented TG formation, similar to CD36 (Chapter 4).  
This TG formation traps FFA inside cells, leading to an increase in FA “uptake”, which 
has been named a “transport mechanism” [189].  While CD36 crosslinking studies have 
shown that CD36 does not form a multimeric complex [190] (even while clustering does 
occur under certain conditions, such as when malaria-infected cells are present [191]), Cav-
1 does form multimeric complexes as well as pores [161, 192]. However, because of 
contributions of metabolism (i.e. TG augmentation), naming Cav-1–mediated FFA uptake 
a “transport mechanism” is premature.  Trapping FFA as TG may also be the reason that 
Cav-1 has been found to be important for dietary FA absorption [193], especially since 
FFA can rapidly diffuse through the cellular PM within sec-msec, which permits it to leave 
the cell as well as enter it (seen Chapter 4). 
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1.5.2. An Overview of the Cavin Proteins 
The cavin family has four members: PTRF/cavin-1, SDPR/cavin-2, SRBC/cavin-
2, and MURC/cavin-4.  All four have cytosolic functions that were described prior to 
caveolae interactions, leading to early, unrelated nomenclature.  
Similar to Cav-3, MURC/cavin-4 is expressed in cardiac and muscle tissues and is 
associated with sarcolemmal caveolae of muscle cells and perturbations in certain human 
muscle diseases [194]. While CD36 has interesting sarcolemma functions (see Chapter 2), 
this is not our focus. 
Until recently, the accepted paradigm was that caveolins were the sole structural 
proteins required for caveolae since their expression was seen as necessary and sufficient 
to drive caveolae biogenesis [194].  However, absence of PTRF/cavin-1 was found to lead 
to the loss of morphologically identifiable caveolae and to diminish protein expression of 
all three caveolin isoforms (even while no alteration at the level of mRNA of caveolins 
were observed) [195]. 
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(A) The interaction of Cav-1 with the cell membrane in the absence of PTRF/cavin-1. (B) The presence of 
PTRF/cavin-1 allows Cav-1 to interact with the cell membrane to form caveolae. (C) Enlarged image of 
PTRF/cavin-1 binding the oligomerization domain of Cav-1 and the association of caveolin oligomers, the 
lipid bilayer, sphingolipids, and cholesterol. Figure derived and modified from [184]. 
 
Furthermore, a recent study using PTRF/cavin-1 null mice showed that these mice 
developed a similar phenotype to Cav-1 knockout mice.  This included abnormal lipid 
metabolism, insensitivity to insulin, decreased mitochondria protein expression in brown 
fat, and reduced TG accumulation [196].  During obesity, a hypoxic state develops within 
adipose tissue, and hypoxia was also recently found to inhibit PTRF/cavin-1 and 
SDPR/cavin-2, along with inhibition of adipocyte caveolae [197]. 
Figure 18. PTRF/Cavin-1 binding to the oligomerization domain of caveolin-1, leading to caveolae 
formation 
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While PTRF/cavin-1 induces caveolae formation together with caveolin, 
SDPR/cavin-2 and SRBC/cavin-3 are uniquely involved as well.  SDPR/Cavin-2 shares 
more than 20% similarities with PTRF/cavin-1 [198], and SDPR/cavin-2 has been shown 
to induce changes in caveolae morphology (but not caveolae number) [194]. SRBC/cavin-
3 was originally identified in screens looking for PKCδ [199].  SRBC/cavin-3 mainly 
associates with caveolin upon caveolae budding to form vesicles (and intracellular Cav-1 
trafficking is markedly impaired in the absence of SRBC/cavin-3) [200].  These findings 
suggest SRBC/cavin-3 may couple caveolae to the intracellular transport machinery 
(Figure 19). 
 
 
  
52 
 
 
Cav-1 is associated with both flat caveolar domains as well as invaginated smooth plasmalemmal vesicles or 
caveolae.  PTRF/Cavin-1 and SDPR/cavin-2 are required for caveolae invagination and SRBC/cavin-3 for 
caveolae budding, to form caveolae vesicles.  Finally, SDPR/cavin-2 overexpression induces enlarged 
caveolae and caveolar tubules. Image derived and modified from [201]. 
 
 
 
Figure 19. Regulation of caveolae morphology and dynamics by cavin family members 
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CHAPTER TWO: CD36 
2.1. History: Discovery, Structure, and Overview 
2.1.1. Early Characterizations 
The discovery of CD36 (cluster of differentiation 36) has complex, heterogeneous, 
and redundant origins, giving rise to a multitude of alternate names (FAT [fatty acid 
translocase], GPIIIb [platelet glycoprotein IIIb], GPIV, SCARB3 [scavenger receptor B3], 
Collagen type I receptor, Thrombospondin receptor, PAS IV, and CHDS7 [coronary heart 
disease susceptibility 7]).  The nomenclature reflects the multifuntionality of the protein 
and the continuing challenges to establish mechanisms of its biological activities. Today, 
CD36 is largely known through its ability to bind modified forms of low-density 
lipoprotein (LDL) as a member of the class B family scavenger receptor (Figure 20) [202], 
but that is by no means the only function of CD36. Along with the well characterized 
function CD36 performs binding oxidized LDL (oxLDL) in numerous cell types and 
subsequent foam cell formation in macrophages [203], CD36 has been robustly shown to 
have many additional diverse functions such as immune response [204], insulin resistance 
and glucose transporter type 4 (GLUT4) trafficking interplay [205, 206], fatty acid (FA) 
interactions and free FA (FFA) “uptake” [41, 84, 207, 208], FA oxidation [209], inhibition 
of angiogenesis [210], cell adhesion [211], malaria infection response [212], advanced 
glycation end product (AGE) uptake [213], and amyloid beta (Aβ) binding [214]. 
Furthermore, CD36 has lesser studied roles in fungal and bacterial response [215, 216], 
pheromone detection [217], cocoon coloration [218], sperm engulfment by cumulus cells 
[219], taste bud lipid sensing [220], apoptosis under ER stress [221], regulation of reactive 
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oxygen species (ROS) formation [222], removal of monocyte generated reactive nitrogen 
species [223], store-operated calcium flux [224], cholesterol efflux [225], mitochondrial 
LCFA transfer [226], and even high-density lipoprotein (HDL) binding/uptake [227]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover page of 2006 Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) showing classes of 
characterized scavenger receptors, which share the defining feature of binding to modified forms of LDL. 
Along with SR-B1, CD36 is a Class B scavenger receptor. Figure derived and modified from [202]. 
 
Broadly, CD36 was first described in 1973 and 1989 by its resistance to proteolysis 
in milk fat globules, with a MW of 88kD [228, 229].  Expediting but also adding to the 
complexity of the CD36 discovery and characterization throughout the 1980’s, the Fourth 
International Workshop on Human Leukocyte Differentiation Antigens impelled 190 
different laboratories from around the world to work together in the performance of more 
Figure 20. Various scavenger receptors, including CD36 
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than 150,000 assays to characterize about 800 antibodies, to “bring order out of the chaos” 
of molecules described on the surface of human leukocytes [230].   As part of this study, 
the Michael Brown and Joseph Goldstein lab raised an antibody (OKM-5) against adherent 
monocytes in 1983—two years before they jointly received the Nobel Prize in Physiology 
or Medicine [231].  This OKM-5 monoclonal antibody was later shown to specifically bind 
CD36 using blocking peptides [232], and OKM-5 opened the door to in-depth 
characterization of CD36 and the realization that glycoprotein IV was immunologically 
related to CD36 [229].  These early findings culminated in the first review of CD36, 
published in 1992, attempting to clarify the status of CD36 and singularly labeling the 
protein as “CD36”  [233]. 
Initially, a confounding factor in identifying CD36 was the differing molecular 
weight values, which depended on cell type and preparation treatments.  For example, 
CD36 from human platelets, mammary epithelial cells, and erythroblasts was reported to 
have MW values of 88, 85, and 78 kD, respectively [229, 234, 235], and treatment of 
bovine protein and human protein with endoglycosidase F to remove carbohydrates from 
CD36 protein gave rise to identical MW values between these purified CD36 proteins 
[233].  More current research has also shown 5 alternatively spliced mRNA’s commonly 
exist in humans [236], which were all seen to be within the 5’ UTR (Figure 21) [237], 
which may have exacerbated the initial complications discriminating and describing CD36. 
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The 15 exons of the CD36 gene on the left (image derived from [238]) and the alternate splice sites on the 
right. Figure derived and modified from [237]. 
 
 
With both alkali-labile O-glycosidic linkages [229] and N-linked glycosidic 
linkages [239], the latter of which are responsible for proteolysis resistance of membrane-
bound CD36, the overall structure of CD36 was found to be highly hydrophobic [233].  
Human placental complementary deoxyribonucleic acid (cDNA) for CD36 was isolated by 
expression cloning in COS cells [240] and confirmed by partial protein sequence data 
attained by Edman degradation [229], which accelerated the field of CD36 research and 
also led to an early structural schematic, which included 10 potential glycosylation sites in 
the human CD36 [233], and which has not been refined until very recently (2013 [241]) 
(Figure 22 and Figure 23). Key structural findings were that (i) mutating all the CD36 
glycosylation’s sites resulted formation of cytosolic aggregates [242]; (ii) the small, 
intracellular domains were also involved in modifications, including ubiquitination at 
K469 and K472 on the N-terminus, and palmitoylation on C-terminal cysteines 3 and 7 as 
Figure 21. Schematic CD36 gene map 
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well as on N-terminal cysteines 464 and 466, depending on cell or tissue type [207, 243], 
and (iii) 6 cysteines formed 3 disulfide bridges in the extracellular domain [244]. 
 
An early, 1992, CD36 schematic (A) (Figure derived and modified from [233]), juxtaposed with one from 
2009 (B) (Figure derived and modified from [204]), emphasizing the lack of significant improvement aside 
from color palette and graphics.  Potential glycosylation sites are marked with a triangle (A) or a blue dot 
(B). 
 
In contrast to all earlier structural schematics (i.e. Figure 22), the recent (2013) 
resolution of the crystal structure of LIMP-2 provided functional insights into family 
members CD36 and SR-B1 and enabled the use of homology modelling to generate a high 
resolution schematic of CD36 (Figure 23).  Even though LIMP-2 does not bind modified 
LDL (it mediates lysosomal delivery of b-glucocerebrosidase [241]), the homology to 
CD36 and SR-B1 is striking.  The structure of LIMP-2 and homology model of CD36 has 
already expanded the research of CD36 as a whole, including a new paper titled: “Three 
Dimensional Strucure Prediction of Fatty Acid Binding Site on Human Transmembrane 
Receptor CD36” [245], and undoubtedly others will follow. 
Figure 22. Two early CD36 structural schematics 
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An updated and new schematic of CD36 (C) and SR-B1 (B) extracellular domains, based on structural 
homology models derived from the crystal structure of hLIMP-2 (A), including the hydrophobicity surface 
representations of hLIMP-2 (A), SR-B1 (B), and CD36 (C).  In yellow highlight are the ligand docking 
tunnels detected in hLIMP-2 (A) and proposed tunnels in the homology models of SR-B1 (B) and CD36 (C), 
including stereoscopic views (related by a 180° turn) of the side chain residues lining the cavity of hLIMP-
2, computed using CASTp14 server. Figure derived and modified from [241]. 
 
Giving rise to new areas of CD36-related functions was the recent accessibility of 
data from the massive ENCODE project, completed in 2009 [246], which included CD36 
in 185 chromatin immunoprecipitation sequencing (CHiP-seq) experiments using different 
cell lines and tissue samples (Table 6).  This combined CHiP-seq data confirm that proteins 
binding to the CD36 gene promoter are involved in numerous, variable, and highly 
Figure 23. LIMP2 and CD36 homology structure with crystal structure resolution 
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important cell pathways.  Examples include interactions with cancer-related proteins such 
as “the guardian of the genome” tumor suppressor p53, E47 (which is associated with 
childhood leukemia and pre-B-cell acute lymphoblastic leukemia), and other major proto-
oncogenes such as c-Jun and c-Fos.  Additionally, many nutrient- or adipose-related factors 
bind to the CD36 promoter region, such as upstream transcription factor 1 (USF1) 
associated with familial hyperlipidemia, peroxisome proliferator-activated receptor gamma 
(PPAR-γ) implicated in many aspects of obesity and diabetes, or the sterol regulatory 
element binding protein’s (SREBP)-1a, -1b, and -1c.  Furthermore, proteins related to a 
variety of additional inflammatory and/or cytokine pathways bind the CD36 promoter.  
This would include nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
and signal transducer and activator of transcription 1α (STAT1α).  Other proteins shown 
to interact with the CD36 promoter have specific functions that are only slightly or not yet 
determined, such as FOXC1 or the POU class 2 homeobox class proteins (POU2F1a, b, or 
c).  Overall, these proteins are major and unrelated players in an array of pathways that 
reflect the diversity of characterized CD36 protein functions, suggesting possible 
evolutionary functional divergence and/or complex cross-interactions between these 
proteins and pathways that are unknown.  Strikingly, some proteins here even additionally 
interact directly with CD36 protein located on the cell surface: for example, the CHiP-seq 
data indicates that NF-κB binds the CD36 promoter while the intracellular C-terminal of 
plasma membrane (PM) bound CD36 is required for oxLDL NF-κB modulation in CHO) 
cells [247]. 
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Numerous key proteins bind the CD36 promoter.  Many of these proteins are involved in diseases such as 
cancer or pathogenic inflammation.  This CHip-seq specifically indicates where these proteins act relative to 
major transcription start sites (red arrows) of CD36, on a 165 base pair scale (bottom scale and upper black 
line). Table derived and modified from [246]. 
Table 6. CHiP-seq showing proteins that interact at or near the CD36 promoter 
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2.1.2. Involvement with Malaria-Infected Red-Blood Cells 
An early CD36 functionality assay emerged when it was discovered that the earliest 
monoclonal antibody to CD36, OKM-5, inhibited in vitro binding of malaria (Plasmodium 
falciparum) infected erythrocytes using three cell types that otherwise bind malaria 
infected cells (human endothelial cells, monocytes, and C32 melanoma cell line) [248].  
Following this, the expression cloned CD36 cDNA was verified as functional by 
expressing it in COS cells, which normally do not bind malaria infected erythrocytes, and 
demonstrating that the COS +CD36 cells are then able to bind malaria parasitized cells 
[240].  Since the severity of malaria infection was found to be proportional to the density 
of malaria-infected erythrocytes that bind to the postcapillary venular endothelium (in 
brain, lungs, and placenta [233]), the discovery that CD36 bound infected cells led to a 
large body of research into the overall adherence abilities of CD36 [212].   
This CD36–P. falciparum-infected cell interaction has been shown in detail, more 
recently, to involve P. falciparum erythrocyte membrane protein 1 (PfEMP-1), which is 
expressed at the surface of infected erythrocytes.  PfEMP-1 binds CD36 between either 
amino acids 146-164 or 145-171 at the PM, leading to uptake [249].  Additionally, the 
CD36-mediated cytoadherence of P. falciparum-infected red blood cells is lost following 
treatment of CD36-expressing cells with the reducing agent DTT [250], indicating that the 
3 disulfide bridges on the extracellular domain of CD36 are potentially effective drug 
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targets for P. falciparum-infected cells using nontoxic reducing agents, such as the drug N-
acetylcysteine. Other CD36-related pathogenic interactions (i.e. oxLDL, Aβ, AGE, FA) 
may have similar drug-target potential. 
2.1.3. Interaction with Collagen and Thrombospondin 
Two other characteristics of CD36 that even predated the important CD36 title of 
“scavenger receptor” was the ability of CD36 to bind thrombospondin (TSP) as well as 
collagen.  The CD36 receptor was initially shown to bind collagen tightly, with a Kd = 0.34 
+ 0.1 nM and a dependence on Mg2+ [211].   Later this finding was shown to be less 
physiologically relevant than initially presumed, because of the diminished ability of CD36 
to bind mature, quaternary-structured collagen, such as collagen that platelets bind during 
aggregation in vivo [251].   
TSP, however, binds to CD36 via the amino acid adhesion motif CSVTCG [252], 
is Ca2+ dependent [253], and has been shown in capillary endothelial cells to mediate a 
potent anti-angiogenic, proapoptotic response through binding CD36 [254].  Therefore, 
CD36, through interacting with TSP, plays an active role regulating/slowing tumor growth, 
inflammation, wound healing, and other pathological processes requiring 
neovascularization and negative regulation of angiogenesis [204].  In 2011, it was further 
shown that TSP-2, currently the most potent of the anti-tumor/anti-angiogenic TSP’s, acts 
in a CD36 dependent manner to achieve anti-angiogenic effects [255]. This interaction has 
been characterized in detail using recombinant CD36 and numerous shortened fusion 
protein (FP) fragments, showing full CD36 binds TSP at a Kd 227 + 19.89nM and the FP 
93-120 has the lowest Kd (8.6 + 3.6 nM) with a maintained Ca2+ dependence, leading to 
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the conclusion that the Cd36-TSP binding domain lies between amino acid residues 93 and 
120 [253]. 
2.1.4. Involvement with Apoptosis 
Shortly after the discovery that TSP and CD36 interact (1992), these two proteins 
were found to cooperate in monocyte-derived macrophage phagocytosis of neutrophils 
undergoing apoptosis [256].  Furthermore, it was observed that TSP-2 was not only anti-
angiogenic in a CD36 dependent manner, but also pro-apoptotic toward human dermal 
microvascular endothelial cells in a CD36-dependent mechanism [255].  
In addition to these TSP-dependent mechanisms, CD36 is directly involved in the 
process of apoptosis intracellularly.  This was first noted when mice on a high saturated 
FA diet induced macrophage ER stress and apoptosis, whereas CD36-/- mice did not show 
macrophage apoptosis under similar conditions [221].  Recent knockdown studies of CD36 
by small interfering ribonucleic acid (siRNA) also showed decreased FA induced apoptosis 
in a CD36-dependent manner [257].   
2.1.5. Interactions with Lipids 
In 1993, the field of CD36 research was profoundly impacted by two discoveries: 
increased oxLDL uptake by CD36 [258] and the ability of FA to increase CD36 mRNA 
[259], leading to comprehensive studies of CD36 involvement in overall lipid and 
apolipoprotein interactions and metabolism. 
The major discovery that CD36 is involved in uptake of oxLDL was first shown by 
transfection of CD36 into HEK293 cells using ox125I-LDL using pulse-chase studies, and 
comparing the resulting CD36-oxLDL high affinity Kd (2-3 nM) to the affinity value 
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determined for macrophage binding of oxLDL.  These experiments were performed under 
the hypothesis that macrophages endogenously express few LDL receptors (LDLr) and are 
unable to efficiently accumulate native LDL; therefore the LDLr is not responsible for 
oxLDL uptake and subsequent foam cell formation [258].  It was further seen that adding 
CD36 antibody to macrophage-like THP cells blocked ~50% of oxLDL binding [258].  
Other oxLDL binding is presumably due to other scavenger receptors (Figure 20) or to 
CD36 that did not contact and bind antibody.  Since LDL contain FFA and esterified FA, 
the uptake via CD36 of oxLDL presented one mechanism of physiological FA uptake. 
That same year (1993), it was discovered that CD36 mRNA is increased upon 
addition of oleic acid and that upon preadipocyte (3T3-F442A) treatment with 
dexamethasone (to induce differentiation), CD36 mRNA also increased, as seen by 
Northern blot [259]. This finding led to the generation of CD36-/- mice which were shown 
to exhibit increased serum triglyceride (TG), cholesterol, and FFA [260].  A follow up 
paper using similar CD36-null mice showed diminished conversion of diglyceride to TG. 
Long chain acyl-CoA synthetase and diacylglycerol acyltransferase activity did not 
account for this decrease and further reduction in two administered iodinated FA analogues 
(BMIPP and IPPA) were found up to 80% in heart, up to 75% in skeletal muscle, and up 
to 70% in adipose tissue [261].  These studies and findings paved the way for future 
research and debate regarding PM-bound CD36 as a FFA transporter, since the overall 
uptake of FFA into cells was clearly increased in correlation with CD36 expression. 
The discovery of CD36-null humans also suggested CD36 involvement in lipid 
metabolism and FA uptake.  After the initial report in 1995, that some Japanese subjects 
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were CD36 deficient [262], other human subjects were shown to have platelet-specific 
CD36 deficiency (3-5% of the Asia and African population), and, more rarely, full CD36 
deficiency in 10% of these people (0.3-0.5% of these populations) [263].  In macrophages 
isolated from CD36-null human subjects, Scatchard analysis of ox125I-LDL binding 
showed a linear plot where the maximum binding was lower by approximately 40% 
in macrophages from subjects with CD36 deficiency than those from normal controls 
[262], in agreement with data acquired in the first study showing CD36 is involved in 
oxLDL uptake utilizing antibodies targeting CD36 to block ~50% oxLDL uptake [258].  
Interestingly, following people long-term with full CD36 deficiency showed that these 
subjects were associated with enhancement of atherosclerotic diseases [264]. 
On the other hand, in apoE and CD36 double knockout mice, there was an observed 
76.5% decrease in aortic lesion area after Western-diet feeding for 12 weeks, when 
compared with the apoE null animals (as well as a 45% decrease comparing normal chow 
mice) [265].  Conversely, muscle-specific CD36 transgenic mice did not alter aortic lesions 
but did enhance FA oxidation in contracting muscle, reduce plasma TG and FA, and 
increase plasma glucose and insulin [266].  Additional controversy regarding these mouse 
models exists, which will be discussed below. These and other early investigations paved 
the way for studies in CD36 research regarding lipid metabolism, lipid induced signaling 
through the CD36 receptor, and other ongoing studies that have major implications in 
understanding lipid homeostasis and diseases involved. 
CD36 and FFA-specific interactions were first characterized indirectly with the 
synthetic molecule, sulfo-N-succinimidyl oleate (SSO) along with FA derivative isopropyl 
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myristate. These molecules added at high concentrations (up to 1 mM) appeared to show 
inhibition of adipocyte FFA uptake. Radiolabeled-SSO [3H-SSO] added to cells was shown 
to bind to an 88kD protein, identified later as CD36 [267, 268].  In a follow-up publication 
by the same group in 1996, CD36 was shown to have a significant homology to M-FABP 
throughout 73% of its sequence (Figure 24), leading to a FFA binding study showing that 
CD36 binds oleic acid, steric acid, and arachidonic acid [269].  This binding study however 
used (i) a highly crude and inaccurate binding assay involving temperature changes and 
Lipidex resin, (ii) an equally crude purification protocol for isolating CD36 protein (using 
wheat germ), and (ii) detergent throughout the entire assay (0.1% Triton). These technical 
shortcomings are evident from the final conclusion that “determination of true dissociation 
constants was not possible since the concentration of free (not micelle-partitioned) FA in 
the aqueous solution cannot be measured or calculated” and the noted limitation that: “If 
the total FA concentrations are factored in, the apparent dissociation constants obtained for 
CD36 and for BSA are similar and both about 1μM” [269].  However, the Kd of BSA has 
been well characterized as early as 1975 to be in the nanomolar range for most FA, 
including oleic acid and stearic acid (e.g. BSA binding site #1 for oleic acid = 2.6 x 10-8 
M; BSA binding site #1 for stearic acid = 1.5 x 10-8 M) [36].  Additionally, albumin has up 
to 9 well-characterized FA binding sites [34], illustrating the potentially vast difference 
between CD36 binding to FA and albumin.   
To date, it has been generally accepted that (i) CD36 directly binds FFA based 
mainly on this single 1996 study (and the FABP homology domain), and (ii) that SSO is a 
‘CD36-specific inhibitor’.  Hence, numerous papers using SSO assume CD36-specific 
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inhibition up to very recent publications [270], including recent reviews [271-275].  
However, the specificity of SSO is not conclusive for several reasons, including inhibition 
of the SSO mitochondrial respiratory chain complex III [276] as well as its likely 
modification of any lysine contacted (in addition to new currently unpublished data by our 
group [see Chapter 4]). 
Adding to the single CD36–FFA binding study, our group has recently investigated 
(i) FA uptake rates with or without CD36 expressed in cells (discussed below) and (ii) the 
binding of CD36 with five FA types from the representative groups: saturated, 
monounsaturated, polyunsaturated, oxidized, and trans FA [41].  Our binding study further 
confirmed and characterized FA directly binds CD36.  It also indicated that CD36 binds 
multiple moles of FA per mole of CD36 (similar to the finding that a single FABP protein 
bound multiple oleic acids using an NMR-based solution structure study [277]).  
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Alignment of a putative domain of CD36 (residues 127-279) with M-FABP, based on the Dayhoff 5-
parameter scoring method.  Boxed residues indicate identical or conserved ones according to the groupings 
KR, ST, PG, QNED, and to hydrophobicity HYWFILVMCA.  The secondary structure of M-FABP is also 
shown below the sequence. Figure derived and modified from [269]. 
 
2.2. CELL AND TISSUE EXPRESSION AND LOCALIZATION 
2.2.1. Tissue Expression Overview 
CD36 is expressed in a number of important human tissues and cells, some of which 
have scarcely, if at all, been investigated (e.g. lung tissue).  Affymetrix mRNA microarray 
data (U1332A) compiled from 126 primary human tissues, reveals that CD36 is expressed 
highly in adipocytes, left ventricle cardiac muscle, derived macrophages, 
lipopolysaccharide-induced macrophages, monocytes, myeloid CD33+ cells, the spleen, 
the endothelium, the small intestine, red blood cells, skeletal muscle, fetal liver, and lung 
tissue, relative to numerous housekeeping genes (Figure 25) [160].  
Figure 24. FABP and CD36 amino acid alignment 
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Adipocytes show the highest levels of CD36 expression (bright red), with cardiac muscle second.  Other 
tissues of interest include macrophages, endothelial cells, red blood cells, skeletal muscle, and lung.  
Numerous other tissues show little/no CD36 expression (teal). Figure data derived and modified from [160]. 
 
 
Additionally, taste buds and the retina are two other tissue types that are known to 
express physiologically important CD36 yet were not part of the Affymetrix mRNA array 
screen in Figure 25. In rodents, CD36 was first identified in chemoreception of LCFA in 
tasting and involved in preference for fatty foods: CD36 null mice were seen to decrease 
this fatty food preference [220].  Retinal pigment epithelium (RPE) cells, which maintain 
one of the highest cellular turnover rates in the human body, express CD36 that is 
postulated to play a crucial role in uptake and clearance (but not in the initial binding), of 
Figure 25. Affymetrix CD36 mRNA microarray data from primary human tissue 
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shed photoreceptor outer segments, when comparing cells isolated from control mice 
compared with CD36 null mice [278]. Along with these new discoveries, the scope of this 
2010 expansive array is currently leading the CD36 field to a more precise investigation of 
cell and tissue expression variability and function. 
2.2.2. Adipocytes and FA uptake 
Adipocytes are a key focus of much CD36 research, with increasing interest 
because of implications of CD36 in diabetes and obesity-related pathogenesis. The large 
extracellular domain has been proposed to bind and facilitate transport of FA through a 
lipid membrane that is often considered impermeable to FA [10, 207]. Despite the 
relatively short length of the CD36 cytoplasmic domains, it has become apparent that CD36 
is an active signaling receptor dependent upon these cytoplasmic domains [203], with 
differing signaling affects based on cell type, localization, and expression levels.  
In a study of whole extract human subcutaneous adipocyte CD36-expression using 
ELISA, it was seen that CD36 content decreased as adipocytes grew larger (Figure 26) 
and, notably, that RT-PCR did not reflect a similar decrease but remained the same [279].  
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Using ELISA, CD36 content/mg in whole adipose tissue extract decreased significantly (P = 0.01) as 
adipocytes grew larger.  Size was measured using the relationship of protein to lipid content. Figure derived 
and modified from [279].  
 
 
This suggests that in subcutaneous adipocytes, CD36 protein is being 
downregulated as adipocyte size expands.  Since mRNA expression levels remain the 
same, the regulation is presumably either occurring at the transport/shuttling process 
(possibly involving ubiquitination of translated protein), or CD36 mRNA is not being 
translated due to increased inhibitory factors or a decrease in translation activating factors.  
It is worth noting that with the growing body of recent evidence showing major metabolic 
distinctions between not only brown adipose tissue (BAT) and white adipose tissue (WAT) 
but between types of WAT such as visceral WAT and subcutaneous WAT, CD36 could 
play different roles in any of these fat depots.  For example, via Prdm16, subcutaneous 
WAT demonstrates a metabolically healthy “brown fat-like” gene program as well as 
thermogenesis, which is nearly opposite the metabolic effects of visceral WAT, even 
Figure 26. ELISA showing CD36 expression relative to adipocyte size 
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though they are both WAT’s [280].  Therefore, a study specifically looking at subcutaneous 
WAT and CD36, should now also include visceral WAT to further understand the basic 
science surrounding diseases such as diabetes or cardiovascular disease.  Interestingly, the 
protein Prdm16 is an important player in the functions of subcutaneous fat, through 
promoting PPARα induction, which leads to PPARγ induction (both are PPAR’s that bind 
the CD36 promoter [Table 6] [280]). Hence, distinguishing other types of WAT and CD36 
expression and effects are areas for future investigation. 
Since adipocytes express CD36 mRNA most highly of all cells (Figure 25) and 
adipocytes are frequently involved in pathogenesis, the localization of CD36 in this cell 
type is likely very important to its function.  Indeed, human adipocyte tissue has been 
documented to contain CD36 mainly in the PM (~80%) and in the cytosol (~20%) with 
very little CD36 localized in the mitochondrial membrane [279].  CD36 null mice have 
been shown to have impaired FA uptake by 60-70% in adipose tissue [261], presumably 
due to lack of CD36 in the PM, and many studies in other cells and tissues have given 
similar reductions in FA uptake and/or metabolism [207], although a mechanism for direct 
FA uptake by CD36 was not decisively shown in these studies, nor was the time-scale of 
uptake carefully resolved. 
Not only is the CD36 localized on the PM of adipocytes, it has also been found in 
adipocyte caveolae.  One group used a stringent caveolae immuno-isolation protocol that 
found, along with the caveolins and cavins, the only proteins in adipocyte caveolae are 
semicarbazide-sensitive amine oxidase (SSAO) and CD36 [281].  These lipid-rich regions 
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are prime candidates for FA uptake or metabolic activation, especially since Cav-1 
augments TG formation [158]. 
While controversies of CD36 in FA transport and metabolism were discussed in 
Chapter 1, adipocyte FA uptake was not discussed.  Our group has recently designed new 
experiments to examine the roles of CD36 in uptake of FA into cells with and without 
CD36 expression.  For these experiments, we first utilized adipocytes because they have a 
high abundance of CD36.  However, since adipocytes also have an abundance of 
intracellular transport proteins and enzymes that facilitate overall FA uptake, these cells 
were found to be too complicated a system to decipher individual steps of FA transport and 
metabolism.  To address this issue of CD36 involvement in FA uptake, we designed new 
experiments with HEK293 cells (published here [282] and further discussed in Chapter 
4).  Briefly, we used HEK293 cells as a model because they do not endogenously express 
CD36.  After transfection of CD36, our HEK293 cells showed comparative levels of CD36 
expression to 3T3-L1 adipocytes and CD36 expression was mainly PM localized.  Next, 
using real-time fluorescent assays with pH sensitive dye (BCECF-AM) trapped inside the 
cells, we found that FFA uptake across the PM occurs within secs with or without CD36 
presence, and the main effect of CD36 was “trapping” FA inside cells in the form of TG 
droplets.  This also confirmed earlier studies that FFA can diffuse by “flip-flop” through 
the bilayer of protein-free small unilamellar vesicles (SUV’s), or cells, within sec-msec 
[75, 77, 283]. 
Prior to our recent publication, numerous models of FFA uptake by CD36 have 
been proposed, but nearly all models for the CD36: FA interaction and direct FA uptake 
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have lacked real-time data.  In addition, there is no biophysical basis or data to support 
most models of transport. One FA uptake model, for example, proposes possible pore or 
channel formation by CD36 dimers or tetramers [10] but, to date, CD36 clustering has only 
been seen with oxLDL as well as malaria-infected cell binding and has been shown not to 
occur in many other contexts [190, 284].  FFA transport through the membrane-associated, 
hydrophobic, regions of CD36 has also been proposed, but this too remains theoretical, 
with no conclusive data.  Adding intrigue to the area of FA uptake and fat metabolism was 
the finding that FA binding protein (FABPpm and FABPc) can interact with the 
extracellular domain of CD36 [285].   
A confounding factor in studies of FA uptake, in particular, is that within a 
physiological system, FA can enter or leave cells simultaneously (unless they are “trapped” 
by acyl-CoA activation) and the methods used to quantify FFA uptake in cells and synthetic 
vesicles have often utilized endpoint measurements (radioactive-labeled FA) or only 
measure the initial uptake rate, which ignores downstream FA metabolism (which often 
drives the rate of FFA into cells) and FFA efflux from cells (i.e. back to albumin, when 
present) [286].  In fact, a body of evidence, summarized in a recent review shows that 
intracellular metabolism increases FFA uptake through increased activation of fatty acids 
to acyl-CoAs (a “trapping” mechanism, to keep FFA inside cells), including long-chain 
acyl-CoA synthetase (ACSL) or very-long-chain acyl-CoA synthetase (ACSVL), at the 
inner PM leaflet or at sites of downstream metabolism [286].  This enhanced FA 
metabolism can then reduce the amount of FFA efflux from the cells, thereby increasing 
the net flux of FA into cells, potentially skewing data attempting to measure membrane 
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protein-mediated FA uptake.  Understanding FFA uptake is particularly important in 
adipocyte cells, where lipid engorged adipocytes can excrete cytokines and FFA that lead 
to inflammation, insulin desensitization, and other pathological conditions [287, 288]. 
CD36 expression is further involved in adipocyte cell signaling and fate by coinciding with 
pre-adipocyte to adipocyte differentiation [289].  This is likely because CD36 is a target 
gene of the nuclear receptor PPAR-γ [290] and raising levels of activated PPAR-γ—a 
“master regulator of adipocyte differentiation” [291]–drives adipocyte differentiation and 
affects CD36 expression simultaneously.  The connection between PPAR-γ and CD36 
levels, furthermore, is of interest because as cells undergo adipocyte differentiation, they 
then express increased levels of CD36, presumably to increase FA metabolism.  PPAR’s 
can be activated simply by binding LCFA [292], which suggests interplay between CD36 
bringing LCFA into the cells and PPAR-γ upregulating CD36 gene expression; i.e., a feed-
forward system. In addition, it has been shown that transcriptional regulation of CD36 
expression is accomplished through CCAAT/enhancer-binding protein alpha (C/EBPα) 
[293], which is another regulator of adipocyte differentiation (cross-regulation between 
C/EBPα and PPAR-γ has also been shown to be important in maintaining the adipocyte 
differentiated state) [294] .  Four members of the C/EBP family, α,β,δ, and CHOP-10, are 
expressed at specific times during adipogenesis, where C/EBPβ and δ are induced very 
early and have been shown to play a crucial role in initiating the differentiation of 
preadipocytes by activating the expression of PPAR-γ. C/EBPα is induced relatively late 
during adipogenesis in culture, after the induction of PPAR-γ [294]. 
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PPAR-γ has also been shown to be activated by oxLDL [295] and a well-established 
role of CD36 is oxLDL uptake [203].  This gives rise to another feed-forward relationship 
between PPAR’s and CD36. Since, currently, ~30% of adults in America are obese [296], 
furthering these investigations of CD36 and its involvement in adipocyte homeostasis has 
never been more timely. 
2.2.3. Cardiac and Skeletal Muscle 
In skeletal and cardiac muscle, which also show very high mRNA CD36 expression 
levels (Figure 25), the CD36 signaling and localization story is especially unique.  In an 
examination of human obesity and type 2 diabetes, LCFA transport into skeletal muscle 
was seen upregulated ~4-fold in the sarcolemma in both obese and diabetic humans.  This 
transport was found specifically to be due to CD36 localization—not increased CD36 
expression—from the PM to the sarcolemma [297].  This finding led to a bevy of 
publications on CD36 translocation in skeletal and cardiac muscle and a recent (2011) 
review of the topic [206].   
It has also been shown that both insulin and contraction similarly effect CD36 and 
GLUT4 trafficking, through similar respective signaling pathways (Figure 27) [206, 285].  
However, insulin resistance and type 2 diabetes show CD36 permanently relocating to the 
sarcolemma, whereas GLUT4 internalizes but does not colocalized to the sarcolemma 
[298].  Hence, contraction-mediated signaling is important for myocytes to increase energy 
production through LCFA but the above study postulates that insulin insensitivity appears 
to be the likely culprit in overabundant CD36 sarcolemma localization. 
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Figure 27. Similarities between CD36 and GLUT4 trafficking 
The effects on CD36 and GLUT4 trafficking by (A) insulin- and (B) contraction- mediated signaling. Figure 
derived and modified from [206]. 
 
 
This difference in insulin-resistant trafficking of GLUT4 (internalizing) and CD36 
(trafficking to sarcolemma) was traced to differences in the actin filaments, cellular pH 
gradients, and vesicle-associated membrane proteins (VAMPs), with no observed 
differences in coat-proteins involved in GLUT4 versus CD36 trafficking [206].  
Additionally, it was later verified that CD36 travels along F-actin, using nanoparticle 
tracking [284]. A related finding showed that electrical stimulation of muscle also increases 
mitochondrially localized CD36 (~35% increase) and not overall CD36 expression, 
suggesting further roles in metabolism; especially since carnitine palmitoyltransferase I 
(CPTI) was coimmunoprecipitated with CD36, in the same study [226]. Since circulating 
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FFA and glucose are the main sources for energy production in the heart [299], it is 
increasingly clear why trafficking CD36 away from the myocyte surface and filling the 
sarcolemma with excess lipid (usually, alongside insulin resistance) might lead to major 
cardiac dysfunction. 
2.2.4. Macrophages and Leukocytes 
In 2006, CD36 was identified in a soluble form in the plasma (sCD36) and shown 
to serve as a marker for insulin resistance and type 2 diabetes [300].  Recently, however, 
sCD36 has been contended to be not truly soluble and not to be a proteolytic fragment, but 
instead a component of circulating microparticles or contaminating myeloid cells (i.e. 
monocytes, macrophages, neutrophils, basophils, eosinophils, megakaryocytes, etc.)  
[301]. 
CD36 expressed in macrophages has a well-characterized and “infamous” role in 
oxLDL uptake, apparently through CD36 recognition of lipid moieties on the oxLDL [302] 
(also seen in computational modeling [303]).  This oxLDL uptake has been shown to be 
independent of caveolae, caveolin-1, and clathrin [304], although work in this thesis has 
found that oxLDL binds CD36 in a mechanism dependent upon FFA [41]. 
Oxidized LDL uptake by CD36 in macrophages leads to signaling activation of Lyn 
kinase, MEKK2, and c-Jun N-terminal kinase (JNK), and resulting in the phagocytosis of 
pro-atherogenic oxLDL [305].  Furthermore, downstream it has been observed that PPAR-
γ is trans-activated via a p38MAP kinase-dependent pathway which upregulates CD36 
expression [290] in a protein kinase c (PKC) dependent fashion [306].  PKC also recruits 
activation of the transcription factor NF-κB [307] upon oxLDL stimulation.  This, in turn, 
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triggers release of tumor necrosis factor alpha/beta (TNFα/β), interleukin (IL)-1β, IL-6, 
and interferon beta and gamma (IFNβ/γ), all of whose expressions are significantly 
decreased in CD36-deficient macrophages, discovered in CD36 null humans (Figure 28) 
[308]. 
 
 
Figure 28. A summary of CD36 signaling in macrophages upon oxLDL binding and inflammatory 
pathways that are involved 
Inflammatory pathways stimulated by oxLDL binding to CD36 include NF-κB and JNK2. PPARγ (which 
includes FA binding sites [309]) also activates the CD36 promoter.  Figure derived and modified from [238].  
 
CD36 expressed in macrophage cells has other roles besides oxLDL binding and 
uptake. Macrophages that engulf apoptotic cells through phagocytosis also employ the 
CD36 receptor by interacting with TSP, and the subsequent signaling cascade inhibits the 
secretion of pro-inflammatory cytokines TNF-α, IL-12, and IL-1β while leading to the 
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secretion of IL-10 (an anti-inflammatory cytokine), though the details of these events are 
not yet fully elucidated [203].  This anti-inflammatory cascade driven by apoptotic cell 
binding is essentially the opposite of CD36-mediated macrophage oxLDL binding, where 
TNFα/β, IL-1β, IL-6, and interferon beta and gamma (IFNβ/γ) were found to be released. 
Furthermore, phagocytosis has also been shown to occur in mononuclear 
phagocytes through a different mechanism involving CD36.  In cooperation with αvβ3 
integrin on the surface of mononuclear phagocytes, CD36 recognizes anionic phospholipid 
phosphatidylserine (PS)—PS which is flipped by Flippase from the inner membrane to the 
outer membrane during apoptosis and seen in distress events (e.g. a myocardial infarction) 
[310].  This recognition also initiates uptake of the apoptotic cells [210].  These 
mechanisms are notably distinct from CD36 involvement in uptake of malaria infected 
erythrocytes, which is accomplished through the binding of PfEMP-1 (discussed above) 
independent of TSP and αvβ3 integrin [249].  
An exciting recent (2013) discovery in the CD36 field involves macrophage cells 
and HIV.  Seeking HIV treatments, it was discovered that soluble anti-CD36 antibodies 
inhibit HIV-1 release of virions from HIV-1 infected macrophages, by clustering newly 
formed virions at their site of budding [311].  This creates a new strategy of treatment that 
hopefully will continue to be developed and also has potential to be useful in decreasing 
atherosclerotic lesions. 
Finally, it is interesting to note that macrophage CD36 regulation can also be 
achieved using two unique and opposing strategies: (1) aspirin has been shown to increase 
CD36 expression and (2) EPA/DHA treatment of macrophages has been shown to decrease 
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CD36 mRNA and protein [312, 313].  Since macrophage CD36 can play pro-inflammatory 
roles (oxLDL uptake) and anti-inflammatory roles (apoptotic cell uptake), deciding 
whether it is therapeutic to increase or decrease CD36 expression, currently appears as a 
paradox. However, it is important to note that balance between pro- and anti-inflammation 
is the key to healthy physiology, and is often very difficult to determine.    
2.2.5. Endothelial Cells 
 In endothelial cells, the most prominent role of CD36 is in binding TSP and the 
ensuing signaling.  Interestingly, the CD36-mediated signaling in endothelial cells has 
elements of the macrophage cell signaling pathways downstream from (1) oxLDL binding 
to CD36 and (2) macrophage engulfment of apoptotic cells through CD36 binding TSP.  
However, the endothelial cell pathway involved in binding TSP is not simply a reiteration 
of stimulated pathways used by macrophages binding TSP or oxLDL.   For example, when 
TSP binds CD36 in endothelial cells, the proto-oncogene tyrosine-protein kinase family 
member, Fyn kinase, is recruited to and activated by the intracellular domain of CD36.  In 
macrophage cells, when oxLDL binds CD36 the recruited and activated tyrosine-protein 
kinase family member is Lyn kinase (Figure 28).  Rather than utilize Fyn kinase to signal 
inflammation though JNK2 and PKC, however, endothelial cells signal apoptosis from 
caspases activated downstream of p38 MAPK [210] (Figure 29). At this point, 
macrophages that engulf apoptotic cells are more similar to the endothelial cell response, 
rather than macrophages binding oxLDL.  
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CD36 is localized in caveolae in endothelial cells.  Upon TSP binding, an apoptotic pathway can occur 
through fyn kinase. Figure derived and modified from [210].  
 
One of the reasons that endothelial cell CD36 binding of TSP is well studied and 
characterized is due to the anti-angiogenic signaling, making this pathway a potential 
cancer therapeutic target.  For instance, while TNF-α and FasL are activated by the CD36-
TSP interaction in endothelial cells, these have been shown not to function primarily as 
inflammatory signals but instead function as downstream inhibitors of pro-angiogenic 
signaling from growth factors such as vascular endothelial growth factor (VEGF) or 
fibroblast growth factor-2 (FGF-2; Figure 30) [204].  
 
 
 
Figure 29. Signaling pathway summary of CD36 binding TSP in endothelial cells 
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While growth factors, such as VEGF, signal angiogenesis, CD36 can again signal via fyn kinase to inhibit 
this angiogenesis. Figure derived and modified from [204]. 
 
Since endothelial cells form the surface lining of different environments (i.e. the 
gut, the blood and lymph vessels, etc.), CD36 may play different roles depending on 
communication with adjacent cells.  Distinguishing the potential differences of CD36 in 
cells at different interfaces has not been done, but may yield differing results. For example, 
like adipocytes, CD36 expressed in endothelial cells CD36 has been shown to localize in 
caveolae [314], provided that CD36 is palmitoylated according to a massive proteomic 
Figure 30. CD36 anti-angiogenic signaling pathway and GFR crosstalk 
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study [315].  This localization, however, may be specific to the enterocytes and may not 
occur in blood vessels.  
A renewed interest in the role of CD36 in endothelial cells has recently been 
initiated by the finding that CD36 and intestinal alkaline phosphatase (IAP) work in a 
coordinated manner to optimize FA transport across enterocytes (most likely through 
trapping FA inside cells, similar to mechanisms elucidated studying adipocytes and model 
HEK293 cells [282]).  The FA transport across enterocytes was found to be dependent 
upon the phosphorylation state of CD36, giving rise to a new paradigm in direct regulation 
of CD36 [316, 317] (Figure 31).   
In early phosphorylation studies published in Science, CD36 ectodomain amino 
acids 87-99 were shown to be phosphorylated by PKC (normally, PKC is intracellular, so 
this is unexpected), and phosphorylation allowed immature collagen to bind CD36 but 
inversely ablated TSP binding to CD36 [318].  More recently, PKC has been shown to be 
membrane bound, at least some of the time, and even regulated by monocytes in the cardiac 
ventricles [319], making extracellular, vesicular, or membrane PKC phosphorylation of 
CD36 possible, although not yet shown in vivo. Further studies in 3T3 fibroblasts have 
demonstrated that CD36 is constitutively phosphorylated and readily dephosphorylated 
upon exogenous IAP addition and that CD36 and IAP coimmunoprecipitate [320]. Since 
ectophosphorylation of CD36 has been shown to inhibit uptake of FFA (again, based on 
longer time scale studies and, possibly, FFA being trapped inside of cells) where 
dephosphorylation of CD36 by IAP reverses this inhibition [321], these findings may 
significantly add to the ability to therapeutically manipulate CD36 in the near future.  
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Recent studies have further shown that the kinase phosphorylation sites on CD36 are Thr92 
and Ser237, of which the Thr92 is PKC phosphorylated and it is unknown whether Ser237 
is ever phosphorylated [316]. 
 
 
 
 
 
 
 
 
 
 
CD36 functions differently in different cell types, in part, due to expression of proteins such as IAP.  When 
IAP dimerized, CD36 has been found to colocalize with IAP and promote LCFA uptake.  Furthermore, this 
occurs within lipid rafts. Figure derived and modified from [316, 317].   
 
2.2.6. Microglia 
 The brain is one area where CD36 has been shown to play an important role, despite 
relatively low levels of mRNA showing CD36 expression in the brain tissues used in the 
Affymetrix array (Figure 25), are the microglial cells (“brain macrophages”).  In a seminal 
paper in 2004, it was demonstrated that in microglia, a CD36-dependent signaling cascade 
is activated via amyloid beta (Aβ) involving the Src kinase family members, Lyn and Fyn 
Figure 31. Schematic depiction of CD36 and dimerized GPI-anchored intestinal alkaline phosphatase 
in a cholesterol-rich plasma membrane raft 
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(as discussed above, under “Macrophages and Leukocytes” as well as “Endothelial Cells”), 
and the mitogen-activated protein kinase, p44/42 [214].  In the same study, macrophages 
(in place of microglial cells) were exposed to Aβ and were found to signal through the 
same CD36 pathways.  It was also shown that disruption of specific Src kinases 
downstream of CD36 inhibited macrophage inflammatory responses to Aβ—including 
ROS and chemokine production—and this inhibition resulted in “decreased recruitment of 
microglia to sites of amyloid deposition in vivo” [214].  These findings present novel 
therapeutic potential in Alzheimer’s disease studies as well as new research avenues for 
preventing macrophage-induced inflammation.  The respiratory burst and phagocytosis due 
to Aβ was later shown in microglia to be linked to the Vav guanine nucleotide exchange 
factor [322], summarized in Figure 32. 
 
 
 
 
 
 
 
 
CD36 has been shown in many studies to bind Aβ.  In both microglia and macrophage cells, this Aβ binding 
to CD36 activates fyn kinase, which leads to secretion of both inflammatory factors and upregulated 
phagocytosis. Figure derived and modified from [203]. 
 
Figure 32. Amyloid beta initiated microglial signaling through CD36 
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 Furthermore, with recent insights into prion proteins binding Aβ oligomers and 
inhibiting their neurotoxicity (in vivo) [323], it follows that microglial CD36 might be 
involved with prion proteins as well.  Indeed, it was found that CD36 participates in prion 
protein activation of microglia [324].  Furthermore, by using drugs to target downstream 
kinases activated by CD36-prion interactions, aspects of prion neurotoxicity (e.g. nitric 
oxide synthase [NOS] activation) were abrogated [325]. These findings give rise to 
potential new CD36-related therapeutic targets and strategies both for Alzheimer’s disease 
and prior diseases. 
 
2.3. Beneficial Functions of CD36 
 Although research in CD36 expression and activation predominantly focuses on 
CD36 in various pathologies (i.e. foam cell formation or Aβ-induced inflammation), CD36 
has been shown to have numerous beneficial functions.  This includes anti-tumor 
properties, anti-inflammatory and anti- pathogenic/parasitic functions, certain positive 
effects of increased FA esterification in organs such as the brain, and even potentially 
positive aspects relating to cardiovascular disease. 
CD36 is involved in anti-tumor activity by significantly attenuating in vitro anti-
angiogenic responses to TSP-1, including blockade of cell migration in response to FGF-2 
[326].  CD36 downregulation also has been shown to broadly be correlated with poor 
clinical outcome in terms of development of metastatic or recurrent disease [327].  
Furthermore, it was recently shown that TSP-2 interaction was not only anti-angiogenic in 
a CD36 dependent manner, but also pro-apoptotic toward human dermal microvascular 
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endothelial cells through a CD36 dependent mechanism involving caspace-3 activation in 
vitro, leading to additional anti-tumor activity [255].   
 CD36 plays important anti-inflammation and pathogen-removing roles.  During 
macrophage phagocytosis of apoptotic cells, a beneficial anti-inflammatory signal has been 
shown to be in part mediated by CD36 [328].  Advanced glycation end-products (AGE) 
are also “scavenged” by CD36 [213], which leads to engulfment of products that can 
otherwise form inflammation-inducing aggregations.  CD36-/- mice also have been seen to 
have greatly reduced capacity to clear pathogens such as bacteria and fungus, especially S. 
aureus [215, 216, 238].  Furthermore, CD36 is not only involved in the sequestration of 
the Malaria parasite, but may even induce an innate immune response to infection that 
promotes additional clearance [212]. 
 Roles of CD36 in FA intracellular metabolism undoubtedly contribute to lipid 
homeostasis and not just over accumulation of fat.  For example, the process of FA delivery 
from adipose tissue to muscle mitochondria involves many regulatory steps, but exercise-
induced, CD36-mediated, FFA entry into the mitochondria of skeletal muscle has been 
shown to be beneficial, unless the FA becomes excessive [209]. Despite the established 
unhealthy and even pathogenic effects of lipid overload (i.e. obesity), FA are vital 
components in diet and contribute to a plethora of beneficial processes, including metabolic 
energy generation and storage, PM synthesis, and protein anchoring [329].  In addition, 
many FFA, especially polyunsaturated FA, have hormone-like properties since they can 
significantly alter gene expression via nuclear receptors such as HNF4 and PPAR’s, initiate 
insulin release through activation of the G-protein-coupled receptor (GPCR) GPR40, 
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modulate toll-like receptor (TLR) signaling in a number of cell types promoting innate 
immunity, and suppress appetite by inhibiting the release of neuropeptide Y (NPY) and 
Agouti-related protein (AgRP) in a subpopulation of hypothalamic neurons [329].  These 
effects all add beneficial aspects to CD36 enhancement of intracellular FA metabolism, in 
specific settings.  
 In another example, CD36 deficient mice have been shown to have normal patterns 
of activity, anxiety, and exploration of novel environments, but appear to have a significant 
impairment in learning ability, because of  FA metabolic defects within the brain of (most 
likely from lack of FA “trapping” inside of cells through FA-CoA activation) [330].  
Although the brain is clearly protected against over accumulation of triglyceride, FA are 
constantly being turned over. Some FFA are used for energy, and new FA are required for 
phospholipid remodeling [331, 332]. Despite the common treatment of the brain as a single 
unit or organ (e.g. using merely white matter versus grey matter to compare FA uptake 
differences in brain [333]), the complexity and variation within the different regions of the 
brain are diverse and each region has unique activities and metabolic preferences [334, 
335].  
 Along with FFA transport/uptake, probably the preeminent CD36-related 
controversy surrounds contradictory data in mouse models lacking CD36 from different 
labs and whether higher expression levels of CD36 play an overall healthy or pathologenic 
role.  In CD36-/- apoE-/- double null mice by Moore et al., the loss of CD36 in apoE−/− mice 
did not reduce and may even increase, the extent of atherosclerotic lesions at the aortic 
valve level, giving rise to a view that CD36 expression is beneficial to health [336].  
  
90 
 
However, CD36-/- apoE-/- double null mice studied in the Silverstein lab, demonstrated 
reduced atherosclerotic lesions (Figure 33) [203].  Additional incongruences led to an 
extensive review attempting to reconcile such robust discrepancy between labs with CD36-
/- apoE-/- mice [238].  Possibilities that were discussed included the potential lack of 
backcrossing (in the CD36-/- apoE-/- mice used) or the presence of pathogens in lab mice 
(since CD36 scavenges various pathogenic particles, as described above).  Furthermore, 
aortic arches were dissected at different time measurements: Silverstein group, at 8 weeks 
and Moore et al., at 12 and 35 weeks. In vivo serial MRI to monitor plaque progression 
over time would be valuable to compare the models in different labs and research appears 
to be started in this area [337, 338]. 
 
 
 
 
 
 
 
 
 
 
 
Mice were dissected and the aorta opened longitudinally. The entire aorta from apo E–null (a) and CD36-apo 
E double-null (b) are shown. Oil red-O–stained lesions occur in all regions of the aorta from these apo E–
null mouse, whereas in the aorta from the CD36-apo E double-null mouse lesions are seen primarily in the 
aortic arch. Images taken at ×20 from the Silvertein group’s mice. Figure derived and modified from [203]. 
 
Figure 33. Atherosclerotic lesion distribution and morphology in control and CD36-deficient mice 
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Aiding in the judgement of the CD36-/- mouse model debates, are long-term, 
ongoing observations in healthy human cohorts that do not express CD36.  If CD36 was 
purely pathological, why is it that [human] “CD36 deficiency has little influence on the 
pathophysiology of hypertrophic cardiomyopathy” [339]?  Even beyond having “little 
influence”, a more recent (2012) study showed that humans that express no CD36 are 
associated with enhanced atherosclerotic cardiovascular diseases [264].  These types of 
findings are discouraging to researchers proposing to utilize mAb injections in order to 
decrease atherosclerotic-type diseases.  They also demonstrate that CD36 has characterized 
or uncharacterized positive effects in macro-physiology. 
 
2.4. Pathogenesis Involving CD36 
While a diverse array of beneficial roles for CD36 exist, it is clear that CD36 has a 
function in pathology as well. This is especially seen within CVD and foam cell formation 
via pro-atherogenic LDL (summarized by Figure 34).  In fact, CD36 expression can even 
induce vascular smooth muscle cells to differentiate into pro-atherogenic foam cells [340]. 
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Oxidized LDL and other inflammatory factors surrounding endothelial cells (EC) cause scavenger receptor 
CD36 activation and ultimately foam cell formation. Figure derived and modified from [210]. 
 
Furthermore, CD36 and scavenger receptor AI/II (SRAI and SRAII) have been 
shown to account for up to 90% of the modified LDL uptake in macrophages [341]. These 
results led to a study using apoE null mice and the addition of a hexarelin derivative (a 
synthetic growth hormone which has no growth hormone releasing properties, which 
binds/blocks CD36).  With hexarelin, atherosclerosis and oxLDL uptake were seen to be 
decreased [342], suggesting a possible prototype for a novel class of anti-atherosclerotic 
agents based on CD36 inhibition. 
Insulin resistance and type 2 diabetes both exhibit permanent CD36 relocation to 
the sarcolemma, at the same time GLUT4 internalizes [206], leading to both large amounts 
of lipid within the sarcolemma and decreased ability for cardiac cells to metabolize FA 
Figure 34. The involvement of CD36 in pro-atherogenic foam cell formation 
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[299].  These relocations of GLUT4 and CD36 are highly problematic because both 
circulating FA and glucose are the main sources for energy production in the heart.  And 
CD36 not only is affecting the heart and other skeletal muscles [297] during insulin 
resistance—it may be playing a role in causing insulin resistance—shown in recent (2011) 
knockdown studies of CD36 by siRNA in pancreatic β-cells that gave rise to decreased 
fatty acid induced apoptosis [257].  In terms of insulin sensitivity, pancreatic β-cell 
proliferation and upkeep is a necessary and beneficial process and apoptosis of pancreatic 
β-cells through CD36 induced mechanisms is highly pathological, ultimately leading to 
decreases in insulin synthesis similar to that seen in type 2 diabetes [343]. 
Despite healthy anti-angiogenic properties, CD36 has also been shown to increase 
melanoma cell migration.  In macrophage cells, integrin α5β3 was seen to bind CD36.  Two 
other integrin family members, α3β1 and α6β1, also were found to bind CD36 and increase 
haptotactic cell migration in cultured melanoma cells while eliminating binding of all other 
alpha chain integrins, shown using migration assays, co-IP’s, and confocal microscopy 
[344]. 
CD36 has been shown to be expressed on platelets, too, further adding to potential 
arterial plaque formation via CD36, but the role of CD36 in platelets is largely unknown 
[203].  Overall, it is likely that many added functions of CD36 in pathological physiology 
will continue be elucidated, especially due to the diverse nature of CD36 as a scavenger.  
The key will be to promote the beneficial roles of the CD36 receptor, while at the same 
time specifically inhibiting the tumorigenic, atherosclerotic, inflammatory-inducing 
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functions of CD36.  Finding these types of drugs, at this point, is already underway and 
appears to be promising [345]. 
CD36 is “intimately involved in lipid metabolism and homeostasis, and strongly 
implicated in pathological conditions associated with metabolic dysregulation, including 
obesity, insulin resistance, diabetes, diabetic nephropathy, and atherosclerosis” [346]. The 
 Monocyte-derived macrophages isolated from patients with deficient expression 
of CD36 bind less oxLDL and accumulate less cholesteryl ester (CE) from oxLDL than 
cells derived from normal controls [241], and oxLDL uptake is damaging to human 
pancreatic β-cells [347].  Pancreatic β-cells incubated in high glucose have increased 
expression of CD36. Macrophages from ob/ob mice have increased uptake of modified 
LDL, which correlates to upregulation of CD36, possibly because of defective insulin 
signaling in macrophages [348]. Recently, a circulating form of CD36 was identified in 
human plasma as a novel biomarker for T2D [346], and its elevated levels correlated with 
increased risk of T2D [349]. 
 
 
 
 
 
  
95 
 
CHAPTER THREE: MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Chemicals and Compounds 
All reagents for buffer solutions were purchased from Sigma-Aldrich (St. Louis, 
MO), unless otherwise stated.  DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DC-
Chol (3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride), DOPE 
(1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) and DPPC (1,2-dipalmitoyl-sn-glycero-
3-phosphocholine) were purchased from Avanti Polar Lipids (Alabaster, AL).  
Dithiothreitol (DTT), tris (2-carboxyethyl) phosphine hydrochloride (TCEP), n-dodecyl-
beta-D-maltoside (DDM), 100x HALT protease inhibitor cocktail without EDTA, and 
bicinchoninic acid (BCA) protein assays were purchased from Thermo Fisher Scientific 
(Wilmington, DE).  Sulfo-N-hydroxysuccinimide (sulfo-NHS), 1-ethyl-3-(3-
dimethylaminopropyl)carbodimide hydrochloride (EDC), sodium acetate buffer (pH 4.5), 
and ethanolamine-HCl (pH 8.5) were purchased from Bio-Rad (Hercules, CA). The acyl 
CoA synthetase inhibitor, triacsin-C, was from Enzo Life Sciences (Farmingdale, NY). 
3.1.2. Fatty acids 
Oleic acid (OA), elaidic acid (EA), palmitic acid (PA), and myristic acid (MA) were 
purchased from Sigma-Aldrich (St. Louis, MO).  Docosahexaenoic acid (DHA), 9S-
Hydroxy-10E,12Z-Octadecadienoic Acid (HODE), linoleic acid (LA), α-linolenic acid 
(ALA), arachidonic acid (AA), and eicosapentaenoic acid (EPA) were purchased from 
Cayman Chemicals (Ann Arbor, MI). 
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3.1.3. Vectors and Lentivirus 
For PTRF/Cavin-1 and Caveolin-1 (Cav-1), the cDNA encoding full-length 
PTRF/Cavin-1 and Cav-1 were synthesized by GenScript (Piscataway, NJ) and 
subsequently cloned into the pCI-neo empty vector from Promega (Madison, WI), using 
the XhoI-XbaI cloning site to insert either PTRF/Cavin-1 or Cav-1 resulting in pCI-neo-
PTRF/Cavin-1 and pCI-neo-Cav1, respectively.  Containing the same vector backbone, 
human pCI-neo-CD36 and human pCI-neo-CD36-12His (C-terminal 12-His tag) were kind 
gifts from Dr. Kenneth Linton (MRC Clinical Sciences Centre, Imperial College, London, 
United Kingdom) [242].  The pCI-neo plasmid was chosen for certain experiments since it 
contains a cytomegalovirus immediate-early promoter (CMV) promoter, designed for 
extremely high protein expression, especially in HEK293 cells (Figure 35).  Similarly, two 
custom lentiviral constructs were designed, cloned, and packaged into crude lentiviral 
particles (GeneCopoeia, Rockville, MD) for use in (i) experiments mimicking 
physiological conditions, and (ii) experiments optimized for highest possible expression of 
CD36 in order to purify the protein.  To mimic physiological conditions, a lentivirus that 
transfers the human CD36 gene with a PGK promoter (lentiviral titer = 2.8 x 108 copies 
per mL) was designed and utilized. For experiments where purifying CD36 was an 
objective, a lentivirus was developed and used that included the human CD36 gene under 
a CMV promoter, attached to a Tev cleavage site, followed by an N-terminal 6x-Histidine 
tag that could be removed by Tev protease (lentiviral titer = 2.8 x 108 copies per mL). 
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Human ubiquitin C promoter (UBC), phosphoglycerate kinase 1 promoter (PGK), human elongation factor 
1α promoter (EF1α), cytomegalovirus immediate-early promoter (CMV), chicken β-actin promoter coupled 
with CMV (CAGG), simian virus 40 early promoter (SV40), and tetracycline-responsive element promoter 
(TRE).  Prevalent mammalian cell lines were used to test these promoters (y-axis), including MRC5, HT1080, 
HEK293T, 129TF, MEF, C2C12, MSC, and CMMT cells (figure from [350]). 
 
 
 
 
 In addition to pCI-neo-CD36, -Cav-1, and -PTRF/Cavin-1 plasmids, 
additional plasmids expressing these proteins (CD36, Cav-1, or PTRF/Cavin-1) attached 
to fluorescent tags were used, as well as other plasmids expressing additional caveolae-
forming genes (Cavin-2/SDPR or Cavin-3/SRBC).  These include PTRF/Cavin-1-
mCherry, which was a kind gift from Carsten Gram Hansen (MRC Laboratory of 
Molecular Biology, Cambridge, UK). Cavin-2/SDPR and Cavin-2/SDPR-mCherry also 
Figure 35. Protein (GFP) expression levels from the same plasmid DNA containing these differing, 
commonly used promoters 
  
98 
 
from Carsten Gram Hansen, Cavin-3-HA obtained from Addgene #27711 (Cambridge, 
MA), Cav-1-eGFP which was a kind gift from Paul Pilch (Boston University, Boston, MA), 
Cav-1-eYFP which was a kind gift from Robert Leutterforst (Institute for Molecular 
Bioscience, University of Queensland, Queensland, Australia), pcDNA3.1-empty and 
pcDNA3.1-CD36-GFP which were a kind gift from Su Xu (Beth Israel Deaconess Medical 
Center, Boston, MA), N1-pDsRed-CD36 which was also a kind gift from Su Xu, and 
finally pTRE2-CD36-Tet-OFF which was a kind gift from Alexander Bocharov (National 
Institutes of Health, Bethesda, MD). 
3.1.4. Antibodies, Western Blotting, Immunoprecipitation, and Immunofluorescent 
Staining Reagents 
For western blotting, #PA1-16813 rabbit anti-CD36 polyclonal antibody was 
purchased from Thermo Fisher Scientific (Wilmington, DE), as well fluorescent 
SuperSignal West Femto developing substrate, SuperBlock T20 (used for blocking with 
glycoproteins, such as CD36), StartingBlock (used for blocking with non-glycosylated 
proteins, such as Cav-1), BlockerCasein (used for blocking phosphoproteins, such as 
PTRF/Cavin-1), and Spectra Multicolor Broad Range Protein Ladder (#26634). Normal 
rabbit IgG #2729 was purchased from Cell Signaling Inc. (Danvers, MA) and both 
monoclonal rabbit anti-CD36 primary antibody (EPR6573) or monoclonal mouse anti-
CD36 primary antibody (JC63.1) were purchased from Abcam (Cambridge, MA).  Also 
purchased from Abcam were rabbit anti-PTRF/Cavin-1 antibody #48824 and rabbit anti-
Cav-1 antibody #2910.  Alexa Fluor® 488 goat anti-rabbit IgG antibody # A-11008, Alexa 
Fluor® 488 goat anti-mouse IgG antibody #A-11001, and ProLong® Gold antifade reagent 
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containing DAPI # P-36931, and Qdot® 655 Goat F(ab')2 Anti-Mouse IgG Conjugate 
(H+L) were all purchased from Invitrogen (Carlsbad, CA). Goat anti-rabbit HRP-
conjugated secondary antibody was purchased from Santa Cruz Biotechnology Inc., # sc-
2030 (Dallas, TX).  In order to study specificity and localization of purported ‘CD36-
specific inhibitor’ suflosuccinimide oleate (SSO), we consulted with Twentyfirst Century 
Biochemicals, Inc. (Marlboro, MA) to design a polyclonal antibody against SSO 
crosslinked to lysine, with the specific epitope design: SSO (sulfosuccinimide oleoyl)-
GQYIKANSKFIGITEL-OH.  This also included peptide synthesis, HPLC purification of 
the peptide to > 85%, sequencing by collision-induced dissociation tandem mass 
spectrometry (CID MS/MS), Nanospray MS, and HPLC analysis.  The final affinity and 
immunodepletion for the final rabbit anti-SSO polyclonal antibody production was from 
the best of three rabbits, accessed by dot blotting. 
3.1.5. Fluorescent Probes 
N-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (FPE), 2,7‑bis (2‑carboxyethyl)‑5‑(and‑6)‑carboxyfluorescein, 
mixed isomers (BCECF-acid), 2,7‑bis (2‑carboxyethyl)‑5‑(and‑6)‑carboxyfluorescein, 
acetoxymethyl ester (BCECF-AM), 8-Hydroxypyrene-1,3,6-Trisulfonic Acid, Trisodium 
Salt (pyranine / HPTS), 6-Dodecanoyl-2-Dimethylaminonaphthalene (laurdan), were 
purchased from Invitrogen (Carlsbad, CA). 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate (Dii-oxLDL) was purchased from Biomedical 
Technologies Inc. (Stoughton, MA). 
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3.1.6. Cell Culture 
All cells were cultured in a culture hood at 37°C and 5% CO2, using the same ratio 
of media per surface area of a given cell culture dish size (see Table 7; all ratios were based 
off 10mL of media for 100mm dish, to prevent cell hypoxia and other inconsistencies).  
Either HeLa cells or Human Embryonic Kidney Cells (HEK293 or HEK293T) were used 
for cell culture experiments and were purchased from American Type Culture Collection 
(ATCC; Manassas, VA).  The exception to this was cells used in suspension culture, which 
were Freestyle™ 293-F cells (#R790-07), adapted to grow in protein-free, serum-free 
media, purchased from Invitrogen (Carlsbad, CA).  Other suspension cell culture reagents 
were also purchased from Invitrogen, including protein-free (for protein purification) 
suspension culture Freestyle™ 293 Expression Medium (no supplementation required; 
#12338-018), Freestyle™ MAX transfection reagent (specific to the Freestyle™ 293-F 
cells; #16447100), and OptiPRO SFM transfection reagent (#12309-050).  For growing 
HeLa and HEK293/ T cells, most reagents were also purchased from Invitrogen, including 
phenol-free, low glucose (5mM) Dulbecco's Modified Eagle's Medium (DMEM; #11054-
020) supplemented with 50units/mL penicillin and 50μg/mL streptomycin (#15070-063) 
and 2mM glutamine (#25030-081), heat-inactivated fetal bovine serum (FBS; #10082-
139), enzyme-free cell dissociation buffer (#13151-014), Opti-MEM (#11058-021), and 
Lipofectamine 2000 transfection reagent (#11668-019). Charcoal-stripped FBS (#F6765) 
was bought from Sigma-Aldrich (St. Louis, MO).  Cells were grown on various sized 
Falcon tissue culture plates (6-well, 12-well, etc.) or Nunc dishes (60mm or 100mm), all 
purchased from Fisher Scientific (Waltham, MA).  For microscopy, 35mm Fluorodish 
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glass bottom cell culture dishes were purchased from World Precision Instruments 
(Sarasota, FL #FD35-100) and 8-well culture slides were bought from BD Falcon (Franklin 
Lakes, NJ). 
3.1.7. Supplies 
For purifying SUV’s after the sonication step, the gravity-flow Econo-Column® 
Chromatography Column with a stopcock was purchased from Bio-Rad (Hercules, CA), 
as were the ProteOn GLM SPR chips. Sephadex-G25 beads were from GE Healthcare 
Sciences (Pittsburgh, PA).  For flow cytometry, 35μM nylon mesh cell strainer and 
suspension cell culture ProCulture glass spinner flasks were purchased both for starting 
cultures in 125mL (#4500125) and growing large cell populations in 500mL (#4500500), 
from Corning (Corning, NY). Recombinant human CD36 (rCD36) lacking both the 
transmembrane and the small intracellular domains was from Sino Biologicals Inc., 
(Daxing, China), and Human Serum Albumin (HSA) was purchased from Sigma-Aldrich, 
(#A3782; St. Louis, MO).  Pierce Protein G Agarose beads for Immunoprecipitation (#PI-
20398) as well as 0.17mm gel-loading flat-tip pipette tips (#05-408-152) for bead 
aspirations, were purchased from Fisher Scientific (Waltham, MA).  For purifying DNA 
plasmids from bacteria, the QIAprep Spin Miniprep Kit or the Plasmid Plus Maxi Kit were 
purchased from Qiagen Inc. (Valencia, CA). For purifying CD36-12xHis, the 3mL resin-
column, HisPur Ni-NTA kit from Thermo Fisher Scientific (#88229; Wilmington, DE) was 
used.  For dialysis to remove imidazole from purified CD36, Thermo Fisher Scientific 
(Wilmington, DE) Slide-A-Lyzer Dialysis Cassettes were used.  To measure recombinant 
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protein purity, the Pierce Silver Stain for Mass Spectrometry kit was used from Thermo 
Fisher Scientific (#24600; Wilmington, DE). 
3.1.8. Instruments and Software 
For quantifying nucleic acid concentrations, the NanoDrop® ND-1000 UV-Vis 
Spectrophotometer was used from Thermo Fisher Scientific (Wilmington, DE). For SPR, 
the ProteOn XPR36 Protein Interaction Array system from Bio-Rad (Hercules, CA) was 
used. For fluorescence spectroscopy, the Spex Fluoromax-2 Fluorescence Spectrometer 
was used from Jobin Yvon (Edison, NJ).  Analysis of this data as well as all graphed data 
was done using Microsoft Excel software, and statistical analysis was performed using the 
free online calculator http://www.usablestats.com/, which incorporates each sample’s 
standard deviation into the Student’s t test. For high-definition scanning of gels and blots, 
the CanoScan LiDE 700F from Canon USA (Melville, NY), was used. For rotary 
evaporation, the RotoVapor R110 from Büchi Analytical Inc., (New Castle, DE) was used.  
 For two-photon microscopy, the LSM Live Duo Scan, mode-locked titanium-
sapphire laser with a multiphoton laser, was used from Carl Zeiss Microscopy, LLC 
(Thornwood, NY). For confocal fluorescence microscopy, a DSU Spinning Disk confocal 
microscope from Olympus Imaging America Inc. (Center Valley, PA) was used.  Image J 
from NIH (Bethesda, MD) was used to analyze microscopy images, with added plug-ins: 
Colocalization Colormap, Colocalization Finder, Color Profiler, Image-Based Tool for 
Counting Nuclei (ICTN), and LOCI Bio-Formats.  Additionally, for processing two-photon 
Laurdan images, a custom-written macro for Image J was used [97]. For flow cytometry, a 
FACScan from Benton Dickinson (Franklin Lakes, NJ) was used with the FL2 default filter 
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at 585/42 to quantify Dii-oxLDL fluorescence (Ex: 514, Em: 550) and data analysis was 
performed using BD Cellquest Pro v5.2 Software or FlowJo vX.0.7 (Ashland, OR).  For 
multi-well, Dii-oxLDL binding assays, the Infinite M1000 PRO fluorescence plate-reader 
from Tecan (Männedorf, Switzerland) was used. Data from all binding assays was analyzed 
using OriginLab version 8.6 software (Northampton, MA). The MiniSpin table-top 
centrifuge from Eppendorf (Hauppauge, NY), the J-6B centrifuge from Beckman Coulter 
(Danvers, MA), and the RC-5B or RC-5C Plus centrifuges from Sorvall / Du Pont 
Instruments (Newtown, CT) were used.  For quantifying protein concentrations, the 
Lambda 25 UV/Vis spectrophotometer was used from PerkinElmer (Waltham, MA).  
 
3.2. Methods 
3.2.1. Fatty Acid Stock Solutions 
For SPR experiments and Dii-oxLDL binding/uptake experiments, FA stock 
solutions were made fresh each day of experimentation. All FA were solubilized in methyl-
beta-cyclodextrin (MβCD) and water/PBS, at a molar ratio of 1 FA: 6 MβCD for OA, EA, 
and HODE, and 1 PA: 12 MβCD, and 1 MA: 10 MβCD, and 1 DHA: 1 MβCD. 
Specifically, 0.7988g of MβCD was weighed and brought up to 2mL’s with ddH20 by 
vigorous vortexing to make a 300mM stock solution.  For OA and HODE (same MW’s = 
296 g/mol), 500µL of 300mM stock MβCD was heated up to 70°C, and to this was added 
7.98µL of OA or HODE for a final 5mM FA: 30mM MβCD stock solution.  For EA, 
0.0141g of EA was added to 500µL of 70°C 300mM MβCD stock solution for a 5mM EA: 
30mM MβCD stock solution. For PA (MW = 254 g/mol), 0.0032g of PA was weighed and 
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added to 500µL of 70°C 300mM MβCD solution.  Into 1,600µL of ddH20, 400µL of the 
PA: MβCD stock was added for a 5mM PA: 60mM MβCD stock solution.  For DHA (MW 
= 329 g/mol), a 5mM MβCD stock was made by weighing 0.01331g of MβCD and bringing 
this up into 2mL of ddH20.  Next, 3.3µL of DHA was added to this 2mL MβCD stock 
solution at RT for a 5mM DHA: 5mM MβCD stock solution. For MA (MW = 228 g/mol), 
0.0057g of MA was added to 1mL of 70°C 250mM MβCD stock solution (0.3328g of 
MβCD into 1mL of ddH20), and 200µL of this MA: MβCD stock was added to 70°C 800µL 
of ddH20 for a 5mM MA: 50mM MβCD stock solution. Since these stock solutions were 
in water, they were added at various volumes into 200mM PBS to make final experimental 
concentrations.  For example, for 5µM OA, 1µL of 5mM OA: 30mM MβCD stock was 
added to 1mL of 200mM PBS, in an SPR experiment.  For 25µM OA, 5µL of 5mM OA: 
30mM MβCD stock was added to 1mL of 200mM PBS, in an SPR experiment, etc.   
Alternatively, and when noted, OA was solubilized in water complexed to BSA 
(MW= 66,463 Daltons) in a molar ratio of 1 BSA: 2 OA.  This was done by adding 0.6646g 
of BSA into 1mL 155mM PBS to give a final BSA concentration of 10mM.  Next, 6.3μL 
of OA was added to this 1mL BSA.   
For positive controls using cholesterol, water-soluble cholesterol was purchased 
from Sigma-Aldrich (#C4951, St. Louis, MO).  After technical inquiry, this product was 
said to contained 40mg of cholesterol per 1g of MβCD (a 1 cholesterol: 7 MβCD molar 
ratio), therefore 0.104g of the cholesterol: MβCD was added to 1mL of ddH20, to give a 
final concentration of 10mM of cholesterol.  Varying concentrations of this 10mM stock 
were added to experiments. 
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  For fluorescence FA uptake assays, it was experimentally determined that FA: 
MβCD and FA dissolved in DMSO performed the same, therefore FA was dissolved into 
DMSO before each experiment.  Additionally, we have previously published a similar 
finding [85].  For these assays, OA in DMSO was added at 6μL per experimental addition 
from stocks of 10mM, 25mM, 50mM, 125mM, and 250mM to give concentrations 20µM, 
50µM, 100µM, 200µM, and 500µM respectively.  For a 10mM OA stock, 3.15μL OA was 
added to 1000µL of DMSO, for a 20mM stock, 6.3µL of OA was added to 1000µL of 
DMSO, etc. 
3.2.2. Stock Solutions of Fluorescent Probes 
A stock solution of 1mM BCECF-AM (MW = 820.7, 688.6, and 556.5 g/mol) was 
prepared per manufacture’s recommendations, due to the mixed isomer MW, by adding 
1,600µL anhydrous DMSO to 1mg of BCECF-AM powder followed by vortexing, 
aliquoting, and storage at -20°C.  For fluorescence experiments, a final concentration of 
0.2µM was added to cells by adding 2µL of 1mM stock BCECF-AM into 10mL’s of 
DMEM.   A stock solution of 1mM BCECF-Acid (MW = 520.45 g/mol) was made by 
adding 2mL sterile 20mM HEPES (pH7.3, using KOH to pH) SUV buffer to 1mg BCECF-
Acid.  A stock solution of 10mM pyranine (MW = 524.4 g/mol) was made by adding 
0.0262g of pyranine into 5mL of 20mM HEPES (pH7.3, using KOH to pH) SUV buffer, 
vortexed, then 1mL aliquots are frozen at -20°C. A 1.8mM stock solution of FPE (aka 
Fluorescein PE or DHPE, MW = 1,182.5 g/mol) was made by adding 5mg FPE into 
2.33mL of DMSO.  A 5mM stock solution of laurdan (MW = 353.55 g/mol) was prepared 
by dissolving 0.0088g laurdan into 5mL DMSO, followed by heating to 37°C for 60min 
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and then a vigorous vortex.  This solution was stored at RT in dark.  For fluorescence 
experiments using live cells containing BCECF-AM or laurdan, MOPS/Krebs (M/K) 
buffer was used (20mM MOPS, 1.1mM MgSO4, 5.1mM glucose, 1.1mM KH2PO4, 5mM 
KCl, 118mM NaCl, 2.5mM CaCl2 and the final pH was adjusted to 7.4).  For experiments 
using SUV’s, 20mM HEPES buffer (pH7.3, using KOH to pH) was used. For experiments 
using cationic vesicles, HEPES/NaCl buffer (20mM HEPES, 150mM NaCl, pH 7.4) was 
used. For Dii-oxLDL assays, fresh 200µg/mL Dii-oxLDL stock containing 0.3mM EDTA 
in DPBS (pH 7.4) was always used directly. 
3.2.3. Measurement of Fatty Acid Binding to and Translocation across the Plasma 
Membrane 
Using 95% confluent HEK293 or HeLa cells cultured in 10cm dish monolayers, 
the serum-containing media was removed, and the cells were incubated in serum-free 
DMEM containing 0.2μM BCECF-AM for 30min at 37°C or with 10µM FPE for 1hr at 
37oC.  Cells were then detached from the dish by adding enzyme-free cell dissociation 
buffer including 1x HALT protease inhibitors (to prevent loss of surface proteins, such as 
CD36) for 5 min, in the dark. The detached cells spun down at 300 x g for 60s and were 
washed three times with 37°C DPBS buffer containing 1x HALT protease inhibitors.  The 
cells were then re-suspended in 37°C M/K buffer containing 1x HALT protease inhibitors 
in a final volume of 3mL, at 1 x 106 cells/mL, and were placed in a pre-warmed (37°C 
cuvette sample holder) fluorescence spectrometer, with magnetic stirring. Into each 3mL 
of cell suspension, oleic acid in DMSO was added at 6µL per addition to give 
concentrations 20µM, 40µM, and 80µM, respectively.  In a typical measurement, real-time 
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monitoring of ratiometric BCECF fluorescence was recorded using dual excitation 
wavelength (λ1 = 490 nm and λ2 = 440 nm) at a fixed emission wavelength (535 nm). 
Real-time monitoring of FPE fluorescence was recorded using excitation and emission 
wavelengths of 496 nm and 519 nm, respectively. For 293-F suspension cells cultured in 
Freestyle 293 expression media, 5.5 x 106 cells (the equivalent of a 10cm dish at 95% 
confluence) were spun down and then 0.2μM BCECF-AM or 10µM FPE was added in 
serum-free DMEM, with all additional steps remaining the same. 
Small unilamellar vesicles (SUV) to study FA flip-flop across bilayer membranes 
were prepared as described in detail previously in publications from this group [74, 351-
353]. Briefly, 50mg of egg phosphatidylcholine (EggPC) was dried by rotary evaporation 
and then lyophilized for 1hr to remove all traces of chloroform. Dried lipids were 
resuspended and hydrated overnight in a solution of 0.05mM Pyranine, or 0.5 mM BCECF-
Acid, in 2mL of HEPES buffer (20mM HEPES, pH7.3, KOH was used to pH). The lipids 
were then pulse sonicated for 1 hr and centrifuged for 30min to remove the metal debris 
left from the sonication step. The SUV’s were washed through a G-25 Sephadex size 
exclusion column using HEPES buffer (20mM HEPES, pH7.3) to remove any free 
pyranine or free BCECF-Acid, and the SUV’s were collected into 4mL total elution volume 
([SUV] stock = 8.2mM). Usually for 1mL/fraction, fractions 6-9 contained the pyranine-
entrapped SUV’s and fractions 14-17 contained the BCECF-Acid-entrapped SUV’s. 
100µL of SUV stock was used to measure the exact concentration of EggPC [354]. 
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3.2.4. Generation of Cationic Small Unilamellar Vesicles with Entrapped Pyranine and 
Delivery to Live Cells 
Cationic small unilamellar vesicles (SUVs) were created for testing pyranine 
delivery into live cells, along with BCECF. At least in vesicles, pyranine has better signal-
to-noise ratio compared with BCECF but pyranine is charged and will not cross the PM 
without a delivery vehicle (e.g. cationic SUVs).  The creation of cationic SUVs was based 
on a protocol previously described and optimized, except using sonication rather than using 
a Lipex Extruder [355].  Using DSPC (1,2-Distearoyl-sn-glycero-3-phosphocholine), DC-
Chol (3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride), and 
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) at a molar ratio of DSPC: DC-
Chol: DOPE 1.3 : 1:  1 (Note: DPPC [1,2-dipalmitoyl-sn-glycero-3-phosphocholine] could 
be used to substitute DSPC with similar effectiveness), lipids were dissolved in chloroform 
and a lipid film was obtained following the removal of the solvent by rotary evaporation 
submersed in a 60°C water bath for 1hr.  Specifically, into 1,583μL of chloroform was 
added 13mM DSPC, 10mM DC-Chol, 10mM DOPE (0.02054g DSPC [822μL of 
25mg/mL]; 0.01074g DC-Chol [powder]; 0.01488g DOPE [595μL of 25mg/mL]), together 
in a large rotary flask.  Dried lipids were then re-hydrated by adding 4mL of sterile 
HEPES/NaCl buffer (20mM HEPES, 150mM NaCl, pH 7.4) containing 1mM pyranine 
dye, and then spinning on a rotary evaporator (without vacuum) for 1hr in a water bath set 
at 10°C higher than the phase temp (Tc) of the phosphatidylcholine it contained (DSPC Tc 
= 55°C or DPPC Tc = 41°C).  Next, the hydrated solution was transferred to a 60x13mm 
Sorvall thick-walled polycarbonate centrifuge tube and sonicated (output 3, 30% duty 
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cycle) on ice and under nitrogen until the cloudy solution became visually clear (~60min). 
Gel filtration was then performed to remove free pyranine by weighing 4.3g of Sephadex-
G25 beads, hydrating the beads in HEPES/NaCl buffer, adding this mixture to a gravity-
flow chromatography column and finally adding 2mL of the clear SUV-pyranine solution 
to the column.  Fractions were collected into clear 1.5mL eppendorf tubes and 4mL of 
vesicles were collected and mixed (usually, around fractions 14-17) per each 2mL of SUV-
pyranine solution added to the column.  The SUV’s containing trapped pyranine from these 
fractions were then stored in the dark, under N2, at 4°C for no more than 1 week. After the 
vesicles are made and purified, they were added to cells in a manner similar to transfection, 
by dripping 1mL of SUV’s (from the most fluorescent 4-1mL fractions combined together) 
into 10mL of serum-free DMEM on a confluent 10cm dish of live HEK293 cells.  The 
SUV’s were incubated with the cells for 60min.  After incubation, the cells were then 
washed 1x in DPBS, stripped with 1mL enzyme free stripper for 5min, collected in a tube, 
spun at 2.1 x g for 60s, and washed 1x in DMEM. The cells were then re-suspended in 
M/K buffer containing 1x HALT protease inhibitors in a final volume of 3ml at 1 x 105 to 
5 x 105 cells/mL and were placed in a fluorescence spectrometer. Into each 3mL of cell 
suspension, oleic acid in DMSO was added at 6µL per addition from stocks of 10mM, 
20mM, and 40mM to give concentrations 20µM, 40µM, and 80µM, respectively.  Real-
time monitoring of pyranine fluorescence was recorded using excitation and emission 
wavelengths of 455nm and 509nm, respectively.  
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3.2.5. Full-Length CD36 Protein Purification 
First, since our goal was to purify CD36 from the plasma membrane for the purpose 
of future SPR experiments (using full-length CD36 rather than TM-domain CD36) as well 
as hydrogen exchange mass spectroscopy structural experiments. Membrane fractionation 
was performed using confluent (3 x 106 cells/mL) 293-F suspension cells cultured in 
Freestyle 293 expression media, 2 days’ post-transfection of pCI-neo-CD36-12xHis.  From 
the spinner flask, 50mL of cells at a time were spun down at 180 x g for 5min at 4°C.  The 
pellet was washed by resuspending into 10mL of 4°C TSC #1 buffer (10mM Tris-HCl pH 
7.4, 0.25M Sucrose, 0.2mM CaCl2, with fresh 1x HALT protease inhibitor added), and 
then frozen at -80°C.  Next, the suspension was thawed on ice and then homogenized on 
ice by passing the lysate through a 21G needle 20x using a 10mL syringe.  This homogenate 
was left on ice for 20min and then 500µL of this was saved as a total lysate (TL) sample, 
frozen at -80°C, for future protein assays and western blots. 
From the homogenate on ice, a nuclear fraction (NUC) was obtained by 
centrifuging at 720 x g for 5min at 4°C.  The supernatant was saved in a new tube, while 
the nuclear pellet was washed 1x in 1mL of TSC #1 buffer and passed through a 21G needle 
15 times.  This nuclear fraction was then spun out by centrifugation at 720 x g for 10min 
at 4°C, and the wash buffer was removed.  The pellet was resuspended into 750µL of 
nuclear buffer (TSC #1 with 10% glycerol and 0.1% SDS added) and sonicated for 3s at a 
power setting of 2-continuous.  This NUC sample was saved frozen at -80°C for future 
protein assays and western blots. 
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Using the supernatant from the previous step in a new tube, this sample was 
centrifuged at 10,000 x g for 10min at 4°C.  The supernatant was saved into a new 
collection tube, containing both the cytosolic and plasma membrane (PM) fractions, while 
the pellet was resuspended into 1mL of TSC #1 buffer, passed through a 21G needle 15 
times, then centrifuged at 720 x g for 10min at 4°C.  This supernatant was discarded and 
the resulting pellet was resuspended into 750µL of buffer TSC #1, resulting in the 
mitochondrial fraction (MT) sample, saved frozen at -80°C for future protein assays and 
western blots. 
Using the supernatant from the previous step in a new tube, this sample was 
centrifuged in an ultracentrifuge at 100,000 x g for 1hr at 4°C.  From the resulting 
supernatant, 500µL was saved as the cytosolic fraction (CYT), and frozen at -80°C for 
future protein assays and western blots.  The rest of this supernatant was discarded.  The 
pellet, however, was suspended into 10mL of TSC #2 buffer (20 mM Tris-HCl pH 6.8, 4% 
[w/v] dodecyl-β-maltoside [DDM], 150 mM NaCl, 1.5 mM MgCl2, 5% [v/v] glycerol, 
with fresh 1x HALT protease inhibitor added), and 500µL of this plasma membrane 
fraction (PM) was saved frozen at -80°C for future protein assays and western blots. 
To purify CD36, this PM fraction suspended into 10mL of TSC #2 buffer was again 
pelleted by ultracentrifugation at 100,000 x g for 20min at 4°C.  To track possible protein 
loss, 500µL of this supernatant was saved (PM2) and frozen at -80°C for future protein 
assays and western blots, while the rest was discarded.  The pellet was resuspended into 
10mL of TSC #3 buffer (20 mM Tris-HCl, pH 6.8, 2% [w/v] DDM, 150 mM NaCl, 1.5 
mM MgCl2, 5% [v/v] glycerol, with fresh 1x Halt protease inhibitor cocktail added) to 
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give ~5mg protein/mL buffer.  The suspension was homogenized on ice by extrusion 5 
times through a 21G needle and then rocked on ice at 4°C for 90min. 
After the 90min interval, insoluble material was pelleted out by ultracentrifugation 
at 100,000 x g for 20min at 4°C and discarded.  From the supernatant, 500µL was saved 
(PM3) and frozen at -80°C for future protein assays and western blots.  
From the remaining PM-containing supernatant, 5mL was added to a 3mL Ni-NTA 
resin column pre-equilibrated with 3mL of TSC #4 (20 mM Tris-HCl, pH 6.8, 2% [w/v] 
DDM, 150 mM NaCl, 1.5 mM MgCl2, 5% [v/v] glycerol, 20mM imidazole, with fresh 1x 
Halt protease inhibitor cocktail added).  This was incubated at 4°C with mixing for 1hr.  
Nonspecifically bound proteins were then washed off using 4 washes of 5mL of TSC #5 
buffer (20 mM Tris-HCl, pH 8, 150 mM NaCl, 1.5 mM MgCl2, 5% [v/v] glycerol, 1% 
[w/v] DDM, with fresh 1x Halt protease inhibitor cocktail added), each with a stepwise 
gradient of 60mM, 80mM, 100mM, or 120mM imidazole, respectively. 
CD36 was eluted by 3 washes of 5mL of TSC #6 buffer (20 mM Tris-HCl, pH 6.8, 
1% [w/v] DDM, 150 mM NaCl, 1.5 mM MgCl2, 5% [v/v] glycerol, 250mM imidazole, 
with fresh 1x Halt protease inhibitor cocktail added).  To remove imidazole for downstream 
applications, dialysis was used. 
3.2.6. Recombinant CD36 Purity Assay 
 To test the purity of rCD36, a silver stain was performed per the manufacture’s 
protocol.  All steps were done at RT.  Briefly, a range of protein concentrations from 0.1 – 
2.0ng, as well as broad range protein ladder, were loaded and run on an 8% SDS-PAGE 
gel using 90V for stacking and 150V for running.  The gel was then washed in ddH20 twice 
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for 5min each.  Then, 10mL of fixing solution (6:3:1 of ddH20, 30% ethanol, 10% acetic 
acid) was added for 15min with rocking, replaced with fresh fixing solution, and rocked 
for another 15min.  Next, the gel was washed in ddH20 and 10% ethanol twice for 5min 
each, after which 2 washes were done for 5min each using pure ddH20.  Next, the water 
was removed, and freshly made Silver Stain Sensitizer was added for exactly 1min, then 
another 2 washes were done using ddH20 for 1min each.  Next, water was removed and 
freshly prepared Silver Stain Enhancer was added for 5min. The gel was then quickly 
washed 2x in ddH20 for 20s each time, and then the water was removed and freshly made 
Silver Stain Developer was added until bands appeared to desired development contrast 
(~2-3min).  After bands developed, the Silver Stain Developer was replaced with Stop-
Solution (5% acetic acid in ddH20) for 30s.  Next, fresh Stop-Solution was added for 
10min.  If mass spectrometry was planned, the gel would then be washed in De-Stain.  
Otherwise, for simply inspecting the gel for protein purity, the gel was washed in ddH20 
twice for 10min each and scanned on a high-definition scanner.  
3.2.7. Surface Plasmon Resonance Analysis 
Using the ProteOn XPR36 Protein Interaction Array system (Bio-Rad) [356], all 
experiments were performed in high-salt PBS (200mM, pH 7.4) running buffer to decrease 
non-specific binding, with or without 5mM MβCD to dissociate FA, at a flow rate of 
30µL/min at 25°C.  ProteOn GLM chips were chosen for the experiment after our first 
initial trials with GLC chips did not give sufficient signal response.   All 6 channels (GLM 
sensor chip), including the empty well used to normalize non-specific binding, were 
activated for 5 min with a mixture of 0.2 M EDC (1-ethyl-3-(3-
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dimethylaminopropyl)carbodiimide hydrochloride) and 0.05 M sulfo-NHS (sulfo-N-
hydroxysuccinimide).  Immediately after activation of the surfaces, proteins were added 
for covalent linking.  Channel 1 was used as a reference. For the negative control, Normal 
Rabbit IgG (Cell Signaling Inc., Danvers, MA, #2729) was diluted into 10mM sodium 
acetate buffer, pH 4.5, at 300µL/well.  Using 0.25mg/mL Normal Rabbit IgG stock 
solution, 5µL/well yielded ~1,300 resonance units (RU), injected across Channel 2. 
Recombinant ectodomain of human CD36 (rCD36) from amino acids 30-439, i.e. lacking 
both the transmembrane and the small intracellular domains, (Sino Biologicals Inc., 
Daxing, China) was diluted into 4:1 PBS: 10mM sodium acetate buffer, pH 4.5 (Bio-Rad) 
at 300µL per/well.  PBS was used since the theoretical isoelectric point of CD36 is 8.19 
[357].   Experimentally it was found that using 0.25mg/mL rCD36 stock solution at 
3µL/well yielded ~1,300 RU and 12µL/well yielded ~5,000 RU in Channel 3 and 4, 
respectively.    For a positive control, human serum albumin (HSA, SigmaAldrich, 
#A3782) was diluted into acetate buffer, pH 4.5, at 300µL/well.  Using 0.25μg/mL HSA 
stock solution, experimentally adding 5µL/well yielded ~1,300 RU, and 10µL/well yielded 
~5,000 RU, in Channel 5 and 6, respectively. Finally, after protein linkage, all 6 channels 
were blocked with 1 M ethanolamine-HCl (pH 8.5).   
Various FA complexed were then injected into channels perpendicular to ligands, 
at six different concentrations, using a twofold dilution series within a variable range, 
dependent upon experimental FA Rmax, which differed for each individual FA tested.  In 
additional experiments, Dii-oxLDL was injected at doses of 1nM, 4nM, and 8nM, with or 
without 150µM OA, using an assigned and approximate MW value for Dii-oxLDL at 
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3,000,000 g/mol.  In these assays, Dii-oxLDL MW was assigned at 3 million Daltons [358] 
for the purpose of Langmuir modeling. The six concentrations were injected 
simultaneously at a flow rate of 200µl/min at 25°C, unless otherwise noted. The GLM 
sensor chip was regenerated with short injection of 1M NaCl between consecutive FA 
measurements.  For Dii-oxLDL regeneration, 3 separate injections of glycine buffer (pH 
3.0), 0.5% SDS, and 1M NaCl, respectively, were used. Results are expressed in arbitrary 
RU with subtraction of RU values from channel 1. Data were analyzed with ProteOn 
managerTM software, using the Langmuir model (A + B ↔ AB) for fitting kinetic data.  
For each FA as well as for all Dii-oxLDL SPR experiments, a set of 5 separate experiments 
were performed and analyzed.  Error bars were not included for visual clarity but were < 
+/- 25 RU for each experiment set.  
3.2.8. Immunofluorescence Staining with Dii-oxLDL and Confocal Microscopy 
For Dii-oxLDL uptake experiments, HEK293 cells were grown in 8-well culture 
slides to ~60% confluence.  Dii-oxLDL (5μg/mL) was premixed into DMEM with 10% 
FBS, or DMEM with 10% charcoal-stripped FBS, or serum-free DMEM with added FA 
doses (OA, EA, HODE, PA, DHA).  For metabolic studies, the acyl CoA synthetase 
inhibitor, Triacsin-C was additionally added to this premixed cocktail at a final 
concentration of 24μM, as our lab has done previously [359].    Prior to being added, all 
FA was solubilized into DPBS with methyl-beta-cyclodextrin (MβCD) at a molar ratio of 
1 FA: 6 MβCD for OA, EA, and HODE, and 1 PA: 12 MβCD, and 1 DHA: 1 MβCD.  
Alternatively, OA was solubilized in water complexed to BSA in a molar ratio of 1 OA: 2 
BSA. Into each cell culture well, 200μL/well of media was added for 90min at 37°C.  All 
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steps after this point were completed under darkness.  After Dii-oxLDL incubation, the 
cells were washed 2x in warm DPBS + 0.1% Tween20 and 1% BSA and then fixed with 
4% paraformaldehyde in DPBS at room temperature for 10 min. The cells were washed 
again with DPBS 1x, permeabilized with 0.1% TX100 in DPBS, washed 2x in DPBS, and 
blocked in 10% BSA in DPBS for 1 hr at RT.  This blocking was followed by overnight 
4°C incubation with monoclonal rabbit anti-CD36 primary antibody or monoclonal mouse 
anti-CD36 primary antibody at a dilution of 1:100.  The cells were then washed 3x 5min 
in DPBS buffer and then incubated with Alexa Fluor® 488 goat anti-rabbit IgG antibody 
or Alexa Fluor® 488 goat anti-mouse IgG antibody for 1hr at RT.  After washing with 
DPBS 3x 5min, the cells were mounted with ProLong® Gold antifade reagent containing 
DAPI and a #1 glass cover slide. The stained cells, including 3-dimensional z-stack images, 
were photographed using a spinning disk confocal microscope and CellSens Acquisition 
Software, maintaining the gain and exposure settings between each channel for all culture 
wells.  Red Dii-oxLDL fluorescence was quantified by opening only the red channel 
images in ImageJ, subtracting background, and using Analyze/Measure to get a total red 
fluorescence value.  This number was normalized by dividing it by the total cell number, 
obtained by converting the DAPI nuclear channel image to binary format and using the 
“Image-based Tool for Counting Nuclei” (ITCN) plugin [360]. 
3.2.9. In Vitro Solid Phase CD36 and Dii-oxLDL Binding Assay with or without Disulfide 
Reduction 
CD36 and Dii-oxLDL binding was measured using slight modifications to 
previously published work [190, 242], such as the use of n-Dodecyl-beta-D-Maltoside 
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(DDM, ThermoScientific) in place of Octyl β-D-glucoside. In brief, rCD36-6xHis purified 
from HEK293 cells lacking both the transmembrane and the small intracellular domains 
(Sino Biologicals Inc., Daxing, China) was added at 1μg/well of a 96-well Ni-NTA-coated 
HisSorb™ plate (Qiagen) as a 100μL aliquot in protein binding buffer (20mM Tris-HCl, 
pH 6.8, 150mM NaCl, 1.5mM MgCl2, 5% [v/v] glycerol, 0.5% [w/v] DDM) and bound 
overnight at 4°C with gentle rocking.  Unbound protein was aspirated and each well was 
washed with 2 x 200μL of RT ligand binding buffer (LBB) (PBS, 1mM MgCl2, 1mM 
CaCl2, 0.5% [w/v] DDM, 0.2% [w/v] fatty-acid-free BSA).  After this wash, 10mM 
Dithiothreitol (DTT, ThermoScientific) or 10mM Tris (2-carboxyethyl) phosphine 
hydrochloride (TCEP, ThermoScientific) were added in LBB, to select wells, for 5min at 
RT with gentle rocking and then removed by aspiration.  Dii-oxLDL was then added in 
LBB (+/- 10mM DTT or 10mM TCEP) in a total assay volume of 100μL.  The binding 
reaction was incubated for 90min at room temperature, with gentle rocking.  Unbound 
ligand was removed and the wells were washed with 3 x 150μL of ice-cold wash buffer 
(PBS, 1mM MgCl2, 0.05% BSA).  PBS (50µL) was added per well prior to determining 
the amount of bound fluorescence using a fluorescence plate-reader (Infinite M1000 PRO, 
Tecan; Ex514nm/Em550nm). Specific binding of Dii-oxLDL was calculated after 
subtraction of the level of Dii-oxLDL bound non-specifically to empty wells. 
Data from all binding assays were analyzed using OriginLab version 8.6 software.  
Saturation binding data that showed saturable binding of ligand to CD36 over a range of 
ligand concentrations were best fitted by the Langmuir adsorption isotherm, shown in 
Equation 1, which describes binding of ligand to a single class of binding site. 
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(Equation 1) 
 
Where B is bound ligand (relative fluorescence units), Bmax is maximal binding 
(relative fluorescence units), [L] is concentrations of ligand (μg/mL), and Kd is the 
concentration of ligand (μg/mL) giving half-maximal binding, and is a measure of the 
affinity of the receptor-ligand interaction. 
3.2.10. Amplifying and Isolating High Quality Plasmid DNA 
Competent E. coli (DH5α) bacteria were generated by growing DH5α bacteria on 
an LB agar petri dish overnight.  The next day, a single colony was picked and transferred 
to 250mL of LB broth for overnight shaking at 22°C.  After overnight shaking, the 
confluent DH5α flask was placed on ice for 10min, and then the cells were spun out using 
2,500 x g centrifuge spin for 10min at 4°C. This supernatant was removed and the cells 
resuspended into 80mL of 4°C Inoue transformation buffer (55mM MnCl2 • 4H2O, 15mM 
CaCl2 • 2H2O, 10mM KCl, 10mM PIPES [from 0.5M PIPES, pH 6.7]).  The cells were 
spun down as before and then resuspended into 20mL of 4°C Inoue transformation buffer 
plus 1.5mL DMSO.  The cells were kept on ice with rocking for 10min.  Next, the 
competent DH5α cells were aliquoted and frozen by immersion into liquid nitrogen and -
80°C storage.  
To add DNA plasmids to DH5α cells, 10μL of competent DH5α cells were added 
to a sterile eppendorf tube, along with 1-2μL of DNA plasmid.  This was incubated on ice 
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for 30min.  Next, heat shock was performed at 42°C for exactly 30sec.  Immediately after 
heat shock, the cells were added to 200μL of SOC media (2% tryptone, 0.5% yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) and 
incubated for 1hr at 37°C with constant agitation.  After incubation, the bacteria were spun 
down on a table top centrifuge (3-5sec), re-suspended into 50μL of SOC, and spread into 
a warm agar plate containing appropriate selection antibiotic for overnight growth.  
To multiply and purify plasmid DNA from the DH5α cells growing on agar, a 
colony was picked and added to a conical what containing 5mL (mini-prep) or 300mL 
(maxi prep) of LB broth with selection antibiotic.  In addition, if the plasmid was a low-
copy plasmid, chloramphenicol was added to increase plasmid copy number per cells, since 
chloramphenicol inhibits chromosomal but not plasmid replication.  This mixture was 
incubated at 37°C overnight with shaking.  After this, a 500μL stock was added to 50% 
glycerol and frozen at -80°C for future use, and the rest of the culture was used with the 
mini-prep (resulting in 5-20μg of final plasmid DNA purified) or maxi-prep (resulting in 
up to 1mg of final plasmid DNA purified) kit, per manufacturer’s directions. Final DNA 
concentration was verified by nanodrop UV-vis spectrophotometry. 
3.2.11. Generation of the Cells that Express CD36, Caveolin-1, and/or PTRF/Cavin-1 
All transfections were done using either HEK293 cells or HeLa cells.  For DNA 
transfection using standard HEK293 or HeLa cells, the cells were seeded 1 day before the 
transfection to achieve 85-95% confluence the next day in a 60mm dish (or alternate dish 
size, see Table 7 for the ratio of Lipofectamine 2000 and Opti-MEM volumes that were 
used). On the day of transfection in a 60mm dish, 22μl of Lipofectamine 2000 per DNA 
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was diluted into 550μl unsupplemented Opti-MEM per DNA and incubated for 20min.  
DNA’s (pCI-neo-empty, pCI-neo-CD36, pCI-neo-Cav-1, pCI-neo-PTRF/Cavin-1, 
pcDNA3.1-GFP-CD36, etc.) were used at a final concentration each at 0.8μg (quantified 
by nanodrop UV-vis spectrophotometer) for a 60mm dish and were also diluted into 500μl 
unsupplemented Opti-MEM and then incubated for 20min. Afterward, the Lipofectamine 
2000 dilution was mixed with the DNA dilution for an additional 30min and then the 
solution was added dropwise to a 60mm dish containing antibiotic free DMEM with 10% 
FBS. Cells were incubated for 6 hr, and then the transfection solution was exchanged to 
antibiotic free DMEM containing 10% FBS.  The next day, cells were lifted using enzyme-
free dissociation buffer and seeded into culture dishes for experiments.  Unless otherwise 
noted, experiments with transfected cells were performed within a 5-day period from day 
1 of transfection, to maximize consistency of protein expression. Alternatively, stable cell 
lines were generated [282] using the same transfection protocol, but adding G418 (see 
Table 7) to the culture media. 
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Culture Vessel 48-
well 
24-
well 
12-
well 
6well/ 
35mm 
60 
mm 
100 
mm 
150 
mm 
T25 T75 T150 
Surface Area 
(cm)2 
 
0.95 
 
1.9 
 
3.8 
 
9.5 
 
21 
 
55 
 
152 
 
25 
 
75 
 
150 
Media / G418 
Volume (mL) 
& [µL] 
 
0.173 
[3µL] 
 
0.345 
[6] 
 
0.691 
[12] 
 
1.7 
[30] 
 
3.8 [66] 
 
10   [176] 
 
27.6  
[486] 
 
4.6 
[80] 
 
13.6 
[240] 
 
27.3 
[480] 
 
~ Cell # at 
Confluence 
 
 
9.5E4 
 
1.9E5 
 
3.8E5 
 
9.5E5 
 
2.1E6 
 
5.5E6 
 
1.52E7 
 
2.5E6 
 
7.5E6 
 
1.5E7 
 
Table 7. Reference table for cell culture vessels 
Quantities used pertaining to cell culture vessel size, media volume, approximate cell number at confluence 
in each given culture vessel, and surface area for transfection mathematical ratios (i.e. DNA concentration, 
Opti-MEM amount, etc.).  The “Media Volume” values were derived from 10mL of media added to 
100mm culture vessel. Numbers in “[ ]” in the “Media Volume” row, indicate how many µL of 100mg/mL 
Geneticin (G418) were added to the culture media, in order to maintaining stable cell line gene expression.  
This concentration was experimentally determined for HEK293 cells.  For HeLa and Freestyle™ 293-F 
cells, ½ the number shown in “[ ]” was used, also experimentally determined using kill curves. 
 
3.2.12. Growing and Transfecting HEK293 Cells in Suspension Culture 
To start suspension cultures, Freestyle 293-F (293-F) cells were grown to 
confluence in T150 dishes, vortexing for 40s to reduce cell clumping at each passage or 
every 3 days. Once these cells were confluent to 3 x 105 cells/mL in 50mL, the cells were 
transferred into at least 50mL of serum-free Freestyle 293 Expression Media in a 125mL 
spinner flask, which was later expanded into a 500mL spinner flask containing at least 
150mL of serum-free Freestyle 293 Expression Media with continual stirring at 100rpm, 
and with CO2 at 6.5%. After all transfections, the cells were grown to the maximal density 
of 3 x 106 cells/mL for protein purification, or less confluence (cell density noted) for other 
experiments. To passage suspension cultures, 3 x 105 cells/mL were added to new media, 
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after vigorous 40sec vortexing to disrupt cell clustering if this was observed to occur even 
with spinning.   
Since the Freestyle 293 Expression media conditions are not compatible to use 
Lipofectamine 2000, Freestyle MAX transfection reagent was used.  For the Freestyle 
MAX transfections, varying volumes were used depending on experimental design.  For 
small scale experiments (i.e. fluorescence cuvette BCECF measurements) the 293-F cells 
were taken out of suspension, transfected overnight, and then resuspended.  In this case, 
for example, a 24-well plate (1.9 x 105 cells) was used, and cells were grown in 350μL of 
antibiotic free Freestyle 293 Expression Media per well.  For the transfection, (1) 1μg DNA 
+ 50μL OptiPRO SFM were incubated together and (2) 1μL Freestyle MAX + 50μL 
OptiPRO SFM were incubated together, both for 5min.  Next, these two cocktails were 
mixed, incubated for 30min, and then directly added to the cells. 
For larger scale CD36-12xHis purifications, 293-SFM cells were grown in a 
suspension volume of 90mL up to 1 x 106 cells/mL and the media was replaced with fresh 
media the day of transfection, using gentle centrifugation.  Cell viability was at least 95%.  
In two Eppendorf tubes, (1) 110μg DNA + 1.8mL OptiPRO SFM were incubated together 
and (2) 110μL Freestyle MAX + 1.8mL OptiPRO SFM were incubated together, both for 
5min.  Next, these two cocktails were mixed, incubated for 30min, and then directly added 
to the spinning flask of cells with 90mL of media.  All experiments with suspended 
transfected cells were performed within a 3-day period from day 1 of transfection, to 
maximize protein expression and consistency.  Cells became confluent around day 3 after 
transfection (3 x 106 cells/mL) and were harvested at this time. 
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3.2.13. Detection of CD36, Caveolin-1, and PTRF/Cavin-1 Expression Using Protein 
Normalization and Western Blotting 
For semi-quantitative detection of protein expression, recently transfected HeLa or 
HEK293 cells were grown on 10cm dishes, washed 1x in 4°C DPBS, then harvested into 
4°C lysis buffer (1x RIPA buffer [50mM Tris-HCl pH7.4, 150mM NaCl, 1mM EDTA, 
1mM EGTA, 1% TX100, 1% Deoxycholate] + 1x HALT protease inhibitors).  Next, the 
samples were lysed by incubation and rocking on ice for 30min and then centrifuged at 
4°C for 10min at 14k x g to remove DNA precipitates. Next, a BCA (bicinchoninic acid) 
protein assay was performed with a small aliquot of each sample along with known BSA 
standards in lysis buffer, and the HEK293 protein samples were then normalized into lysis 
buffer and 1x Laemmli buffer (50mM Tris-HCl, pH 6.8, 2% SDS, 10% (w/v) glycerol, 
0.02% bromophenol blue, 5% (v/v) 2-mercaptoethanol).  The sample were normalized to 
the desired final concentration (ranging from 20-100μg per SDS-PAGE gel well), boiled 
for 5min at 95°C, and loaded into an 8% SDS-PAGE gel.  After electrophoresis, the 
proteins were transferred to a nitrocellulose membrane under 100V for 90min. Next, the 
membrane was blocked in either SuperBlock T20, StartingBlock T20, or Blocker Casein 
in TBS, for glycoproteins, regular proteins, or phosphorylated proteins, respectively.  
Blocking was performed for 1hr at room temperature, and then the blots were immediately 
incubated with primary antibody at a 1: 1,000 dilution (in respective blocking buffer) or 
other dilution per manufacture’s recommendation or experimental optimization. Primary 
antibody was incubated overnight at 4°C, followed by 3x 5min TBST washes.  Next, a 1hr 
incubation was completed with goat anti-rabbit HRP-conjugated secondary antibody at 1: 
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100,000 in TBST, or a different experimentally determined dilution. Finally, the membrane 
was washed 3x 5min in TBST buffer and incubated with fluorescent SuperSignal West 
Femto substrate in a dark room and processed via film exposure. 
3.2.14. Detection of CD36, Caveolin-1, and PTRF/Cavin-1 Expression Using Confocal 
Microscopy 
HeLa or HEK293 cells transfected with empty vector control, CD36, Cav-1, or 
PTRF/Cavin-1 were grown in 8-well culture slides to ~50% confluence.  The cells were 
washed 1x in warm DPBS and then fixed with 4% paraformaldehyde (in DPBS) at room 
temperature for 10 min. The cells were washed again with DPBS 1x, permeabilized with 
0.1% triton X-100 (TX100; unless otherwise noted), and washed 2x in DPBS.  In most 
cases, these washes were followed by blocking.  In cases of high nuclear background signal 
(experimentally determined), the cells were covered at this point by Image-iT FX signal 
enhancer to reduce this nuclear noise, and incubated for 30min at RT.  This was washed 
3x5min in DPBS and then blocking was performed.  The cells were blocked in 10% BSA 
for 1 hr at RT.  Immediately after, 1 hr RT incubation with anti-CD36, -Cav-1, or -
PTRF/Cavin-1 was performed, at a dilution of 1:100 unless otherwise stated.  The cells 
were then washed 3x 5min in DPBS buffer and then incubated with Alexa Fluor secondary 
antibodies at a 1:100 dilution for 1hr at RT.  After washing with DPBS 3x 5min, the cells 
were mounted with mounting media containing DAPI and then a cover slide sealed on the 
edges using generic nail polish. The stained cells were then photographed using a spinning 
disk confocal microscope, maintaining the gain and exposure between images. 
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3.2.15. Verification of CD36 Function and Dii-oxLDL Levels through Flow Cytometry 
HEK293 cells expressing control empty vector or CD36 cultured in 60mm dish 
monolayers were grown to ~80% confluence.  To this serum-containing media was added 
10μg/mL Dii-oxLDL for 60min at 37°C.  Alternatively, serum-free DMEM was used, with 
or without added doses of FA.  The cells were then removed from the dishes using enzyme-
free cell dissociation reagent and spun down at 300 x g for 60 seconds.  Optionally, the 
cells were fixed in 4% paraformaldehyde.  Next, with or without fixation, cells were then 
permeabilized for 3min by re-suspension into 0.1% Triton X-100 and then spun down 
again.  A final wash was performed using DPBS and the cells were re-suspended into fresh 
DPBS.  After straining the cells through a 35μM nylon mesh cell strainer, a flow cytometer 
was used to quantify Dii-oxLDL fluorescence.  
3.2.16. Confocal Microscopy of Sulfo-N-Succinimidyl Oleate and CD36 
HeLa or HEK293 cells transfected with empty vector control or CD36 were grown 
in 8-well culture slides to ~50% confluence.  The cells were washed 1x in warm DPBS and 
then 200μM SSO was added in serum-free DMEM for 30min.   After incubation, the cells 
were washed 1-3x in warm DPBS to remove unbound SSO.  Next, the cells were fixed 
with 4% paraformaldehyde (in DPBS) at room temperature for 10 min. The cells were 
washed again with DPBS 1x, permeabilized with 0.1% TX100 (unless otherwise noted), 
and washed 2x in DPBS.  The anti-SSO antibody was experimentally determined to give 
high nuclear background signal Image-iT FX signal enhancer to reduce this nuclear noise 
was added to the cells and incubated for 30min at RT.  This was washed 3x5min in DPBS 
and then blocking was performed.  The cells were blocked in 10% BSA for 1 hr at RT.  
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Immediately after, 1 hr RT incubation with mouse anti-CD36 and rabbit anti-SSO was 
performed, at a dilution of 1:100 each.  The cells were then washed 3x 5min in DPBS 
buffer and then incubated with goat anti-mouse 488 Alexa Fluor and goat anti-rabbit 594 
Alexa Fluor secondary antibodies at a 1:100 dilution for 1hr at RT.  After washing with 
DPBS 3x 5min, the cells were mounted with mounting media containing DAPI and a cover 
slide sealed on the edges using generic nail polish. The stained cells were then 
photographed using a spinning disk confocal microscope, maintaining the gain and 
exposure between images. 
3.2.17. Co-Immunoprecipitation of Sulfo-N-Succinimidyl Oleate or Caveolae Proteins 
and CD36 
Starting with HEK293 or HeLa cells transfected with either CD36, PTRF/Cavin-1, 
Cav-1, Cav-1 co-transfected with CD36, PTRF/Cavin-1 co-transfected with CD36, or 
empty vector control, cells were grown to ~90% confluence in 10cm dishes and 200μM of 
SSO was added in serum-free DMEM for 30min at 37°C.  Next, to remove free SSO, the 
cells were washed 2x in warm DPBS.  The cells were then washed 1x in ice cold DPBS 
and then harvested into 1mL each of 4°C Optimized Lysis Buffer (1x “Optimized” RIPA 
buffer: 50mM Tris-HCl pH7.4, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1x HALT 
protease inhibitors, with optimizations performed using by adding or leaving out 1% 
Deoxycholate, and adding one of either 1% Triton X-100, 0.47% Tween 20, 35.7% 
CHAPS, 7.78% Big CHAP Deoxy, 0.27% PPS Silent Surfactant, or 0.33% DDM, based 
on their respective critical micelle concentrations [see Table 8 and Figure 36 for details]).  
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Figure 36. Chemical structures of detergents used in optimizations for co-IP experiments, illustrating 
structural diversity of each 
 
Triton X-100 is commonly used in co-IP experiments to solubilize proteins, as is T20 (tween 20).  DDM 
(dodecyl-β-maltoside) is mass spectrometry compatible and often solubilizes proteins while preserving 
their activity. PPS (sodium 3-(4-(1,1-bis(hexyloxy)ethyl)pyridinium-1-yl)propane-1-
sulfonate) is also commonly used with mass spec and is a cleavable surfactant for potential 
removal. CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate]) is zwitterionic and 
is also commonly used to purify membrane proteins.  Big CHAP deoxy (N,N-Bis[3-(D-
gluconamido)propyl]deoxycholamide) is a non-ionic detergent analog of CHAPS and has reduced 
electrostatic interactions and differing properties due to possessing deoxycholic acid and a gluconamide polar 
group. 
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Detergent CMC (mM) MW (g/mol) M x 0.001L 1% of TX100 
Equivalence 
TX100 0.24 647 0.155 
g/100mL 
1.0g/100mL 
Tween 20 0.06 1,227 0.0736 
g/100mL 
 0.47g/100mL 
CHAPS(i) 9 615 5.535 
g/100mL 
35.7g/100mL 
Big CHAP 
Deoxy 
1.4 862 1.2068 
g/100mL 
7.78g/100mL 
PPS(i) 0.128 415.5 0.0415 
g/100mL 
 0.27g/100mL 
DDM(i) 0.17 510.6 0.051 
g/100mL 
0.33g/100mL 
 
Table 8. Reference table used for optimizing detergent present in 1x RIPA buffer in co-
pmmunoprecipitation (Co-IP) assays 
Detergent types in the far left column are non-ionic unless an (i) is noted after the detergent name. Each 
detergent was chosen based on structural non-redundant features and/or distinct physical properties (Figure 
36).  Most co-IP 1x RIPA buffer contains 1% of TX100 and this was used as a default co-IP detergent.  The 
equivalent of 1% TX100 was determined for each detergent based on the ratio of MW and each detergent’s 
unique CMC, to normalize each detergent to TX100.  This was done because too much or too little detergent 
can have deleterious effects.  Also, a lower CMC is a more powerful or disruptive (i.e. longer hydrophobic 
tail, etc.) detergent (CMC numbers were derived from RT samples in water.  This and other information about 
individual detergents and structures were derived from product sheets of Sigma-Aldrich and similar 
manufacture’s). 
 
 
To remove DNA precipitates the samples were incubated on ice for 30min and 
centrifuged at 4°C for 10min at 14k x g.  The supernatant was added to new tubes and a 
small amount of each was saved as total lysate control. Into each sample, 1μg of antibody 
was added for 2hrs, rocking on ice to allow antibody to bind target sites. At this point, 
protein G agarose beads were washed 2x in 4°C DPBS and then in 1x in 4°C Lysis Buffer, 
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maintaining the original volume.  The beads were vortexed and 25µL was immediately 
pipetted into each sample.  The samples were then incubated on ice for 60min, with 
rocking, to allow antibodies to bind the beads.  Next, free antibodies were washed off by 
spinning each sample at 850 x g and then washing 5x each in 4°C lysis buffer by using 
centrifuge spinning and a flat-tip gel-loading pipette tip to aspirate media between spins, 
which lowered bead loss and increased wash efficiency. After the final wash, 1x Laemmli 
Buffer (50mM Tris-HCl, pH 6.8, 2% SDS, 10% (w/v) glycerol, 0.02% bromophenol blue, 
5% (v/v) 2-mercaptoethanol) was added and the samples were boiled for 5min at 95°C, 
then loaded onto an 8% SDS-PAGE gel.  Standard western blotting (as described above) 
was then performed to probe for proteins that have precipitated (control) and co-
precipitated. 
3.2.18. Detection and Localization of CD36 and Dii-oxLDL in HEK293 Cells Using 
Immunofluorescence Staining 
HEK293 cells recently transfected with pCI-neo-CD36, pcDNA3.1-CD36-GFP, 
pcDNA3.1-GFP, or pCI-neo-empty vector control were grown in 8-well culture slides to 
60% confluence.  Various FA solubilized with MβCD or BSA and Dii-oxLDL (5μg/mL) 
were premixed into 200μL/well of media (either low glucose DMEM with 10% FBS, serum 
free DMEM, or DMEM with 10% charcoal-stripped FBS) and added to the cells for 90min 
at 37°C.  Additionally, in certain experiments, 24μM Triacsin C was added with the Dii-
oxLDL.  All steps hereafter were completed in maximum darkness.  After Dii-oxLDL 
incubation, the cells were washed 2x in warm DPBS + 0.1% Tween20 and 1% BSA and 
then fixed with 4% paraformaldehyde at room temperature for 10 min. The cells were 
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washed again with DPBS 1x, permeabilized with 0.1% TX100 for 3min (unless otherwise 
noted), washed 2x in DPBS, and blocked in 10% BSA for 1 hr at RT.  This blocking was 
followed by 1 hr RT incubation with monoclonal mouse anti-CD36 primary antibody 
(JC63.1) at a dilution of 1:100.  The cells were then washed 3x 5min in DPBS buffer and 
then incubated with Alexa Fluor 488 goat anti-rabbit IgG antibody at a dilution of 1:100 
for 1hr at RT.  After washing with DPBS 3x 5min, the cells were mounted with ProLong® 
Gold antifade reagent with DAPI and a cover slide. The stained cells were then 
photographed using a spinning disk confocal microscope, maintaining the gain and 
exposure between images. 
3.2.19. Fluorimeter Studies of the Membrane Lipid Packing Status Using the Fluorescent 
Probe Laurdan 
All fluorescence spectroscopy measurements were carried out using a fluorescence 
spectrometer at 37°C using a circulating temperature bath unless otherwise stated.  HeLa 
cells transfected with pCI-neo-CD36 or pCI-neo-empty vector control were cultured in 
10cm dish monolayers and grown to ~80% confluence.  For each experiment, the cellular 
media was replaced with serum-free DMEM containing 5µM laurdan with various doses 
of FA solubilized in a denoted FA: MβCD molar ratio or cholesterol solubilized in a 7:1 
MβCD: cholesterol molar ratio.  The laurdan was incubated for 90min at 37°C, unless 
otherwise noted.  After incubation, adherent cells were detached using enzyme free cell 
stripper, spun down at 300 x g for 60s, and the cells were then washed three times with 
37°C DPBS buffer containing 1x HALT protease inhibitors.  The live cells were then re-
suspended in 37°C M/K buffer containing 1x HALT protease inhibitors in a final volume 
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of 3mL, at 1 x 106 cells/mL, and were placed in a pre-warmed (37°C cuvette sample holder) 
fluorescence spectrometer, with magnetic stirring.  Alternatively, the adherent cells 
containing laurdan were detached using enzyme free cell stripper and then washed in ice 
cold Sucrose Fractionation Buffer (10mM Tris-HCl pH 7.4, 0.25 M Sucrose, 0.2 mM 
CaCl2, 1x Halt Protease Inhibitor Cocktail [Pierce]) using a 300 x g centrifuge spin for 
60s.  The cells were then resuspended into Sucrose Fractionation Buffer containing 1x Halt 
and lysed on ice by passing through a 21G needle ~20 times.  The nuclear fraction was 
then spun out at 720 x g for 5min at 4°C.  The remaining supernatant was spun at 10,000 x 
g at 4°C for 10min to remove the mitochondrial fraction (pellet).  Next, the remaining 
supernatant was spun at 100,000 x g for 1hr at 4°C in order to pellet the PM.  This entire 
PM pellet was resuspended into 500μL of 37°C M/K buffer, pH 7.4, in a final volume of 
3mL, and placed in a 37°C heated fluorimeter with continual stirring. For each sample, the 
laurdan emission spectra was measured from 390nm to 590nm, with excitation at 360nm, 
using 2nm slits. Raw data from all fluorimetry was graphed and normalized to 100 at the 
emission spectra starting wavelength (390nm), for improved visualization.  Excitation GP 
(exGP) values were calculated similar to previous studies [132], using Equation 2. 
 
(Equation 2) 
 
From Equation 2, I440 and I490 are the emission intensities at the characteristic 
wavelength of the gel phase (440nm) and the liquid crystalline phase (490nm), respectively 
(discussed in detail in Chapter 7).  Experiments were performed in triplicate and statistical 
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analysis was performed incorporating each sample’s standard deviation into the Student’s 
t test (the Welch-Satterwaite Procedure).  Early fluorimeter experiments often included 
emission GP (emGP) spectra [120], but these have largely been abandoned since exGP 
usually is sufficient and emGP is the subject of ongoing debate concerning the 
solvochromatic effect in laurdan emission spectra [142]. 
3.2.20. Multiphoton Microscopy Studies of the Membrane Lipid Packing Status Using the 
Fluorescent Probe Laurdan 
HeLa cells recently transfected with various caveolae-inducing genes and/or CD36 
or empty vector control (pCI-neo-empty) were cultured to 50% confluence in 35mm glass 
bottom cell culture dishes. The cell culture media was replaced with serum-free DMEM 
containing 5µM laurdan (4μL of 5mM stock solution in 100% DMSO added to 2mL’s of 
DMEM), with or without FA solubilized in MβCD or cholesterol also solubilized in 
MβCD, for 90min at 37°C.  The adherent cells were then washed 3x in DPBS and left in 
DPBS. Laurdan fluorescence was excited with a mode-locked titanium-sapphire laser with 
the multiphoton laser excitation set at 800 nm. The images were obtained with a 60x oil 
immersion objective (1.3 numerical aperture). The emitted light was collected in the ranges 
400–460 and 470–530 nm, as previously described [97].  The general polarization was 
calculated using the equation: 
 
(Equation 3) 
 
  
133 
 
Analysis of the physical properties of ordered and disordered membrane domains 
were performed using a custom written macro from [97] and with Image J software.  The 
macro set the background values to zero and utilized both multiphoton images (400-460 
and 470-530) into a single image using Equation 3.  The GP distribution was obtained from 
the average histogram of at least 3 cells, normalized by using nonlinear fitting algorithm 
into two Gaussian distributions.  The general range of the GP values was set between -1 
and +1, with higher values corresponding to the higher order in the membrane. 
3.2.21. Quantum Dot Nanoparticle Tracking of CD36 with or without Fatty Acid 
HeLa cells recently transfected with pCI-neo-CD36 or pCI-neo-empty vector 
control were cultured to 50% confluence in 35mm glass bottom cell culture dishes. The 
live cells were then washed twice in 1x DPBS and then incubated in blocking buffer (5% 
BSA in DPBS) for 30min at 37°C.  Next, primary mouse monoclonal anti-CD36 (JC63.1) 
antibody was added at a dilution of 1:100 in PBS for 1hr at 37°C.  After this antibody 
incubation, the cells were washed 3x for 5min each time, in 1x DPBS.  Next, the cells were 
incubated for 1hr with QDot-labeled (anti-mouse) secondary at a dilution of 1:500 in PBS 
at 37°C.  After this incubation, 2 washes for 5min each were done using 1x DPBS and a 
final wash was done using serum-free DMEM.  Finally, single cells were imaged using 
multiphoton microscopy in a 37°C chamber containing 5% CO2, with or without added 
doses of FA solubilized in MβCD (or control MβCD added alone) to serum-free DMEM.  
CD36 nanoparticles on the cell surface in single cells was tracked prior to adding FA and 
for various time points after adding FA. 
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3.2.22. Whole-Genome Microarray of HEK293 Cells with or without CD36 Expression 
and/or Fatty Acid 
 In triplicate replicates, HEK293 cells at ~50% confluence were transfected in 10cm 
dishes with either pCI-neo-CD36 (6 dishes) or pCI-neo-empty control vector (6 dishes).  
The next day at 70% confluence, half of these dishes (3 of CD36 and 3 of empty vector 
control) were given 20μM OA (solubilized in MβCD) in serum-free DMEM and half were 
given MβCD vehicle only in serum-free DMEM, for 24 hours.  The cells were then 
harvested on ice and RNA was purified according to manufacturer’s instructions for the 
Qiagen RNeasy kit.  Finally, the RNA was frozen in aliquots and some was brought on ice 
to the Boston University Medical Campus Microarray Core Facility, where each of the 12 
samples was tested using an Affymetrix Gene Chip (Human Gene 2.0 ST Array).  
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CHAPTER FOUR: EFFECTS OF CD36 ON FATTY ACID TRANSPORT AND 
MEMBRANE FLUIDITY 
4.1. Rational 
 As an essential nutrient, FA acids are physiologically delivered to cells for 
utilization by several channels, which include transfer from plasma albumin and receptor-
mediated uptake of LDL. The multi-functional protein CD36 has been implicated in both 
of these processes [191, 361] but uptake mechanisms are not understood.  We begin here 
with uptake of FA and discuss LDL in the next Chapter. 
Mechanisms for CD36 catalysis or direct involvement in the transfer of unesterified 
FA across the plasma a membrane have been studied for decades but have remained 
elusive. Although CD36 has been found to enhance FA uptake into several cell types, 
especially adipocytes [259, 272, 362, 363], it is not clear whether this occurs by accelerated 
flux of FA across the plasma membrane, by enhancement of FA metabolism, by cell 
signaling, or a combination of these mechanisms. By contrast, the more recently discovered 
family of transporters, the FATP’s, were shown to activate FA and hence drive uptake by 
catalyzing formation of acyl CoA, the first metabolic precursor for FA utilization inside 
cells [10, 364, 365]. This activation provides both a metabolic and a biophysical 
explanation, since the acyl-CoA is very impermeable to the lipid bilayer of membranes 
[366-368] and hence is trapped on the cytosolic leaflet where it is formed. In contrast, the 
unesterified FA are able to move rapidly and bi-directionally across cell membranes [369].   
Here, following previous work within our group, we sought to shed new insights 
into how CD36 enhances unesterified FA uptake into cells by separating contributions of 
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transport of FA in the plasma membrane from intracellular utilization.  Our initial 
hypothesis was that FA uptake across the PM occurs via diffusion.  In other words, FA 
uptake is enhanced by CD36 via intracellular metabolism rather than by active transport 
across the PM.  Our strategy to address this encompassed both the design of the cell system 
and the methods applied. Our group previously developed an experimental cell system to 
study the involvement of caveolins in the transport of FA in the plasma membrane of cells 
that have relatively limited FA metabolism. With HEK293 cell lines containing virtually 
no endogenous CD36 or caveolin-1, we had demonstrated enhanced binding of FA to the 
cytosolic leaflet with increased expression of caveolin-1 [158].  In the present study we 
expressed CD36 both in HEK293 and HeLa cells without expression of caveolin-1.  We 
used fluorescence methods to monitor binding of oleic acid (OA) to the extracellular 
membrane leaflet and its movement to the cytosolic compartment in real time, as well as 
investigations of metabolic outcomes based on previous work done in our group. 
 
4.2. Results 
4.2.1. Characterization of CD36 expression and function in HEK293 and HeLa cells. 
We first characterized our HEK293 and HeLa cell lines expressing CD36 using 
western blotting and immunofluorescent staining.  Neither of these cells types 
endogenously express CD36 [293, 370]. As shown in Figure 37A, CD36 was not detected 
in HEK293 cells transfecssoted with empty vector control (pCI-neo-empty) but was 
detected in HEK293 cells transfected with CD36 (pCI-neo-CD36) at a molecular weight 
of ~88 kDa, indicating that CD36 was overexpressed in HEK293 cells in the mature, 
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Figure 37. CD36 expression, knockdown, and localization 
glycosylated form.  In addition, HeLa cells transfected with CD36 also showed CD36 
expression (Figure 37B) and CD36 siRNA showed +75% knockdown of HeLa CD36 
expression (Figure 37C).  To determine whether the expression level of transfected CD36 
expression in our HEK293 cell model was comparable to its endogenous expression in 
adipocytes, our group previously examined CD36 expression in 3T3-L1 fibroblasts and 
adipocytes (Appendix 2: Figure A1A). The intensity of the CD36 band detected from the 
HEK293-CD36 cells was comparable to that of 3T3-L1 adipocytes, indicating that CD36 
was expressed in HEK293 cells at or near physiological levels.  
 
 
 
 
 
 
 
 
 
(A.) Representative western blot of HEK293 cells transfected for < 1 week with empty vector control or 
CD36 (single band shown at ~88kD) and beta actin loading controls (single band shown at ~42kD).  This is 
also published by our group [208]. (B.) Representative western blot of HeLa cells transfected with empty 
vector control or CD36 (~88kD) and beta actin loading controls (~42kD). (C). Representative western blot 
of HeLa cells expressing CD36 transfected for 24hr and then with control siRNA (left) or CD36 siRNA 
(right) transfected in for 24hr and beta actin loading controls (~42kD). Quantifications of knockdown were 
performed using ImageJ comparing control siRNA and CD36 siRNA and the CD36 siRNA expression was 
decreased 86.1% +/- 6.9% (n=3).  (E.) Micrographs of HEK293 and HeLa cells transfected with CD36 
labeled with JC63.1 anti-CD36 primary antibody and Alexa Fluor conjugated secondary antibody.   
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We also examined localization of CD36 in HEK293-CD36 cells and HeLa-CD36 
cells using immunofluorescent staining (Figure 37D) to complement previous subcellular 
fractionation studies (Appendix: Figure A1) in which CD36 was detected predominantly 
in the PM fraction. As shown in Figure 37D, using an anti-CD36 antibody combined with 
a secondary antibody conjugated with an Alexa Fluor fluorescent probe, we detected red 
fluorescent signal mainly on the PM in both the HEK293 and HeLa cell models, further 
confirming that CD36 was expressed on the plasma membrane.  In Chapter 5, we further 
show CD36 localization on the PM in many additional confocal microscopy images. 
After confirming CD36 expression and localization in the PM, we then established 
that the PM-expressed pCI-neo-CD36 in our HEK293 cells was functional.  Most 
importantly, we showed that CD36 functioned to take up oxLDL, since this is one of the 
well-established roles of mature, glycosylated membrane-localized CD36 protein [341, 
371].  An assay was designed in order to test the functionality of expressed CD36, taking 
advantage of the known ability of CD36 to uptake fluorescent Dii-oxLDL when compared 
to control cells without CD36 expression.  As shown in Figure 38, the same number of 
cells expressing CD36 incorporated more fluorescent Dii-oxLDL (red) than empty vector 
control cells (green) that did not express CD36.  Since numerous other oxLDL scavenger 
proteins exist [202], the low level of Dii-oxLDL uptake in the control HEK293 cells may 
be due to low-level expression of one or more of these other scavenger receptors.  
Alternatively, the control cells may represent the background level of fluorescence, while 
the cells with CD36 give significantly more signal. 
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Using 10μg/mL Dii-oxLDL (1,1'-dioctadecyl-
3,3,3',3'-tetramethylindocarbocyanine 
perchlorate), HEK293 empty vector control cells 
and cells which express CD36 were incubated for 
30min in serum-containing media.  HEK293 
control cells (green) and HEK293 cells which 
express CD36 (red) are shown.  The figure has been 
published by our group and is modified from [208]. 
 
 
 
4.2.2. Kinetic measurements of fatty acid transport across membranes of (i) model 
vesicles and (ii) live cells using multiple fluorescence probes. 
In order to test the hypothesis that FA can cross the PM via diffusion rather than a 
protein-mediated transport mechanism [372], we measured the lipid bilayer movement of 
FA into protein-free phospholipid vesicles as well as FA movement into HEK293 and 
HeLa cells with or without CD36 expression.  In addition, the sensitivity and response to 
FA doses were analyzed. Importantly, these experiments utilize real-time FA uptake 
assays, rather than endpoint measurements. 
 First, real-time adsorption of FA to the outer membrane of model vesicles was 
measured by using the fluorescent probe FPE, which is incorporated into the outer leaflet 
of the phospholipid bilayer.  FPE reports changes of membrane surface potential and 
indicates how rapidly FA is arriving into the outer membrane leaflet. As we have 
previously characterized in model membranes, arrival of varying chain length FA cause a 
Figure 38. Flow cytometry measuring of 
fluorescence uptake of Dii-oxLDL 
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drop in FPE fluorescence [373]. This decreased fluorescence response was confirmed and 
sensitivity to doses of OA as low as 1µM were also observed (Figure 39A). 
To follow the temporal transport of the added OA after establishing its rapid outer-
leaflet binding, we further monitored the arrival of OA at the inner membrane leaflet of 
phospholipid vesicles by using the fluorescent pH indicators BCECF or pyranine trapped 
inside vesicles. As previously described, both BCECF and pyranine detect protons released 
into vesicles after movement of FA in its uncharged form cross the lipid bilayer [74, 352, 
374].  We observed a rapid fluorescence decrease in both BCECF and pyranine after 
addition of OA, with pyranine showing significantly greater sensitivity to low doses of OA 
compared to BCECF (Figure 39B-C).   
Next, we began transitioning from these protein-free vesicles (predominantly 
phosphatidylcholine), to the more complicated live-cell model system. Since BCECF-AM 
(acetoxymethyl ester) is not charged, it can readily diffuse through cell membranes and 
enter cells, becoming trapped inside as intracellular esterases cleave the ester bond 
releasing BCECF, which is charged [375].  Pyranine, however, is membrane-impermeant.  
Since pyranine fluorescence measurements gave significantly better signal-to-noise ratios 
and were more sensitive to lower OA-doses compared to BCECF inside vesicles, we began 
development of a novel live-cell pyranine “transfection” delivery system using cationic 
liposomes (DSPC: DC-Cholesterol: DOPE [1.3: 1: 1]) based on techniques developed by 
another group to successfully deliver Oregon Green dye into live glioma cells [355].   
For these cationic liposome assays, pyranine-entrapped cationic vesicles were 
created (Chapter 3), transfected into HEK293 cells, and then measured for fluorescence 
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after several washes to remove free extracellular pyranine vesicles.  Significant 
intracellular pyranine fluorescence was observed when compared to control empty vesicles 
transfected into HEK293 cells, which gave almost no intrinsic fluorescence signal (data 
not shown), but HEK293 cells containing entrapped pyranine still showed high signal noise 
and low sensitivity to exogenous FA additions (Figure 39D).  Therefore, this is an area of 
ongoing work that needs to be further optimized in order to achieve better signal-to-noise 
with pyranine.  For the purpose of additional FA uptake studies below, BCECF was used 
consistent with prior work in our lab. 
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(A) Small unilamellar vesicles (SUVs) containing FPE were added to a cuvette under constant mixing. The 
FPE fluorescence intensity was recorded before, during, and after the addition of 1µM or 10µM oleic acid. 
The red arrow indicates the time point when OA was added in each representative experiment. (B) The 
fluorescence intensities of SUVs containing entrapped BCECF-Acid or (C) entrapped pyranine with 20µM 
and 1µM oleic acid added, respectively. (D) The fluorescence intensity of live HEK293 cells transfected with 
cationic SUVs containing entrapped pyranine before, during, and after the addition of 40µM oleic acid.  
Signal to noise was low. In each case, the fluorescence intensity is an arbitrary relative unit (R.U.). 
 
 
In live HEK293 and HeLa cells, with or without CD36 expression, the adsorption 
of FA into the outer membrane was determined.  As with vesicles, the FPE probe that 
incorporates into the outer leaflet of the membrane was utilized, and we found that FPE 
fluorescence decreased rapidly and immediately upon addition of exogenous OA to both 
Figure 39. Detection of oleic acid binding to and transport across bilayer membranes 
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empty vector control and CD36 expressing cells (Figure 40A-B and 40E-F), indicating 
that adsorption of OA to the outer membrane leaflet in cells was fast and independent of 
CD36 expression.  As expected, the signal-to-noise was lower in cells compared to 
vesicles.   
Next and again similar to protein-free vesicles above, the arrival of OA into the 
cytosolic leaflet was monitored by using the fluorescent intracellular pH indicator BCECF. 
As shown in Figure 40C-D and 40G-H, BCECF fluorescence decreased rapidly and in a 
dose responsive manner after additions of OA doses in both control cells and cells 
expressing CD36. With lower concentrations of added OA, the same rapid decrease was 
observed but with smaller total drop in fluorescence, as expected. These results suggest 
that the overall delivery of OA into the cells was rapid and independent of overexpression 
of CD36 on the plasma membrane. After the initial rapid decrease, BCECF fluorescence 
remained steady within the same time of monitoring in both types of cells, suggesting that 
— by comparison to our previous work using rat adipocytes [76] — intracellular utilization 
of the added OA was minor or trivial in either HEK293 and HeLa cells within the short 
time period monitored by fluorescence.  
Note that the low signal to noise in these BCECF fluorescence traces made BCECF 
insensitive to small changes compared to pyranine traces in vesicles from Figure 39, 
however the BCECF probe remains the standard probe for measuring intracellular pH 
changes in live cells.   
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Oleic acid was added to HEK293 (A-D) and HeLa (E-H) cells, with CD36 expression (B, D, F, H) or with 
control empty vector (A, C, E, G).  FPE and BCECF showed fast decreases in fluorescence (within seconds) 
when OA was added and was quantitatively similar for both cell lines. In each case, the fluorescence intensity 
is an arbitrary relative unit (R.U.).  Figures C and E have been published by our group and are modified from 
[208]. 
Figure 40. Real-time measurements of oleic acid binding to and transport across the plasma 
membrane 
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4.2.3. Evaluating the effects of sulfo-N-succinimidyl-oleate (SSO) on CD36 and 
intracellular functions.  
Our novel measurements elucidated the rapid entry of FFA into the intracellular 
space of live cells by diffusion with or without CD36 expression.  Historically, several 
plasma membrane proteins, including the scavenger receptor CD36, have been proposed 
as mediators of FA “active transport” through the PM [376]. One prevalent argument is 
that specific small molecules (Appendix: Table A1) inhibit FA uptake from the external 
medium to the cytoplasm, but the mechanisms have not been elucidated. To separate 
potential effects of these inhibitors on membrane transport from effects on metabolism, our 
group previously performed biophysical measurements using fluorescence assays to 
monitor binding and transmembrane movement of FA in cells and vesicles.  Even in the 
presence via pre-treatment of these small molecule ‘inhibitors’, addition of FA to live cells 
and protein-free vesicles resulted in a rapid (sec) pH drop of BCECF (Appendix: Figure 
A2).   
One ‘inhibitor’, sulfo-succidimidyl oleate (SSO), has been considered impermeable 
to the PM and specific to inhibiting CD36.  However, direct investigation into SSO entry 
into cells or vesicles done previously by our group has found that direct SSO addition to 
HEK293 cells and vesicles can cause a rapid intracellular pH drop (Appendix: Figure A3).  
As part of this study, we have also confirmed this is also true in HeLa cells (data not 
shown). We therefore further investigated SSO uptake into cells and vesicles.  Our 
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hypothesis was that SSO enters cells and alters intracellular metabolism rather than FA 
activate transport at the PM. 
To first determine if SSO acidified the intracellular space because the molecule was 
rapidly hydrolyzed to release OA (e.g. within seconds), we first measured the half-life of 
SSO hydrolysis in our experimental buffers for live cells (“M/K buffer”) and vesicles 
(Figure 41).  
 
 
 
 
 
 
 
 
In (A), measurements of SSO hydrolysis in M/K buffer were performed at 37°C using spectrophotometry at 
up to 30min under constant stirring.  Similar results were seen using serum-free DMEM at 37°C (data not 
shown). In (B), measurements of SSO hydrolysis were done in SUV buffer at 37°C using spectrophotometry 
at up to 10min, where complete hydrolysis was observed.  Half-life measurement was described in Chapter 
3. 
 
SSO is a highly acidic molecule that is expected be ionized even when bound at the 
membrane interface and release of OA could acidify cells. The half-life of a structurally 
similar molecule, DSP (dithiobis[succinimidyl propionate]), has been reported to be 4-5hr 
in buffer cooled to 0°C and pH 7.0 [377].  In our SUV and M/K cell buffers at 37°C, the 
SSO hydrolysis half-life was found to be 3.7 min (Figure 41A) and 9.6 min (Figure 41B), 
A. 
Figure 41. Measurements of SSO hydrolysis in various buffers 
B. 
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respectively.  Although hydrolysis is significantly faster at 37°C than at 0°C, neither of 
these buffer conditions predict that SSO hydrolysis and release of OA is rapid enough to 
explain the immediate pH drop seen in Appendix: Figure A3 when SSO was added 
directly to live cells or SUV.   
Because of the rapid pH change from SSO and the relatively slow hydrolysis, we 
next hypothesized that the highly acidic sulfate group of SSO may titrate in the membrane 
interface due to a shift in its pKa to a higher value (similar to the FA carboxyl) and allow 
a percentage of this inhibitor (i.e. the un-ionized form) to flip-flop across the membrane 
and pre-acidify the internal volume prior to adding OA.  This would enable SSO to (i) enter 
cells and (ii) modify intracellular proteins covalently, potentially disrupting metabolism.  
Hydrolyzed SSO would not be able to modify intracellular proteins.  
To examine and discriminate these possible mechanisms, we developed a novel 
rabbit “anti-SSO” antibody including extensive positive and negative controls. First, using 
a dot blot, the antibody was observed to bind lysates of SSO-treated live cells (Figure 
42A).  As a control, lysates of cells not treated with SSO were blotted and very little binding 
was observed (Figure 42A).  Furthermore, as shown by the comparison in Figure 42B, 
CD36 expression was not required to observe anti-SSO binding. 
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Dot blot showing two 200μM SSO-treated and two untreated HeLa cell lysates, (A.) with and (B.) without 
CD36 expression.  A protein assay and β-Actin were used as loading controls (C.). The anti-SSO antibody is 
highly specific to SSO-treated cell lysates. 
 
To visualize effects with this anti-SSO antibody and see if intracellular SSO may 
be modifying intracellular proteins, we performed confocal microscopy on HeLa cells. As 
a negative control, we first tested anti-SSO antibody without any SSO pre-treatment in 
cells expressing CD36 or with empty vector control.  The cells were fixed with 
paraformaldehyde prior to adding antibodies, and the control cells were also permeabilized 
to allow antibodies to enter the intracellular space (Figure 43A). Because significant 
nuclear background binding was initially observed (data not shown), Image-iT® FX Signal 
Enhancer was used after the fixation process, resulting in only very faint fluorescence from 
non-specific binding (Figure 43A, anti-SSO panel).  In cells expressing CD36 (Figure 
43A, shown in red), anti-SSO antibody did not have any direct interaction with CD36. 
 
A. 
 
B. 
Figure 42. SSO treatment detected by dot blot using anti-SSO indicates anti-SSO antibody specificity 
to SSO-modified proteins 
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Figure 43. SSO modifies numerous plasma membrane and intracellular localized proteins, including 
CD36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HeLa cells with or without 20min SSO treatments in serum-free DMEM were washed and fixed with 
paraformaldehyde.  In specified experiments the cells were permeabilized with 0.1% TX100 after fixing, to 
allow antibodies to enter the intracellular space. In each image, DAPI is blue, anti-SSO antibody is green, 
and anti-CD36 antibody is red.  (A) Negative controls are shown using HeLa cells probed with rabbit anti-
SSO antibody, mouse anti-CD36 antibody, and DAPI stain, without any SSO treatment in empty control 
vector (upper row) and CD36 (lower row) expressing cells. (B-C) Positive controls are shown of HeLa cells 
expressing empty control vector without permeabilization of the PM, probed with rabbit anti-SSO antibody, 
mouse anti-CD36 antibody, and DAPI stain.  Before fixing, these cells were either treated with (B) 100μM 
SSO or (C) 200μM to investigate anti-SSO antibody dose responsiveness.  Note that even without CD36 
expression, increasing SSO treatment causes increasing anti-SSO antibody binding. 
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Next, SSO was added to the live cells for 20 min prior to fixing and staining the 
cells, as before (Figure 43 and Figure 44). We chose to use 100μM or 200μM SSO doses, 
since 200μM is the dose commonly used in many previous FA uptake experiments [267] 
(note: 400μM is now being used with more frequency [270, 275, 378]). The cells were 
initially not permeabilized (Figure 43B-C and Figure 44A) in order to investigate 
extracellular-localized CD36 and the specificity of SSO binding to CD36. In accord with 
CD36 localization in the PM of HEK293 cells by fluorescence  [379], confocal microscopy 
in this study with HeLa cells also confirmed CD36 was predominantly localized in the PM.  
Even in unpermeabilized cells, the anti-SSO antibody was seen to be dose-responsive.  For 
example, cells treated with 100μM SSO prior to fixation showed low anti-SSO antibody 
binding. (Figure 44A).  However, cells treated with 200μM SSO prior to fixation gave 
significant anti-SSO binding.  Similarly, in unpermeabilized cells that did not express 
CD36, 200μM of SSO treatment prior to fixation gave much higher signal than 100μM 
SSO.  The surprising result (Figure 43B-C) was that even in cells without CD36 expression 
(anti-CD36 stained in red), anti-SSO antibody gave noticeably high amounts of antibody 
binding (anti-SSO stained in green), indicating that SSO is not only modifying lysines on 
CD36 but is modifying numerous other PM-localized proteins as well. 
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Figure 44. Three-dimensional confocal microscopy of SSO-modified protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A-C) HeLa cells expressing CD36 were treated with SSO at varying doses and then probed with rabbit anti-
SSO antibody (green), mouse anti-CD36 antibody (red), and DAPI stain (blue).  Again note that increased 
SSO treatment causes increasing anti-SSO antibody binding. (A) Cells treated with SSO doses were fixed 
without permeabilizing. Under these conditions, anti-SSO antibody detects SSO-modified proteins (green) 
and SSO-modified CD36 (yellow) and some unmodified CD36 (red). Unmodified CD36 is especially 
observed at 100μM SSO, where 200μM SSO appears to modify most of the CD36.  (B) Cells treated with 
SSO doses, fixed, and then permeabilized indicate that SSO modifications are occurring inside the cells.  To 
further investigate potential intracellular SSO modifications, (C) 3-dimensional confocal microscopy was 
used.  (Ca. – Cd.) Starting from the bottom of the dish and moving up, CD36 (red), SSO-modified CD36 
(yellow), and SSO-modified proteins (green) are all observed and (Cf. – Ci.) show 3-D reconfigurations 
rotated on the Z-axis.   (Ce.) A colocalization colormap from ImageJ was used to show areas of highest 
colocalization with nuclear background colocalization signal from DAPI being masked. 
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In live cells with CD36 expression and treated with SSO prior to fixation, the anti-
SSO again was dose responsive in the permeabilized cells (Figure 44B). Similar to 
unpermeabilized cells that expressed CD36, anti-SSO staining indicated (i) some 
colocalization with CD36 (seen as yellow), (ii) some CD36 protein that was not SSO-
modified (seen as red), and (iii) some proteins other than CD36 that were nevertheless 
reacting with SSO (seen as green).  The partial but incomplete colocalization with CD36 
was further verified using three-dimensional confocal microscopy in experiments with 
100μM SSO treatment and PM permeabilization (Figure 44C); the images showed 
significant intracellular localization of anti-SSO within the z-plane (Figure 44C, f-i). 
Overall, these findings indicate that SSO is not inhibiting FA uptake across the PM 
but could inhibit intracellular metabolic processes via non-specific cross-linking of SSO of 
intracellular lysines, although our methods do not prove this mechanism. 
4.2.4. Determination of membrane fluidity in response to fatty acids and expression of 
CD36. 
Because FA are sequestered and present within the PM forming immediate, energy-
efficient, FA micro-reserves, we hypothesized that PM localized FA may enhance fluidity 
thereby enhancing FA transport in a CD36-dependent manner.  Fluidity changes from 
different FA tail sizes have been investigated using fluorescence probes in simple model 
membranes but very little has been done using live cells.  In addition, although some studies 
of the effect of proteins on PM fluidity have been published, no studies have examined the 
effect of CD36 on PM fluidity in the presence of exogenous FA.  To this end, we used of 
the fluidity-sensitive probe laurdan with short-term exogenous oleic acid (OA) additions 
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(> 90min) beginning with numerous controls since the use of laurdan with FA in live cells 
expressing CD36 is novel. 
As a positive control for laurdan response, we first investigated the response to 
laurdan in cells using cholesterol solubilized in methyl-beta cyclodextrin (MβCD) for 
delivery. Cholesterol is a well-characterized PM fluidity modulator.  Cholesterol has been 
shown by numerous methodologies (and other fluorescence probe types) to increase 
membrane rigidity in various types of membranes, especially after addition beyond 60 
minutes [380-382].  In addition, and for all our experiments in live cells, lovastatin was 
added to inhibit potentially variable endogenous cholesterol production.   
In the first control experiment, laurdan +/- 5mM cholesterol was added to live cells 
for 90min.  Additional doses of cholesterol were also tested but are not shown.  After the 
incubations, live cells were then detached, washed, lysed, and the PM was isolated using 
fractionation. Using various conditions, including cholesterol and FA additions, whole live 
cells were also tested (data not shown). All these experiments showed little or no exGP 
differences, indicating that the assay is not sensitive enough to detect these types of fluidity 
changes in whole live cells.  
To overcome this limitation and focus on the PM, exGP values were obtained for 
fractionated PM in a continuously stirring cuvette, as described in Chapter 3, and, as 
expected, cholesterol caused a significant decrease in fluidity in cell PM compared to PM 
not treated with 5mM cholesterol (Figure 45B).   
As an additional control, we used MβCD to extract existing cellular cholesterol 
from the PM.  Based on previous work, addition of 5mM MβCD for 2 hr was the minimum 
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dose and time for extracting 80-90% of total PM cholesterol [383]; therefore, we utilized 
this dosage and time for extraction.  Other doses were tested (not shown) but did not show 
drastic or unexpected differences.  With the 2hr addition of 5mM MβCD, laurdan exGP 
was even lower than cells without no treatments, suggesting that cholesterol was removed 
from the PM by MβCD, as expected. 
As a final control to investigate potential rescue of cellular cholesterol levels, 
another 2hr addition of 5mM MβCD was performed in live cells to extract cholesterol and 
then, at this 2hr time point, 5mM cholesterol was added back to the cells for 90min.  This 
addition resulted in exGP values comparable to untreated control cells (Figure 45D). 
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In un-transfected HeLa cells containing laurdan, PM was isolated and exGP was measured using fluorescence 
spectroscopy.  In the live cells and prior to fractionating the PM, all cells were given 4μM of lovastatin, 
similar to [384], as well as various other conditions.  In (A.), nothing but laurdan and statin were added for 
90min to the live cells, prior to fractionation.  In (B.), laurdan, statin, and 5mM cholesterol were added for 
90min. In (C.), 5mM MβCD was added to the live cells for 2hr, while laurdan and statin were added for last 
90min of this 2 hr MβCD incubation period.  This condition was seen to increase fluidity, presumably due to 
removal of native cholesterol from the PM. In (D.), 5mM MβCD was added to the live cells for 2hr, similar 
to (C.).  However, after this 2hr incubation period, laurdan, statin, and 5mM cholesterol were added for 
90min.  In each case, higher exGP values indicate overall higher membrane order.  Approximately 100,000 
cells were used for each experiment and cells or fractionated membranes were added to M/K buffer in 
cuvettes.  Emission spectra from separate experiments were collected and exGP values were calculated as 
described in Chapter 3, represented as means +/- the standard deviation where n = 3.  By a Student’s t test 
incorporating unequal variances, *p < 0.05 and **p < 0.005, only comparing (A.) and (B.) or (C.) and (D.). 
 
Next, using this same fluidity model and the laurdan probe, CD36 expression was 
investigated beginning with CD36 and empty vector cell controls. CD36 has been shown 
to promote uptake of lipids (LDL and FFA) [385], which could in principle bet enhanced 
by changes in the PM fluidity with CD36 present.  However, direct investigations of 
fluidity have not been performed comparing cells with and without CD36.  While we found 
that CD36 does not enhance the rate of FA uptake via transport across the plasma 
Figure 45. Laurdan controls testing cholesterol and methyl-beta cyclodextrin 
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membrane (see above at 4.2.2. and also see [282]), the extent that CD36 might sequester 
FA within the PM or increase FA diffusion through the lipid bilayer of the PM remains 
unknown.  Furthermore, since (i) CD36 directly binds FA [41], (ii) CD36 is palmitoylated 
[243], and (iii) CD36 is found within caveolae [281] (and our group has shown that 
caveolae sequester FA in the cytoplasmic leaflet of the PM [158]). 
Laurdan has rarely been used in live cells and never in live cells expressing CD36 
compared to empty vector control cells.  Therefore, we first used an array of control 
experiments.  For these controls, live HeLa cells were incubated for 90min with laurdan as 
well as with (i) OA, (ii) OA plus Triacsin C – a potent inhibitor of acyl-CoA synthetase, 
(iii) OA after transfection with CD36 and then siRNA – control siRNA or siRNA against 
CD36, or (iv) OA first and then MβCD to remove the OA.  Emission spectra were then 
measured in each control using the fractionated PM fractions (rather than live cells since 
PM was previously found to give optimal signal-to-noise sensitivity).  
First we observed that laurdan exGP in CD36 expressing cells in serum free media 
was not significantly different compared to empty vector control cells via laurdan exGP.  
However, when 100μM OA was added, a significant decrease in laurdan exGP was 
observed compared to FA-free PM (Figure 46, green and grey bars).  It is important to 
note that similar PM fractionation laurdan experiments have been performed with or 
without OA in cells, but these experiments were done without using CD36 expression 
[117]. 
Interestingly, CD36-expressing cells had a higher exGP value indicating a more 
rigid PM than empty vector control PM.  This unexpected and novel finding indicates that 
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CD36 may be driving FFA from the PM into the intracellular space via some unknown 
mechanism.  To investigate whether acyl CoA activation might be playing a role, the potent 
inhibitor of acyl CoA synthetase—Triacsin C—was added to cells containing laurdan and 
100μM OA (Figure 46, orange).  Triacsin C at least partially ablated the exGP difference 
between the CD36 and control empty vector cells, indicating the likelihood of acyl CoA 
involvement. 
An additional control utilizing siRNA was performed (i) to investigate the effects 
of knocking down CD36 and (ii) to confirm that a consistent pattern exists with exGP 
between CD36 and empty vector control cells when OA is present (Figure 46, yellow).  
Again in the presence of 100μM OA, when CD36 was knocked down using siRNA, the 
exGP value was lower when compared to control siRNA transfected cells.  This finding is 
consistent with the change observed from CD36 expression.  In control and CD36 siRNA 
conditions, however, the exGP values were higher overall.  We therefore tested 
Lipofectamine 2000 reagent by itself (the siRNA transfection delivery agent) and found 
that Lipofectamine 2000 addition alone caused an increase in exGP when compared to no 
Lipofectamine 2000 (Figure 46B.).  This could be due to Lipofectamine 2000 (proprietary) 
reagent fusing and incorporating in the PM bilayer as illustrated in the Figure 46 
Schematic, although the working model for transfection reagents is usually considered to 
be endocytosis-mediated [386, 387], in which case the cell membrane invaginations may 
be responsible for altering the fluidity.  This was not investigated further. 
Finally, after 100μM OA treatment for 90min as in the above experiments, 3 rapid 
washes were performed using buffer containing 700μM MβCD in order to remove OA 
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(Figure 46, blue).  Rapid washes were used because longer washes using MβCD was found 
to give inconsistent results, likely due to cholesterol removal along with the OA removal 
(data not shown).  Our group has previously characterized the rapid extraction of OA using 
700μM MβCD [85], and in this experiment, the exGP were observed to rise nearly to the 
level of FA-free controls. Furthermore, other doses of MβCD were tested (data not shown) 
with variable results, again, probably due to issues of extracting cholesterol, FA, or both.  
In addition, we found an unexpected decrease in exGP with CD36 expression after MβCD-
induced OA extraction, possibly because CD36 directly binds OA.  Exogenous FFA bind 
directly to CD36 in addition to the lipid bilayer. This potential direct binding of FFA to 
CD36 will be explored in depth in the next Chapter using SPR.  
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Plasma membrane fluidity was measured by fluorimetry and quantified using laurdan exGP, under a variety 
of conditions in the presence of lovastatin.  All conditions were performed using serum-free media containing 
5μM laurdan onto HeLa cells expressing CD36 or control empty vector and 100μM OA. (A) First, OA was 
added for 90min (green/grey) and then OA plus 5μM Triacsin C were added for 90min (orange). Next, cells 
expressing CD36 were transfected, using Lipofectamine 2000, with either control siRNA of CD36 siRNA.  
OA was also added to these cells for 90min (yellow).  Finally, using cells incubated with OA for 90min, OA 
was removed by washing 3x with DMEM containing 700MβCD. (B) Lipofectamine 2000 was added alone, 
at doses used for siRNA transfections, to cells expressing CD36. Higher exGP values indicate overall higher 
membrane order.  Approximately 100,000 cells were used for each experiment, and the fractionated 
membranes were added to M/K buffer in cuvettes.  Emission spectra from 3 separate experiments were 
collected and exGP values were calculated as described in Chapter 3, represented as means +/- the standard 
deviation.  By a Student’s t test incorporating unequal variances, *p < 0.05 and **p < 0.005.   The schematic 
illustrates a possible mechanism for Lipofectamine 2000 membrane fluidity alteration via PM fusion. 
 
 
Figure 46. A relative panel of plasma membrane fluidity experiments in HeLa cells including additions 
of oleic acid, Triacsin C, MβCD, siRNA, and Lipofectamine 2000 
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Following these control experiments, we compared whole cell fluidity versus 
(fractionated) PM fluidity, under FA-free and serum-free conditions.  Using HeLa cells 
incubated with laurdan maintained at 37°C in the presence of protease inhibitors, 
fluorescence emission spectra were taken in whole-live cells and fractionated PM, both 
with or without CD36 expression (Figure 47). 
 
 
 
 
 
 
 
 
 
 
 
Whole cell fluidity (diamonds) versus PM fluidity (circles) was measured by fluorimetry and quantified using 
laurdan exGP in HeLa cells expressing CD36 (blue) or control empty vector (salmon).  All cells were pre-
incubated with both 5μM laurdan in serum-free DMEM for 90min and then washed in PBS.  In each case, 
higher exGP values indicate overall higher membrane order.  Approximately 100,000 cells were used for 
each experiment and cells or fractionated membranes were added to M/K buffer in cuvettes.  Emission spectra 
from separate experiments were collected and exGP values were calculated as described in Chapter 3, 
represented as means +/- the standard deviation. n = 5 for live cells and n = 3 for membrane fractionation 
experiments.  By a Student’s t test incorporating unequal variances, *p < 0.05 and **p < 0.005, only 
comparing whole cell CD36 and empty vector control membrane fluidity or plasma membrane CD36 and 
empty vector control.  In neither case was a significant difference was observed. 
 
Figure 47. Whole cell and plasma membrane fluidity with or without CD36 expression 
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Without exogenous addition of FA or cholesterol, CD36 did not significantly alter 
membrane fluidity neither in whole cells nor in isolated PM in serum-free growth media.  
Nor did it appear that CD36 interacted with laurdan probe in these experiments, in 
agreement with other studies using a variety of membrane-inserted peptides [388].  In 
addition, the ability of CD36 to bind endogenous lipid or undergo palmitoylation is likely 
not, by itself, enough to drastically change cellular fluidity under serum-free conditions. 
Since the laurdan controls validated our approach to studying CD36 and membrane 
fluidity, we progressed to studies with known amounts of added FA. Fluorescence 
spectroscopy experiments comprised isolated PM from HeLa cells with control empty 
vector or CD36 expression with exogenous OA doses (0, 20, 50, 100, or 500μM OA; 
Figure 48A.). Almost no fluidity changes were observed at 20μM, but at 50μM and 100μM 
OA, significant differences were observed compared to FA-free controls.  In addition, the 
100μM OA dose was correlated with the most significant difference between PM isolated 
from CD36 and the control empty vector.  The highest dose of OA (500μM) abolished this 
significance, possibly because of compromises in cell health (higher rates of cell 
detachment were observed with 500μM OA additions [data not shown]). 
Despite these differences between control cells and CD36-expressing cells, it is 
important to note that addition of OA resulted in the general trend of slightly increasing 
fluidity.  This is in agreement with other membrane fluidity studies with OA [389]. 
Furthermore, expression of CD36 did not enhance this increase in fluidity but actually 
caused unexpected membrane rigidity to a slight degree (Figure 48A).  This does not 
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support a hypothesis that CD36 can enhance FA uptake across the PM by enhancing 
fluidity-driven diffusion. 
Since the CD36-dependent enhancement of intracellular uptake of exogenous FA 
is likely time dependent, we next performed time point fluidity experiments with shorter 
time additions of OA (Figure 48B). Laurdan exGP was measured using PM from HeLa 
cells +/- CD36 that had been treated with OA for different time points, despite the laurdan 
remaining on the cells for a full 90 min in each case.  The 100μM dose of OA was chosen 
since it has shown the largest difference in Figure 48A.   
In these experiments, the exGP steadily was found to decrease when OA was 
present for longer periods of time, up to ~60min, and then plateau. This data needs to be 
reconciled with our BCECF data, which indicates that exogenous FA moves into and across 
the PM within seconds.  However, since laurdan was pre-incubated and the laurdan 
molecule intercalates into the PM with a FA tail, in this protocol OA may displace the less 
hydrophobic molecule after its addition. 
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Figure 48. Fluidity measurements using isolated plasma membranes from HeLa cells with or without 
CD36 expression along with oleic acid doses and for varying time points 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma membrane fluidity measured by fluorimetry and quantified using laurdan exGP, including doses of 
OA (A) and various time points (B), using HeLa cells expressing CD36 (green) or control empty vector (light 
blue).  All cells were pre-incubated with 5μM laurdan for 90min in serum-free DMEM, either (A) containing 
0, 20, 50, 100, or 500μM OA or, (B) this media was replaced by DMEM containing laurdan and OA for 
various time points (0, 5, 15, 30, 45, 60, 75, or 90min).  Higher exGP values indicate overall higher membrane 
order.  Approximately 100,000 cells were used for each experiment, and the fractionated membranes were 
added to M/K buffer in cuvettes.  Emission spectra from 3 separate experiments were collected and exGP 
values were calculated as described in Chapter 3, represented as means +/- the standard deviation.  By a 
Student’s t test incorporating unequal variances, *p < 0.05 and **p < 0.005, comparing CD36 and empty 
vector control and each condition compared to 0μM or 0min controls. 
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To complement our fluorescence spectroscopy studies and to enable visualization 
of cell fluidity, we used two-photon microscopy.  The rapid internalization of laurdan into 
the interior of the cell makes it a uniquely useful probe for single cell intracellular lipid 
fluidity measures with two-photon microscopy [97, 130].  Furthermore, a simple macro 
has been developed for ImageJ to combine two images into GP [97]. In both CD36 
expressing and control cells, our images of cell fluidity using two-photon microscopy 
revealed that OA surprisingly increased highly-ordered lipid microdomains, even while 
decreasing overall order (Figure 49). This overall increase in membrane fluidity has 
previously been noted using both DHA and OA in various model liposomes [390].  Other 
studies have also shown ordered microdomains with exogenously added FA in model 
membranes. For instance, differential scanning and isothermal titration calorimetry using 
1-palmitoyl-2-oleoyl phosphatidylethanolamine (POPE) vesicles found that OA had little 
effect on membrane fluidity (except at doses of 200µM) but induced important changes in 
membrane lipid organization even at low OA doses [139].  Our data, however, is the first 
study with two-photon microscopy using laurdan as a probe of the effects of adding OA to 
live cells with CD36.  It is also important to note that CD36 caused a difference in PM 
organization (Figure 49E versus Figure 49F), which should be investigated in the near 
future because it might help elucidate the mechanisms for the increased CD36-driven 
intracellular metabolic changes.  
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(A-F) Two-photon 60x images measuring whole cell fluidity and organization are shown using the 
ratiometric laurdan GP equation. HeLa cells expressing empty vector control (upper row) or CD36 (lower 
row) were used with FA-free controls (A-B) or addition of 100μM OA (C-D), added for 90min with serum-
free media containing 5μM laurdan. The 16-color lookup table (LUT) corresponds to the GP values in the 
image, with –1.0 indicating low order (high fluidity) and +1.0 indicating high membrane order.  (E-F) 
Enlarged images from white boxes from C or D magnifying the PM edge of OA-conditioned cells.  Possible 
early formation of lipid droplets is observed in F., which may be regional increases in order in the PM to 
increase order when OA is present at 100µM in CD36 expressing cells. 
 
 
 
 
 
 
 
Figure 49. Two-photon micrographs measuring fluidity in whole live cells with or without CD36 
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4.2.5. Visualization of triglyceride droplet formation in HEK293 cells using BODIPY 
500/510: OA 
Since our laurdan studies indicated that CD36 possibly initiates lipid droplet 
formation within the PM, and our real-time fluorescence measurements of FA uptake 
indicated that CD36 does not enhance the already fast transmembrane diffusion, direct 
investigations were done on lipid droplets with and without CD36 expression.  FA uptake 
in cells (e.g. BCECF, etc.) suggests that CD36 enhances uptake of FA by increasing 
esterification of FA rather than PM transport rate.  Therefore, we hypothesized that CD36 
expression increases intracellular lipid droplet size or quantity.  Recently, our group 
investigated the metabolic fate of exogenous [14C]-oleic acid added to the HEK293 cells 
with and without CD36 expression, quantified over time periods by incubating the cells 
with [14C]-labeled oleic acid.  We found that [14C]-TG was significantly enhanced within 
30min when CD36 was expressed, compared to empty vector control cells. The 
quantitative analysis of these results is shown in Appendix: Table A2 and the data shown 
in Appendix: Figure A4 (data collected by Xu, S. and figures created by Jay, A. [208]). 
Since measuring [14C]-TG does not give information about the size, number, or 
localization of lipid droplets, we next designed experiments to investigate this.   For this, 
HeLa (Figure 50) and HEK293 cells (Appendix: Figure A5) with and without CD36 
expression were incubated with a mixture of BODIPY 500/510: OA for 24 h. The BODIPY 
500/510 is not metabolized identically to OA (rate and extent of esterification to TG), and 
this design utilized BODIPY 500/510 as a probe for OA esterification, as is common [391].  
In addition, unlike the [14C]-TG studies, BODIPY gives insight into lipid droplet size 
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Figure 50. Detection of lipid 
droplets formation in HeLa 
cells with or without CD36 
expression using single cell 
imaging 
relative to the whole cell and intracellular space.  As shown in single cell images (Figure 
50 and Appendix: Figure A5), fluorescent lipid droplets accumulated in cells with and 
without CD36; however, cells overexpressing CD36 accumulated a greater number of 
droplets and larger droplets. 
 
 
 
BODIPY 500/510: oleic acid 
was added to HeLa control 
empty vector cells (A and B) 
and HeLa-CD36 cells (C and 
D) separately and incubated 
for 24 hours followed by three 
times washing using PBS. 
 
We designed and began parallel experiments with SSO pre-treatment and BODIPY 
500/510: OA incubations to extend our studies into a new avenue.  These experiments were 
unsuccessful, however, because the SSO pre-treatment caused complete cytotoxicity 
before the BODIPY 500/510: OA incubation was complete (24hr).  While this issue was 
not resolved in these studies, it may be worth pursuing using shorter SSO treatments (less 
than 20min) along with anti-SSO microscopy to confirm that the shorter timed SSO 
treatments still cause intracellular perturbations.  
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4.3. Discussion 
CD36 was originally characterized as a fatty acid transport protein in the plasma 
membrane of adipocytes by classical biochemical measurements of uptake [392], a major 
finding supported subsequently by newer molecular biology methods [393]. The adipocyte 
plasma membrane has several other proteins postulated to play important roles in 
modulating the transmembrane flux of FA, which include caveolin-1 and FATP [394]. 
Attempting to understand the detailed molecular mechanisms of any of these proteins in 
membranes is challenging because FA enter fat cells [76] and HepG2 cells [77] in vitro  on 
a time scale of seconds or less [75]. The exogenous FA is metabolized within a few minutes 
and the intracellular pH, as monitored by BCECF fluorescence, rises to its initial value 
within this time [76, 158].  To overcome the confounding influence of metabolism on 
biophysical transport mechanisms in the plasma membrane, and in an extension of our 
previous studies focusing on caveolin-1, we utilized a simpler cellular system (HEK293 
and HeLa cells) for studying FA transmembrane movement because these cells lack CD36 
and FATP, and metabolizing FA is not their primary function. 
Focusing first on transport in the plasma membrane, our application of two 
fluorescent probes, FPE and BCECF (Figure 40), permitted individual monitoring of 
adsorption to the outer leaflet (binding) and translocation of FA across the plasma 
membrane in real time, respectively.  Binding of FA was complete within about 10sec and 
independent of CD36 overexpression.  Notably, our FPE probe could have detected 
alternative outcomes.  For example, if the  majority of the FA were initially bound in the 
hydrophobic extracellular domain of CD36, a potential binding site predicted from its 
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amino acid sequence [395],  a small portion of these FA would not have appeared in the 
lipid bilayer until released by CD36. If the FA desorption occurred slowly (minutes) into 
the lipid bilayer, a slow initial decrease in FPE fluorescence would have been observed, 
contrary to our observation of a single fast phase.  In our previous analogous experiment 
with HEK293 cells overexpressing only caveolin-1, we observed a similar fast component 
with FPE. Note that our experimental design of adding OA in DMSO rather than using 
albumin as a FA donor presented conditions favorable for observing interactions of the 
added OA with CD36 without the competition of albumin in the media for FA binding 
[396]. 
 The BCECF probe, located in the cytoplasm as seen in Figure 51B, measures the 
combined steps of adsorption and transmembrane movement. The fast drop in BCECF is 
an indication of both fast adsorption and rapid arrival of FA at the cytoplasmic leaflet. A 
slower BCECF fluorescence decrease might be expected in cells overexpressing CD36 if 
FA transport across the plasma membrane is mainly controlled or heavily mediated by 
CD36, as hypothesized from some previous studies [10, 259, 268, 392].  These results 
taken together suggest that FA transport across the membrane is mainly through diffusion 
that does not normally require CD36.    This is consistent with recent studies in CD36-/- 
mice compared to wild-type mice that showed no statistical differences in arachidonic acid 
or DHA concentrations in the different brain regions (neither of which can be synthesized 
de novo in the brain and therefore they must be supplied from the blood) [397]. 
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Figure 51. Schematic depiction of FPE and BCECF fluorescence probes and membrane localization 
of each 
(A) FPE in the outer membrane leaflet and (B) BCECF inside the cytosol and the fatty acid involvement 
with each. 	
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 Our observation of very fast binding of OA, together with the expected slow 
metabolism in HEK293 cells (Figure 40), permitted observation of smaller and slower 
fluorescence changes in the first few minutes after adding FA.  
Our novel and detailed studies of SSO properties demonstrate for the first time that 
SSO alters intracellular pH and modifies intracellular proteins other than CD36 
(Appendix: Figure A3 and Figure 42-44).  This demonstrates that at least some SSO 
crosses the PM without hydrolysis in an intact form (Figure 52B). The ability of SSO to 
diffuse through the membrane supports the acidification (sec to min) of the internal volume 
of cells and vesicles. Also, depending on which proteins are SSO-modified, these covalent 
changes may contribute to additional side-effects in longer-term metabolism of FA. 
Combining our real-time fluorescence data with our SSO data further confirms that FA 
diffuse rapidly across biological membranes and do not require a protein transporter to 
catalyze their transmembrane movement. 
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(A) Schematic showing the structure of sulfo-N-succinimidyl oleate (SSO) and a speculative model of SSO 
flip-flop through the PM, initiated by the hydrophobic tail of the oleate group inserting into the outer-leaflet 
of the PM and then the NHS substituent flip-flopping to the inner leaflet before entering the cytosol.  Flip-
flop of 200μM SSO into live cells appears to equilibrate after ~100s (Appendix: Figure A3) and modify 
numerous PM and intracellular localized proteins, within 20min (Figure 42-44). (B) Proposed chemistry of 
the non-specific and covalent modification that occurs when SSO reacts with the ε-amine group of any lysine 
enough exposed. 
 
 
 
Figure 52. Speculative SSO flip-flop model and proposed chemistry of SSO reacting with ε-amine group 
on lysine 
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In our studies of membrane fluidity as measured by laurdan in cells, we observed 
an expected PM decrease in fluidity in the presence of OA. However, in cells expressing 
CD36 compared to control cells, we observed an unexpected decrease in PM fluidity in the 
presence of OA, which could be reversed using siRNA knockdown of CD36 expression or 
low-dose methyl-beta cyclodextrin washes. Therefore, CD36-driven fluidity changes are 
likely not the cause of increased FFA uptake into cells that accompanies CD36 expression.  
Furthermore, we found that exogenous OA also induces highly ordered microdomains or 
rafts only in cells expressing CD36 within 90min, as seen by two-photon microscopy.  
These need to be investigated further as a potential source of CD36-dependent intracellular 
lipid droplet formation. 
The effects of overexpression of CD36 in HEK293 and HeLa cells on TG formation 
were very significant.  A very significant increase in the incorporation of exogenously 
added OA was seen in these cells compared to empty vector control cells. Our data showed 
that CD36 significantly promoted synthesis of TG and MG and PL but not DG (Figure 50 
and Appendix: Figure A4-A5). In a separate experiment to determine if the total enhanced 
synthesis of MG and PL originated from MG or PL or both, a double TLC was performed 
that allow quantification of MG and PL separately. The majority of the total enhanced MG 
and PL content was due to increased synthesis of MG (results not shown). This further 
supports our conclusion that CD36 accelerates FA esterification, especially synthesis of 
TG. Evidence has shown that in rat adipocyte cells almost all FA are converted into TG 
and the utilization of free FA can be correlated with the BCECF fluorescence recovery 
[76].  Thus, compared to rat adipocyte cells, HEK293 cells overexpressing CD36 do not 
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metabolize FA fast enough within 15mins to cause a pH change that can be detected by 
BCECF. 
 The structure of lipid droplets is composed of a hydrophobic core containing 
mainly TG surrounded by a phospholipid monolayer with multiple attached proteins that 
regulate lipolysis and storage [398]. After a 1hr incubation of the cells with BODIPY 
500/510: OA, faint lipid droplets were visualized in cells overexpressing CD36 (data not 
shown), and these became more observable at longer incubation times (e.g. 24 hours), 
presumably because small droplets fused over time.  Although fluorescent droplets were 
observed inside both HeLa and HEK293 cells, they were larger in size and amount in the 
cells overexpressing CD36 than empty vector control cells.  This finding corresponds with 
the recent finding that increased heart CD36 levels lead to intra-myocardial lipid 
accumulation [399]. 
Taken together, these new findings suggested that CD36 does not play a major role 
in blocking or accelerating FA plasma membrane transport (schematically illustrated in 
Figure 53), which likely occurs via diffusion. CD36 expression affected overall uptake by 
enhancing FA esterification, especially synthesis of TG and lipid droplet formation, which 
may initiate within the PM. Our studies suggest a focus on mechanisms that enhance 
esterification such as signaling mechanisms and interactions of CD36 with enzymes such 
as acyl CoA synthases.  
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Fatty acid flip-flip through the plasma membrane with CD36 expression. TG droplet formation is enhanced 
with CD36 expression but the rate of fatty acid flip-flop is not significantly altered. 
 
  The biophysical methods used in our study are not sensitive enough to detect 
binding of a single FA molecule in the extracellular domain, as proposed by several studies, 
although it could be sensitive to binding of multiple FA molecules, as in our study of 
HEK293 cells with caveolins [158]. FA binding to CD36 could also occur when FA diffuse 
laterally in the lipid bilayer to the transmembrane domains of CD36. Future studies will 
explore biophysical strategies to explore these binding interactions, which could be 
important for signaling functions and effects on metabolism.  However, the present studies 
strongly suggest that if they occur, they do not affect mass transport or enhance the kinetics 
of FA translocation in the plasma membrane. The methods applied permitted distinction of 
Figure 53. Schematic depiction of fatty acid flip-flop 
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biophysical transport from metabolism as contributors to the overall uptake of FA but did 
not unravel the mechanisms of stimulation of TG synthesis.  As with all studies of 
overexpression of a protein, levels of other proteins can be increased; this will be one focus 
of our future work.  More immediately, however, how CD36 and FA might influence LDL 
uptake was investigated because LDL is a FFA uptake source.  This will be the subject of 
the next Chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
  
177 
 
CHAPTER FIVE: ANALYSIS OF THE INTERACTION OF CD36 WITH FATTY 
ACIDS AND OXIDIZED LOW-DENSITY LIPOPROTEIN 
5.1. Rational 
Low density lipoprotein (LDL) transport lipids, including FA in both esterified and 
unesterified forms, and the receptor-mediated uptake of LDL permits entry of the lipids in 
cells.  The scavenger receptor family, which includes CD36, has expanded to encompass 
eight different subclasses of structurally unrelated receptors which, under the classical 
definition, share the defining feature of binding modified forms of LDL [202, 400].  The 
uptake of modified lipoproteins by scavenger receptors is thought to be central to foam cell 
formation and is widely believed to represent one of the major activation events stimulating 
the proinflammatory phenotype of lesional macrophages [202, 401, 402].  Furthermore, 
scavenger receptors initiate signaling cascades that regulate macrophage activation, lipid 
metabolism, and inflammatory programs that may influence the development and stability 
of atherosclerotic plaques [403, 404]. CD36 is a prominent member of the scavenger 
receptor family in part due to its robust catalysis of oxidized LDL (oxLDL) uptake and the 
CD36-specific atheroinflammatory signaling connected to these events [402].  
Furthermore, its expression in cells is associated with cardiovascular disease, which 
includes surface expression on platelets, adipocytes, skeletal and cardiac myocytes, 
capillary endothelial cells, most professional phagocytes, and epithelial cells in gut, kidney 
and breast [405].  
While the physiological relevance of oxLDL has been questioned and also debated 
due to mixed results from various randomized controlled trials using antioxidant therapy 
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to treat oxLDL, 14 clinical cohort studies have demonstrated an association between 
oxLDL measurement and cardiovascular events [69].  Furthermore, specifically CD36 and 
oxLDL levels have recently been shown to be associated with cardiovascular risk factors 
in young subjects [402]. 
CD36 binds oxLDL with an affinity as high as or higher than any other currently 
examined scavenger receptor family members [406, 407].  Early studies illustrated the 
significant role of CD36 in binding/uptake of oxLDL based upon a genetic polymorphism 
in the CD36 gene identified in Japanese subjects shown to result in deficient expression of 
CD36 (the NAKa− phenotype) [408]. Monocyte-derived macrophages isolated from these 
patients were seen to bind ~40% less oxLDL and accumulate ~40% less CE from oxLDL 
than cells derived from normal controls [262].  The site of this oxLDL binding to CD36 
has been identified and recently mapped to amino acids 157-171, with critical lysines at 
positions 164 and 166 [241, 409, 410].  This is consistent with the pH profile and salt 
concentration dependence, which suggest an electrostatic contribution to the CD36-oxLDL 
binding [410].   
Additionally, CD36 is part of the conserved scavenger receptor cysteine-rich 
superfamily (SRCR-SF) characterized by the presence of one or several repeats of an 
ancient and highly conserved protein module [411].  The three characterized disulfide 
bonds in the ectodomain of CD36 [244] are active in CD36-mediated cytoadherence 
of Plasmodium falciparum (malaria)-infected red blood cells [250], indicating potential 
oxLDL binding to CD36 through disulfide bonds and treatment strategies using reducing 
strategies such as targeted nanodrugs. 
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While the best characterized function of CD36 is to bind and internalize oxLDL, 
another widely studied role of CD36 is direct binding of FA [269] and augmenting FA 
uptake [84, 207, 282], as was discussed in Chapter 4.  We found that CD36 increases FA 
uptake through intracellular esterification but does not increase mass transport of FA across 
the plasma membrane; transport which occurs within seconds in cells with or without CD36 
[282].  Therefore, this raises questions regarding the mechanism and role of FA binding to 
CD36.  
Studies of FA uptake using the probes sulfo-N-hydroxysuccinimidyl (NHS) ester 
of oleate (SSO) and the FA derivative isopropyl myristate showed apparent inhibition of 
adipocyte FA uptake, and a subsequent study showed that radiolabeled SSO bound 
covalently to CD36 [267, 268]. CD36 was shown to have a significant homology to M-
FABP throughout 73% of its sequence, suggesting a FA binding region was present in the 
extracellular domain, yet the only reported study of natural FA showed very weak binding 
to CD36 with apparent dissociation constants of about 1μM [269]. However, the 
approaches used had several technical limitations and showed FA to have similar low 
affinity for albumin, which has well-characterized binding constants in the nanomolar 
range [36].   
Serendipitously, using SSO as a probe of FA binding, point mutations of CD36 also 
appear to disrupt oxLDL binding to CD36 and inhibit FA uptake in CHO cells [267, 270].  
Furthermore, new studies have indicated that certain FA inhibit oxLDL binding to synthetic 
CD36 peptide fragments [412, 413]. Along with our recent findings, these new studies 
provide a strong rationale for applying new methods to better characterize FA binding to 
  
180 
 
CD36 and the involvement of CD36 and FA in oxLDL uptake.  Our hypothesis is that FA 
is involved in the CD36-dependent uptake of oxLDL. 
To this end, we applied and optimized a new methodology to study CD36 binding 
of various label-free FA from five FA structural groups (trans FA, saturated FA, 
monounsaturated FA, polyunsaturated FA, and oxidized FA).  In addition, experiments 
included multiple ω-3 and ω-6 FA. Our hypothesis was that CD36 binding to oxLDL is 
modulated by FA binding. Our chosen method to investigate this hypothesis, surface 
plasmon resonance (SPR), provided quantitative information about affinity, specificity, 
and kinetics.  Next, we used confocal microscopy to provide insight into molecular 
mechanisms for the binding of CD36 with oxLDL together with each of the above FA, by 
investigating Dii-oxLDL uptake using a fluorescence binding/uptake assay. Our findings 
support the proposed electrostatic mechanism of CD36 binding of oxLDL, along with FA 
acyl chain contributions.  Finally, we have found that binding of CD36 to oxLDL is 
independent of the CD36 disulfide bonds using dithiothreitol (DTT) and tris(2-
carboxyethyl)phosphine (TCEP) reductions. 
 
5.2. Results 
5.2.1. CD36 binds oleic acid with comparable kinetic on/off rates to albumin but with 
decreased affinity and/or binding sites 
Based on homology of FABP and CD36 (discussed above), our beginning 
hypothesis is that CD36 can bind many types of FA with rapid association and dissociation.  
To first investigate potential binding of CD36 to natural FA without potentially perturbing 
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labels, we applied a new methodology, SPR, and a novel approach to solubilize FA for this 
binding assay.  Fully glycosylated recombinant CD36, purified from HEK293 cells without 
the TM domains, was linked to an SPR sensor chip surface, and various oleic acid (OA) 
doses were pulsed across the chip surface to investigate the potential binding affinity and 
kinetics of the OA interaction with CD36.   
Since applying FA bound to MβCD for SPR analysis is a novel technique, 
numerous optimizations were first performed regarding variables such as (1) amount of 
salt in PBS running buffer (standard 150mM gave too much background binding as in 
Figure 54), (2) pH of running buffer, (3) addition of detergent in the running buffer, (4) 
SPR chip binding capacity and selection, (5) density of CD36 added for binding to the chip, 
(6) pH of buffer used to link proteins to the SPR chip, (7) experimental temperature, (8) 
various flow rates, (9) FA dose optimizations, (10) regeneration buffer options, etc. A 
representative example of our early SPR optimization experiments using standard 150mM 
PBS buffer is shown in Figure 54. In this example, the empty well subtraction was not 
performed to emphasize the high degree of background binding of FA to this well and the 
effect this high background binding has on other wells.  As explained in Chapter 1 and 
[40], FA is able to rapidly associate and dissociate to a variety of surfaces, so this binding 
was not unexpected.  Using 200mM PBS and no detergent successfully eliminated high 
background binding and was used for all other SPR experiments.  
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Figure 54. An early optimization experiment using surface plasmon resonance of CD36, IgG, and HSA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panels A. and D. are EDC/NHS activated and ethanolamine quenched lanes from a single 6-well Bio-Rad 
Proteon XPR36 GLM SPR chip, which have increasing concentrations of 1 OA: 6 MβCD pulsed across the 
surface.  All buffers used in this experiment were standard 150mM PBS, pH 7.4, and PBS+tween did not 
resolve all the background binding.  Later, we found that 200mM PBS, pH 7.4, with no added detergent, did 
resolve most of the non-specific background binding, as shown in below Figures. 
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 After showing that 200mM PBS eliminated most background binding, we next ran 
extensive controls.  Since the design of the experiment necessitated maintaining FA in a 
soluble form in high concentrations, we first investigated the use of MβCD to deliver OA 
(representative data shown in Figure 55B, C, E, G).  We used MβCD as a delivery vehicle 
to overcome solubility limitations and artifacts.  Our lab has characterized the interactions 
of several FA with MβCD and demonstrated that in aqueous buffer, FA dissociate from 
MβCD and partition into lipid bilayers within msec [85, 414]. Additionally, FA: MβCD in 
PBS buffer is more physiologically relevant than typical organic solvents used to solubilize 
FA (e.g. DMSO).  Note that we tested FA solubilized in varying amounts of DMSO (data 
not shown) but found MβCD was the best method for delivery.  Organic solvents are 
incompatible with SPR at high volume percentages due to their high refractive index 
leading to maximal SPR response units (RU) and we found this was the case even at low 
DMSO percentage amounts.  In our SPR experiments, we tested up to 5mM MβCD with 
CD36 linked to the SPR chip surface and saw no significant binding or dose dependency 
in these controls (Figure 55A – C).   
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Panels A. and D. are EDC/NHS activated and ethanolamine quenched lanes from a single 6-well Bio-Rad 
Proteon XPR36 GLM SPR chip, which have increasing concentrations of (A.) MβCD and (D.) 1 OA: 6 
MβCD pulsed across the surface. To correct for non-specific empty lane binding, panels B. and C. are 
normalized to A.   The specific wells contain (B.) HSA bound to the chip surface with only MβCD pulsed 
across and (C.) CD36 bound to the chip surface with only MβCD pulsed across, in increasing doses. No 
significant binding of MβCD to CD36 or HSA were observed.  Panels E., F., and G. are normalized to D. 
and show (E.) HSA, or (F.) CD36, or (G.) IgG bound to the chip surface with OA: MβCD pulsed across, in 
increasing doses. Binding of OA is seen with HSA (panel E.); Ka = 1.0e3 1/Ms, Kd = 7.9e-3 1/s, and KD = 
7.9e-6 M. Binding of OA is seen with CD36 (panel F.); Ka = 1.0e3 1/Ms, Kd = 8.2e-3 1/s, and KD = 8.2e-6 M.  
Although these may not represent accurate KD’s, the relative value is important. Note that when higher 
amounts of OA were added with CD36, no higher signal was observed (data not shown).  G. No significant 
binding of OA was observed with IgG bound to the chip.  
The lower left Schematic (far left) illustrates an NHS-activated SPR chip surface with (middle) CD36 
mobilized by covalent linkage and (right) FA being pulsed through the flow channel containing CD36. The 
covalent linkage of CD36 is at amino acids 30 and 439 (full length protein is 1-472), which is adjacent to the 
lipid bilayer in the full length protein. 
Figure 55. Surface plasmon resonance of CD36 and HSA binding to oleic acid but not control 
cyclodextrin 
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For comparison with our CD36 results, we performed parallel experiments with 
human serum albumin (HSA) as a positive control.  HSA was covalently linked to the SPR 
chip surface with the same RU amount bound as CD36 (experimentally determined, as 
described in Chapter 3; Figure 55B, E).  We found that HSA also did not bind FA-free 
MβCD. HSA also bound and released OA rapidly and with a high RU response (for 
example, Figure 55E), which was expected from extensive previous studies of FA binding, 
including those in our lab with albumin [34, 415] and FABP1 [277, 416].  As an additional 
negative control, we bound IgG to the chip surface and saw no OA binding, as expected 
(Figure 55G). Figure 55F shows our SPR data for OA binding to CD36 with a dose-
responsive RU response.  There was a large RU increase between 100μM and 200μM, 
relative to the other OA doses, which was also seen in the positive control HSA.  The upper 
range of RU saturation for CD36 was found at ~200μM OA, and higher OA doses were 
found to not significantly increase RU signal beyond 200μM OA concentrations (Rmax). 
5.2.2. Serum is required for large quantity CD36-mediated oxidized LDL binding 
Although our SPR experiment does not directly quantify the number of OA binding 
sites, the comparison of data for HSA (with 9 known sites) and CD36 provides the first 
biophysical evidence for the likely presence of several binding sites on CD36. Most of the 
focus on interactions of CD36 with FA has been on binding of a single FA molecule to a 
site in the large ectodomain with structural homology FABP, and how such binding could 
promote mass transport of FA through the plasma membrane [10, 207].  FA binding (either 
one or several molecules) would not likely be sufficient binding for mass FA transport but 
could affect binding of LDL, especially with evidence that site-specific CD36 inhibitors 
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have indicated that FA and oxLDL bind CD36 in the same peptide region [270].  
Consequently, this led us to hypothesize that CD36 binding to FA was necessary for 
oxLDL binding to CD36. We first investigated the potential of physiologically significant 
FA binding using serum and an established fluorescent-labeled oxLDL (Dii-oxLDL) 
binding/uptake assay.  We began by adding Dii-oxLDL to HEK293 cells expressing CD36 
(pCI-neo-CD36) in either DMEM with 10% fetal bovine serum (FBS), which contains a 
mixture of biological FA, or DMEM without serum (Fig. 2). HEK293 cells expressing 
empty vector control (pCI-neo-empty) were used as a negative control (Figure 56u–x and 
56C). 
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Merged 20x confocal micrographs of HEK293 cells, transfected with pCI-neo-CD36 (a.-t.) or pCI-neo-empty 
vector control (u.-x.), with 5µg/mL Dii-oxLDL (shown in red in the merged image) added for 90min at 37°C 
in DMEM with 10% FBS (a-d), DMEM without serum (e.-h.), DMEM with 10% charcoal-stripped FBS (i.-
l.), or serum-free DMEM with only OA added back (m.-x.). After Dii-oxLDL incubation, the cells were fixed 
and stained for CD36 (shown in green in the merged image) and the nuclear stain DAPI (shown in blue in 
the merged image).  Under different conditions, CD36 surface distribution appears to change (a., e., i., m., 
and q.) especially with or without serum (a. versus e.) or when increasing doses of OA were added (m. versus 
q.). White arrows in each merged image (d., h., l., p., t., x.) indicate representative enlarged cells in the 
original color scheme, shown on the right side bars. All OA added was complexed to MβCD (1 OA: 6 
MβCD), as in SPR experiments. 
 
As shown in the top row of Figure 56a–d, robust binding of Dii-oxLDL occurred 
in the presence of serum, but very little binding was detected when serum was not present 
Figure 56. Micrographs of cells with or without CD36 expression showing oxLDL dependence on 
serum and/or oleic acid doses 
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in the assay (Figure 56e–h). Additionally, when 10% FBS was used that had been 
charcoal-stripped to remove hydrophobic molecules (i.e. FA, hormones, etc.), the Dii-
oxLDL binding was again nearly completely eliminated (Figure 56i–l).  Since oxLDL 
purified from human plasma contains enough FA to affect LDL electronegativity [417], it 
is possible that the observed small amount of basal Dii-oxLDL binding may be 
accomplished through FA already present on oxLDL. 
 
 
 
 
(A.) Quantification of red fluorescence pixels (Dii-
oxLDL) from Figure 3 a.-l., after background 
subtractions, in a 20x magnified, 200 cell field and (B.) 
quantification of red fluorescence pixels where doses of 
OA were added (m.-x., 1mM OA addition confocal 
images not shown in Figure 3).  (C.) Additional control 
merged confocal micrograph of HEK293 cells transfected 
with pCI-neo-empty control vector, with 5μg/mL Dii-
oxLDL (red) added for 90min at 37°C in DMEM with 
10% FBS. The cells were then fixed and stained for CD36 
(green) and DAPI (blue). 
 
 
 
 
 
 
 
 
Figure 57. OxLDL quantification from Figure 56 
and additional control 
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5.2.3. Oleic acid enhances CD36-mediated oxidized LDL binding 
FBS has been shown to contain a ratio of saturated, monounsaturated, and  
polyunsaturated FA (34.0%, 34.3%, 27.8%, respectively), with almost 30% of the total FA 
composition being comprised of OA [418].  Since SPR demonstrated that CD36 binds OA 
and that Dii-oxLDL uptake was dependent on the presence of serum, we hypothesized that 
OA will increase oxLDL binding and uptake in CD36-expressing cells.  To this end, we 
added doses of OA to Dii-oxLDL in serum-free DMEM to HEK293 cells expressing CD36 
(Figure 56m–t) or to empty control vector (Figure 56u–x).  The OA was solubilized by 
MβCD in Figure 56, but we also tested OA solubilized by BSA and found similar results 
to MβCD (Figure 58E-H).  Dii-oxLDL binding was rescued with OA added to the serum-
free media, as expected.  In addition, the surface localization of CD36 was observed to be 
altered at higher doses of OA, and binding became even greater than with serum (Figure 
56q–t, Figure 57A, and Figure 58). Another experiment was carried out with the inhibitor 
of FA activation. Since CD36 enhances esterification of exogenously added FA [282], 
which requires activation of the FA, therefore we inhibited the first step of FA activation 
by using the acyl-CoA synthetase inhibitor, Triacsin C.  With Triacsin C present for the 
90min incubation of Dii-oxLDL and OA, no significant difference was seen compared to 
the parallel experiment without Triacsin C (Figure 58A-D). 
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Figure 58. OxLDL uptake using BSA delivery of oleic acid and Triacsin C inhibitor 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
(A) – (D) Representative 20x confocal micrographs of HEK293 cells transfected with CD36, treated with 
24μM Triacsin C and with 5ug/mL Dii-oxLDL (red) for 90min at 37°C in serum-free DMEM with 100μM 
OA solubilized in MβCD (1 OA: 6 MβCD molar ratio). The cells were then fixed and stained for CD36 
(green) and DAPI (blue). (E) – (H) Merged confocal micrographs of HEK293 cells transfected with CD36, 
with 5ug/mL Dii-oxLDL (red) added for 90min at 37°C in serum-free DMEM with 250μM OA solubilized 
in BSA at a 1:2 molar ratio BSA: OA. The cells were then fixed and stained for CD36 (green) and DAPI 
(blue). 
 
Having demonstrated binding of oxLDL to the surface receptor CD36 by confocal 
microscopy (Figure 56), we next determined whether Dii-oxLDL was internalized by the 
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cells expressing CD36 (uptake) or only binding CD36 at the plasma membrane, where 
CD36 is predominantly localized in our HEK293 cell system [282].  To discriminate these 
two possibilities, we expressed GFP-CD36 and used 3-dimensional confocal microscopy 
to visualize the Dii-oxLDL location in the z-plane relative to CD36 localized at the cell 
surface and relative to the cell nuclei (Figure 59A–C).  The merged image panel shows 
that most of the Dii-oxLDL bound by cells expressing GFP-CD36 (yellow color, Figure 
59C) was internalized; indicating that binding to CD36 was followed by oxLDL uptake 
when OA is present, within the 90min incubation.  This is a very crucial discrimination and 
the experiment was repeated 3 times.  In addition, for each confocal microscopy experiment 
and including other FA types (i.e. Figure 56, 59, 61, 62, and 64), internalization of Dii-
oxLDL was observed.  
Next, to focus directly on FA effects of oxLDL binding to CD36, we performed 
additional in vitro SPR experiments in which Dii-oxLDL was pulsed across the SRP chip 
surface containing bound-CD36 in the presence and absence of OA. Based on the above 
microscopy and SPR findings, we hypothesized that oxLDL will bind CD36 at higher R.U. 
when OA is present rather than absent, even though human oxLDL contains some 
endogenous FFA.  In these SPR pulses, we observed significantly more binding of Dii-
oxLDL to CD36 when 150μM OA was present along with Dii-oxLDL, than with Dii-
oxLDL alone, and very little binding of oxLDL to the negative control, IgG (Figure 59D-
F). For example, when 4nM oxLDL by itself was pulsed across CD36, the RU of binding 
is ~130 (Figure 59E, green line).  When 4nM oxLDL with 150µM OA: MβCD was pulsed 
across CD36, ~400RU of binding was observed (Figure 59F, green line), even though OA: 
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MβCD by itself only adds ~100RU (expected RU of binding: 130RU + 100RU = 230RU; 
observed = ~400RU).  This indicates that OA may be opening or facilitating an oxLDL 
binding site on CD36 to increase oxLDL binding.  Furthermore, since human-source 
oxLDL contains FA, it is possible that the FA present on oxLDL is enabling the binding to 
CD36 seen when additional OA is not added (Figure 59E and Figure 56e–l). Experiments 
with FA-free oxLDL would need to be performed in future studies to better determine if 
this is the case, which has not yet been done. Since the RU is low, the much higher 
concentrations of an exogenously added FA produce higher RUs.   
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Representative confocal micrograph, including 3-dimesional z-stack plane (left edge of each image) at 60x 
magnification, of HEK293 cells transfected with GFP-CD36 (A., green), with 5µg/mL Dii-oxLDL (B., red) 
added for 90min at 37°C in serum-free DMEM containing 100μM OA: MβCD (1 OA: 6 MβCD). The cells 
were then fixed and stained with nuclear stain DAPI (C., blue in the merged image).  The small yellow 
regions in the merged image indicate colocalization of EGFP-CD36 and Dii-oxLDL. In the merged image, 
arrow (1) illustrates CD36 (green) localized on the cell surface and arrow (2) indicates Dii-oxLDL and CD36 
(yellow/red) taken into the cell at the nuclear level, indicating uptake rather than cell surface binding. 
Panel D. is negative control IgG bound to a GLM SPR chip, while E.–G. show CD36 bound to a 
GLM chip with comparable RU amounts to IgG bound.   For E. and F., doses of 0, 1, 4, and 8nM of oxLDL 
were pulsed for 60s in PBS, followed by a PBS wash without Dii-oxLDL.  In F., 150μM OA: MβCD (1 OA: 
6 MβCD) was added to each dose of Dii-oxLDL. Panel G. is from Figure 55F., to contrast the effects of OA: 
MβCD added without oxLDL.  Similarly, in F. the black arrow highlights the 0nM oxLDL dose and a binding 
response due to the presence of 150μM OA: MβCD.   
In each panel, note the difference in scale.  Also note the RU change from oxLDL alone in E. is 
~30, ~130, and ~250 for 1nM, 4nM, and 8nM oxLDL, respectively. With OA: MβCD, an additional ~100RU 
is expected, but instead RU change in F. is ~200, ~400, and ~500 for 1nM, 4nM, and 8nM, respectively. 
D. Only slight binding of oxLDL was observed with IgG bound to the chip. Significant binding of oxLDL is 
seen with CD36 (panel B.); Ka = 1.0e3 1/Ms, Kd = 1.7e-4 1/s, and KD = 1.7e-7 M.  Increased binding of 
oxLDL is seen with CD36 with 150μM OA present (panel C.); Ka = 1.0e3 1/Ms, Kd = 4.4e-4 1/s, and KD = 
4.4e-7 M. As with SPR and FA, these may not represent accurate KD’s but the relative value is important.  
Figure 59. Three-dimensional micrograph of oxLDL uptake and SPR of oxLDL binding CD36 with or 
without oleic acid 
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5.2.4. Other Structurally Distinct Classes of Fatty Acid Bind to CD36 Via SPR and Alter 
OxLDL Uptake Differently 
The OA trans isomer, elaidic acid (EA), is commonly formed by the partial 
hydrogenation of vegetable oils and commonly consumed by humans. Trans FA are 
considered detrimental dietary components and increase risk of cardiovascular disease 
[419].  We hypothesized that CD36 binds a number of structurally distinct FA types.  
Testing this hypothesis using SPR and EA, we found that EA bound to both CD36 and 
HSA but with slower and possibly biphasic kinetics of adsorption (Figure 60A and 60E).  
These biphasic kinetics of EA binding further substantiate the presence of multiple FA 
binding sites on CD36 that were mentioned above. Along with each experiment using HSA 
and CD36 in Figure 60, we included IgG as a negative control; under no condition was 
IgG seen to bind any FA above +/- 10 RU, indicating FA binding was specific only to HSA 
and CD36 (Figure 55G shown as representative, other control data not shown). 
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Panels A.–D. contained HSA bound to a GLM SPR chip.  Panels E.–H. contained CD36 bound to a GLM 
chip in the same RU amount as HSA as described in detail in Chapter 3. All wells were normalized to the 
empty well (empty well not shown) to correct for non-specific binding, and none of these FA showed 
significant binding to IgG (data not shown).  A. Binding of EA is seen with HSA; Ka = 1.0e3 1/Ms, Kd = 
1.8e-3 1/s, and KD = 1.8e-6 M. E. Binding of EA is seen with CD36; Ka = 1.0e3 1/Ms, Kd = 5.1e-3 1/s, and 
KD = 5.1e-6 M. B. Binding of HODE is seen with HSA; Ka = 1.0e3 1/Ms, Kd = 6.7e-3 1/s, and KD = 6.7e-6 
M. F. No significant binding of HODE to CD36 was seen. C. Binding of PA is seen with HSA; Ka = 1.0e3 
1/Ms, Kd = 1.2e-2 1/s, and KD = 1.2e-5 M. G. Binding of PA is seen with CD36; Ka = 1.0e3 1/Ms, Kd = 1.1e-
2 1/s, and KD = 1.1e-5 M. D. Binding of DHA is seen with HSA; Ka = 1.0e3 1/Ms, Kd = 1.3e-2 1/s, and KD = 
1.3e-5 M. H. Binding of DHA is seen with CD36; Ka = 1.0e3 1/Ms, Kd = 1.2e-2 1/s, and KD = 1.2e-5 M. Note 
the differences in RU scale.  In each experiment, the highest FA dose shown represents at or near saturation 
(Rmax).  All FA used was complexed to MβCD with 1:6 FA: MβCD, except for PA (1:12) and DHA (1:1). 
 
Figure 60. Human serum albumin and CD36 binding to EA, HODE, PA, and DHA 
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Because EA is considered an unhealthy dietary FA, we were especially interested 
in whether EA by itself increased Dii-oxLDL uptake as assayed by confocal microscopy. 
We found uptake to be even more pronounced than OA at much lower doses, with doses 
higher than ~100μM showing no additional uptake (~Rmax of Dii-oxLDL uptake).  
Interestingly, the presence of EA even at lower doses appears to drastically affect the CD36 
distribution on the cell surface, especially when compared alongside other FA types, 
(Figure 61a–d, added alongside other FA representative groups, for comparison).  This 
issue would be valuable to explore in future studies. 
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Figure 61. Micrograph showing oxLDL uptake in cells with CD36 with EA, HODE, PA, or DHA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Merged 20x confocal micrograph of HEK293 cells transfected with CD36, with 5µg/mL Dii-oxLDL (shown 
in red in the merged image) added for 90min at 37°C in serum-free DMEM with 100μM EA (a-d) and HODE 
(e-h), 250μM PA (i-l), and 500μM DHA (m-p), all complexed to MβCD as in SPR experiments.  Higher 
doses of HODE were found to abolish cytoadherence and higher EA doses did not increase Dii-oxLDL uptake 
(data not shown).  PA was found to increase Dii-oxLDL up to about 500μM (data not shown), similar to the 
Dii-oxLDL Rmax when OA was present (Fig. 2m-2t).  
After Dii-oxLDL incubation, the cells were fixed and stained for CD36 (shown in green in the merged 
images) and DAPI (shown in blue in the merged images). Significant Dii-oxLDL binding is only seen with 
added EA (a-d) and PA (i-l) but not with HODE (e-h) or DHA (m-p).  Additionally, CD36 surface distribution 
changes with each FA (a, e, i, m), especially with EA (a). Furthermore, Dii-oxLDL uptake was substantial 
and highly diffuse at the cell surface when EA was added (panel j and enlarged cell example).  White arrows 
in each merged image (d, h, l, p) indicate representative enlarged cells in the original color scheme, shown 
on the right side bars. 
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Since the oxidized FA HODE is the most abundant oxidized FA in oxLDL [420], 
we used SPR to test whether CD36 could bind HODE. This FA is a naturally produced 
signaling molecule with an -OH group. Unexpectedly, we observed dose responsive 
binding of HODE with HSA but no binding to CD36 (Figure 60B and 60F).   When HODE 
was included in the serum-free Dii-oxLDL uptake assay, no increase in Dii-oxLDL uptake 
was observed in doses up to 100μM (Figure 61e–h).  Doses of HODE above 100μM were 
tested but led to a dramatic loss of cytoadherence and no noticeable Dii-oxLDL uptake 
difference (high dose data not shown; low n per microscopy field). 
To investigate other physiologically important FA classes, we selected saturated 
PA and polyunsaturated DHA for SPR and Dii-oxLDL uptake studies.  We found CD36 
bound both DHA and PA, with particularly high binding responses with DHA before 
reaching saturating doses (Figure 61H).  Despite the high binding response of DHA with 
CD36 on SPR (Figure 60), DHA did not increase Dii-oxLDL uptake, even at the high dose 
of 500μM DHA in serum-free media (Figure 61m–p).  This suggests that DHA is binding 
CD36 while inhibiting oxLDL uptake and provides a molecular basis for explaining other 
studies showing DHA decreases oxLDL uptake [15].  Furthermore, while PA showed 
binding saturation to CD36 at relatively low doses on SPR compared to other FA classes 
that were investigated (Figure 60G), PA increased Dii-oxLDL uptake with dose saturation 
comparable to OA (saturation at ~500μM PA), while again appearing to change the CD36 
surface distribution at higher doses (Figure 61i–l and Figure 62). 
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Figure 62. Palmitic acid doses and response of CD36-mediated Dii-oxLDL uptake 
 
 
 
 
 
 
 
 
 
 
Merged 20x confocal micrograph of HEK293 cells transfected with CD36, with 5µg/mL Dii-oxLDL (shown 
in red in the merged image) added for 90min at 37°C in serum-free DMEM with different doses of PA 
complexed to MβCD as in SPR experiments.  After Dii-oxLDL incubation, the cells were fixed and stained 
for CD36 (shown in green in the merged images) and DAPI (shown in blue in the merged images). 
 
 
5.2.5. Omega 3 fatty acids bind CD36 but do not increase oxLDL uptake  
Omega 9 FA, which are common dietary components found in foods like canola 
oil, sunflower oil, and almonds (Chapter 1), bound CD36 and strongly enhanced Di-
oxLDL uptake (Figures 55-59).  In addition, omega 3 DHA bound to CD36 on SPR 
(Figure 60H) but did not promote Dii-oxLDL uptake (Figure 61m-p).  This led us to next 
investigate the significance of omega FA number on oxLDL uptake.  The FA we selected 
were arachidonic acid (AA; ω-6), linoleic acid (LA; ω-6), eicosapentaenoic acid (EPA; ω-
3), and alpha-linolenic acid (ALA; ω-3). 
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Figure 63. Human serum albumin and CD36 binding to AA, LA, EPA, and ALA 
Preliminary SPR experiments verified that all four of these FA bound to CD36 on 
SPR as well as the positive control HSA (Figure 63).  IgG was also tested for FA binding 
as a negative control but showed no binding above 10 R.U. (data not shown) even at 200μM 
doses of each FA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panels A.–D. contained HSA bound to a GLM SPR chip.  Panels E.–H. contained CD36 bound to a GLM 
chip in the same RU amount as HSA. All wells were normalized to the empty well to correct for non-specific 
binding, and none of these FA showed significant binding to IgG (data not shown) and n = 3.  Error bars are 
not shown for clarity (< +/- 25 RU for each experiment set). Each FA bound both HAS and CD36 in varying 
degrees. All FA used was complexed to MβCD with 1:3 FA: MβCD, except for LA (1:4). 
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Similar to all other FA that bound CD36 in Figure 60, AA, LA, EPA, and ALA 
also gave very rapid associations and rapid dissociations of binding.  And while each FA 
bound CD36, the RU of binding was low.  This indicates that higher doses of each FA 
should be tested and more CD36 and HSA should be linked to the SPR chip (or a chip with 
great capacity should be used) to enhance signal-to-noise in future studies. 
Binding and uptake of Dii-oxLDL to live HEK293 cells in serum-free media was 
tested next in the presence of each ω-6 and ω-3 FA, solubilized in MβCD as in all 
experiments with FA. While each of these FA were found to bind CD36 via SPR, only ω-
6 (AA and LA) gave significant enhancements of Dii-oxLDL uptake (Figure 64A-B).  
Similar to DHA above, even at high doses of EPA and ALA, the effects of these ω-3 FA 
were minimal for Dii-oxLDL uptake in these cells expressing CD36. 
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Separate and merged 60x confocal micrographs of HEK293 cells transfected with CD36, with 5µg/mL Dii-
oxLDL (shown in red in the merged image) added for 90min at 37°C in serum-free DMEM with 500μM of 
AA, LA, EPA, or ALA complexed to MβCD as in SPR experiments.  After Dii-oxLDL incubation, the cells 
were fixed and stained for CD36 (shown in green in the merged images) and DAPI (shown in blue in the 
merged images), n = 1.  Uptake was not yet quantified due to limited cell numbers from these preliminary 
experiments. 
 
 
 
 
A. 
B. 
C. 
D. 
Figure 64. Omega 3 fatty acids enhance uptake of oxLDL in HEK293 cells while omega 3 fatty acids 
do not 
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5.2.6. CD36 binds oxidized LDL independently of its disulfide bonds 
Extending studies to gain insights into localizing FA and oxLDL binding on CD36, 
we performed a recombinant CD36 Dii-oxLDL binding assay, previously applied to study 
CD36 binding to various modified forms of LDL, including oxLDL [190].  However, we 
included a heretofore uncharacterized disulfide bond reduction of CD36, employing both 
the commonly used reducing agent dithiothreitol (DTT), as well as tris(2-
carboxyethyl)phosphine (TCEP).  TCEP has the advantage of being a more powerful 
reducing agent, is considered irreversible by leaving two free cysteines, and, most 
importantly, TCEP does not reduce metals such as Ni-NTA, used here to immobilize 
CD36-6xHis. 
We hypothesized that CD36 binding to oxLDL is dependent upon disulfide bonds, 
similar to CD36 binding to certain other ligands.  However, even under strong reducing 
conditions, no difference in Dii-oxLDL binding to CD36 was observed (Figure 65).  This 
indicates that the CD36 disulfide bonds are not required for oxLDL binding and may not 
be a useful drug target for potentially inhibiting oxLDL uptake by CD36. Additionally, our 
KD (KD = Ka/Kd) values for each of the three conditions (~25 μg/mL +/- ~8) were similar 
to previously published values for oxLDL binding CD36-12xHis (KD = 10.44 +/- 0.08 
μg/mL [190]), despite our use of dodecyl-beta-maltoside in place of octylglucoside in the 
ligand binding buffer and the wash buffer. Homology modeling of CD36 based on the 
crystal structure of family member LIMP2 also indicates that the three disulfide bonds of 
CD36 reside on one “face” of the CD36 protein [241], so we infer that FA and oxLDL is 
likely to bind to CD36 on the other face of its tertiary structure (Discussion, Figure 66). 
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Interaction of CD36 bound to a Ni-
NTA coated plate with Dii-oxLDL 
added at concentrations of 0, 1, 2.5, 5, 
10, 15, 20, 25, 30, 35, or 40μg/mL for 
90min at room temperature with no 
disulfide reduction (black squares), 
10mM DTT added (red circles), or 
10mM TCEP added (blue triangles).  
Both DTT and TCEP were added in 
oxLDL binding buffer for 5min and 
then aspirated just prior to adding 
doses of Dii-oxLDL in oxLDL 
binding buffer.  Binding curves were 
depicted with relative fluorescence 
units for ligand binding plotted as a 
function of ligand concentration.  
Curve fitting was conducted as 
described in Materials and Methods 
from which values for KD and Rmax were determined.  CD36 with no reduction bound oxLDL with a KD = 
27.9 + 2.1 μg/mL; Rmax = 8.2 + 0.3 μg/mL.  CD36 with added DTT bound oxLDL with a KD = 29.2 + 8.6 
μg/mL; Rmax = 8.7 + 1.2 μg/mL.  CD36 with added TCEP bound oxLDL with a KD = 22.8 + 4.6 μg/mL; Rmax 
= 8.2 + 0 μg/mL.  Three independent experiments were performed for each data set. 
 
 
 
5.3. Discussion 
5.3.1. Fatty acid binding: novel findings from surface plasmon resonance 
In very recent studies, biophysical approaches have yielded valuable new insights 
into the structure of CD36 and the molecular interactions of FA analogues in the 
extracellular region with homology to FABP [241, 245]. Throughout the long history of 
CD36 research, the hypothesis of a single FA binding site has been proposed as a potential 
mechanism for transport of FA across the plasma membrane into cells [78], as a taste bud 
sensor of FA [421, 422], and/or as an important site for uptake of oxLDL [371]. Our recent 
Figure 65. Oxidized LDL binding to 
CD36 with or without reduced 
disulfide bonds 
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study combining biophysics, cell biology, and metabolism in HEK293 cells with and 
without CD36, led to the finding that while CD36 does not enhance FA transport across 
the plasma membrane, its presence enhances intracellular triglyceride accumulation [282]. 
New work by other investigators has led to additional evidence of the involvement of a 
single FA binding site in oxLDL uptake [270]. And although an early study suggested 
binding of more than one FA molecule to CD36 [269], the methods used were not accurate 
and were indirect with separation methods (Lipidex resin). 
Here we show that a new approach to study FA binding to CD36 (SPR) yielded the 
novel finding that the ectodomain of CD36 likely binds several molecules of FA, which 
could have important ramifications beyond the binding of a single FA molecule for CD36 
function. The experimental design (Figure 55, Schematic), including the use of 
cyclodextrin delivery, permitted quantitative and direct evaluation of the binding of natural 
FA without the use of high concentrations (up to 1mM [423]) of nonphysiological probes 
such as SSO and/or without separation procedures such as column chromatography (e.g. 
Lipidex resin [269]). SPR showed that CD36 binds structurally different long chain FA, 
including OA, EA, and PA (monounsaturated FA, trans FA, and saturated FA, 
respectively), and polyunsaturated ω-3 FA (DHA, EPA, and ALA) and ω-6 FA (AA, LA), 
but not the oxidized FA HODE.  Moreover, the FA binding was dose dependent and 
exhibited affinities similar to those of FA on human serum albumin (HSA), as measured in 
parallel experiments by SPR and in agreement with previously measured values [36]. The 
RU values indicate different apparent affinities/saturation of the CD36 binding site(s); for 
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example,  PA (~10μM), EA (~100μM), DHA (~150μM) and OA (~200μM), whereas the 
very low RU for HODE indicates no significant binding (Table 9). 
In comparison with CD36, FA interactions with albumin have been characterized 
in detail by many biophysical methods, including NMR spectroscopy and x-ray 
crystallography approaches [415]. Nine individual sites on HSA have been recently been 
detected by 2D NMR, and several NMR peaks were correlated with crystallographic sites 
well characterized for long chain FA [34]. Binding constants measured by 2D NMR on a 
site specific basis varied only by a factor of 10 between the highest and lowest affinity 
sites, with affinity constant (KD) values similar to those reported by earlier studies (Note: 
KD = Kd/Ka with units of M) [34, 36]. 
The high affinity FA binding to CD36 has the important implication that binding at 
some or all sites could affect protein conformation. The similarity of the kinetics of 
dissociation of FA from albumin and CD36 observed in our experiments carries the 
implication that FA have a long enough residency time to have effects on protein structure, 
but also a short enough residency time to allow rapid equilibration between the surrounding 
aqueous environment, the plasma membrane, and albumin in the plasma (Figure 66A). By 
contrast, low affinity binding with weak interactions, as suggested by some previous 
studies [269], would not likely affect protein structure and function, or equilibration among 
the different pools of FA. Furthermore, the amount of FA bound (mol/mol of CD36) could 
alter protein conformation (Figure 66B), as has been observed for HSA [415], and the 
apparent bi-phasic binding curve, seen with EA especially, indicates that this is the case. 
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Thus, the existence of these multiple sites could provide a stronger sensor for extracellular 
and membrane-bound FA concentrations, than would a single site.  
 
 
A. Dissociation of long chain FA from albumin and phospholipid bilayers occurs in a time of msec-sec [424] 
and we expect generally similar kinetics for the CD36 binding sites, especially with our SPR data. The high 
abundance of the PM must be taken in account to determine the partitioning of FA between proteins such as 
CD36 and the surrounding membrane. B. Using homology modeling of CD36 from the recently published 
crystal structure of CD36 family member LIMP-2 [241], we designed this schematic showing a possible 
mechanism for oxLDL binding, after FA opens the binding site, based on combining our FA binding studies 
(SPR) and Dii-oxLDL binding/uptake data (microscopy).  The site of FA and oxLDL binding is presumably 
on the opposite face of the CD36 protein structure (left side, as the CD36 protein is oriented in the schematic) 
from the disulfide bond-rich region (right), as we found disulfide bond reduction does not alter oxLDL 
binding. LDL is shown in the upper background with a single apolipoprotein B-100 wrapping the particle 
and white dots on the LDL indicate oxidation. One of the implications of the newly characterized FA sites 
on CD36 is that as the concentration of FA in the plasma and/or PM increases, the sites on CD36 will have 
high occupancy, further increasing oxLDL binding and uptake. Fig. not drawn to scale. 
 
 
5.3.2. Effects of fatty acid on oxidized LDL uptake by CD36 
To study effects of FA on CD36-mediated uptake of oxLDL, we utilized our 
HEK293 cell line designed to express CD36 in its natural glycosylated form, at levels 
Figure 66. Schematic summary of CD36, albumin, and the plasma membrane bilayer with exogenous 
fatty acid exchange 
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comparable to its endogenous expression in adipocytes [282]. As with  our previous studies 
of CD36-mediated uptake of FA, HEK293 cells offered advantages of low or absent 
endogenous expression of other purported FA transporters (including CD36) [282], and 
slow metabolism of exogenous FA [158], which permitted focus on mechanisms related to 
CD36.  For the present study, these HEK293 cells are also advantageous because they lack 
multiple scavenger receptors found on adipocytes and most other cell types, as recognized 
in other studies using HEK293 cells [425, 426]. Our rationale for using HEK293 cells is 
further supported because uptake of modified lipoproteins by other scavenger receptors is 
thought to be central to foam cell formation [427], which has previously been observed to 
occur over a relatively long time period (1-3 hours) [426] and could confound our 
observation of binding and internalization of oxLDL.  
Studies of cells are also complicated because FA bind and acidify the lipid bilayer 
and most of the added FA may bind (partition) to the plasma membrane surrounding CD36 
(Figure 66A). The presence of the cell membrane must be considered in interpreting the 
effects of added FA on CD36-mediated uptake of oxLDL. The rapid dissociation of FA 
from the lipid bilayer and plasma albumin will permit binding to sites on CD36 by 
equilibration, as illustrated in Figure 66A. Furthermore, FA diffuse both laterally and 
across the fluid lipid bilayer. We can assume that FA entering the membrane (even from 
an intracellular origin), or in the proximity of the membrane, will bind to sites on CD36, 
and we can predict that higher concentrations of FA will lead to greater occupancy of CD36 
sites. Furthermore, from our cell-free binding studies with SPR, we can predict that effects 
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of FA on CD36 might be differentiated from non-specific effects by dependence on the FA 
structure. 
Our major findings in our HEK293 cells are that: (i) oxLDL uptake was limited in 
serum free media without added FA and in charcoal-stripped FA-depleted serum; (ii) 
addition of exogenous ω-9 and ω-6 FA to serum-free media enhanced oxLDL uptake to a 
level observed with serum; (iii)  PA and EA also enhanced oxLDL in a dose-dependent 
manner; (iv) ω-3 FA did not enhance CD36-mediated uptake of oxLDL although it bound 
to CD36 in our SPR assay; and (v) HODE did not enhance uptake of oxLDL, and did not 
bind to CD36 in our SPR assay.  These findings are summarized in Table 9. 
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Table 9. A summary of fatty acids that altered oxLDL binding to CD36 
The FA we tested that bound CD36 are listed using “+” symbols to indicate binding of the FA to CD36. 
Similarly, uptake of Dii-oxLDL in live HEK293 cells is indicated with “+”.  In general, when a FA bound 
CD36, uptake of Dii-oxLDL ensued, except for ω-3 FA. HODE showed no binding (-) and no enhancement 
of oxLDL uptake (-). 
 
 
The work presented is the first systematic study of the effects of FA in a 
physiological system (live cells) with both oxLDL and FA present in quantifiable amounts. 
Although published results to date from other groups have used similar assays with labeled 
oxLDL in cells expressing CD36, they have not shown dependence of oxLDL binding upon 
serum and/or FA.  This is likely due to different experimental conditions and because the 
studies were not comprehensive. For example, other studies have used monocyte-like or 
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macrophage-like cell lines that express other compensating oxLDL scavenger receptors 
that likely bind oxLDL in a FA-independent manner (e.g. THP-1 cells [428]).  
Additionally, our study used high doses of FA for in vitro experiments (up to 500µM to 
observe the Rmax of Dii-oxLDL uptake), physiological FA concentrations range between 
250 - 3,000μM, dependent on factors such as fasting/nutrition state, and exercise [429]. As 
shown by other investigators, lower levels of oxLDL uptake can be seen with highly 
sensitive oxLDL detection techniques such as radiolabeling (125I-oxLDL) or high-
magnification / high-exposure microscopy, to observe oxLDL binding/uptake, even in 
serum-free media [241, 430, 431].  
We quantified the differences between Dii-oxLDL uptake using serum-free media 
(small levels of uptake), serum-containing media (large levels of uptake), and increasing 
doses of FA in serum-free media (increasing levels of Dii-oxLDL uptake, rescued to 
serum-containing levels). We did not observe any unusual cell phenotype changes, in the 
short time frame of our observation (Figure 56).  Similarly, OA and PA increase CD36 
surface expression [35] but our experimental time scale is not likely to increase surface 
expression of CD36 enough to drastically alter oxLDL uptake. However, our finding that 
CD36 surface distribution was changed using different doses of FA is of interest and an 
aim in our future work.  
5.3.3. Implications of our uptake studies for protein structure: disulfide bonds of CD36 
CD36-mediated cytoadherence of P. falciparum (malaria) infected red blood cells 
is lost following treatment of CD36-expressing cells with the reducing agent DTT [250].  
This finding indicates therapeutic potential in reducing agents, such as the nontoxic 
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drug N-acetylcysteine, to prevent or treat malaria complications due to infected red blood 
cell cytoadhesion.  However, these same treatment strategies may not be useful in 
preventing oxLDL binding and internalization through a CD36-dependent mechanism, 
since we observed that disulfide reduction did not affect Dii-oxLDL binding to CD36 
(Figure 65).  Our results also imply that the FA and oxLDL binding site on CD36 is not 
located in the cysteine-rich region that interacts with P. falciparum-infected red blood cells, 
but possibly on the other face of CD36, as represented by the bound OA in Figure 66B. 
5.3.4. Evidence for direct mechanistic effects of FA on oxidized LDL uptake by CD36 
Since CD36 binds and initiates uptake of oxLDL and we found FA to be required 
for this CD36-dependent mass-transport of oxLDL, we speculate that FA binding alters the 
protein conformation with functional consequences. The structure LIMP-2 [241] provides 
a very plausible mechanism for homologous family member CD36 uptake of cholesteryl 
esters through a hydrophobic groove.  OxLDL fits into a large central cavity homologous 
to the LIMP-2 cavity for glucocerebrosidase. We speculate that CD36 maintains a “closed” 
conformation to oxLDL binding until a specific FA (i.e. OA, EA, and PA) is present.  FA 
binding could shift CD36 into an “open” conformation that is favorable to oxLDL binding 
(Figure 66B). The one well-characterized FA binding site and the oxLDL binding site 
appear to be on the same region, specifically K164 [270]. Binding to this site and other 
sites could influence oxLDL binding, and contribute to opening or closing the binding 
pocket. 
The contribution of direct FA binding enhancement of Dii-oxLDL docking to CD36 
is supported by our in vitro SPR results, pulsing oxLDL together with OA (Figure 59D-
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F).  This interpretation is consistent with recent observations that fragments of the CD36 
protein on multiwall plates had up to 50% less binding of oxLDL when certain FA 
(including OA) were present at extremely high (around 1mM) concentrations; levels which 
outcompete the oxLDL at this (single) oxLDL binding/docking site [302].  Other studies 
of CD36 binding or “scavenging” diverse lipid ligands also indicate a pH profile and salt 
concentration dependence, suggestive of an electrostatic mechanism of lipid binding [410].  
Since the FA in these assays is mainly deprotonated in the extracellular environment (i.e. 
OA pKa = 9.85, etc. [432]), FA could facilitate oxLDL docking through anionic 
interactions with CD36. Hydrophobic interactions with the FA acyl chain appear to play a 
contribution, since the two least hydrophobic FA studied either do not bind to CD36 
(HODE) or do not enhance uptake of oxLDL (DHA). Since DHA binds avidly to CD36 
(SPR shows higher binding than to HSA; Fig. 4D and 4H), it could promote an “open” 
oxLDL binding conformation on CD36 unfavorable for the binding of oxLDL.  This 
finding agrees with previous data showing that DHA lowers oxLDL uptake [433].  
Conversely, it is interesting to note that EA is the most abundant trans-FA found in 
atheromatous plaque [434, 435], and we found that EA bound CD36 on SPR and 
aggressively increased Dii-oxLDL. 
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CHAPTER SIX: FUTURE DIRECTIONS 
6.1. Summary 
Our FA uptake studies using dual-florescence assays revealed that CD36 enhances 
fatty acid uptake by increasing the rate of intracellular esterification but not transport across 
the plasma membrane.  Rapid FA diffusion occurred across the PM irrespective of CD36 
and FA diffusion was not enhanced by CD36-dependent membrane fluidity changes 
(Chapter 4). In fact, our experiments using laurdan revealed that CD36 actually made the 
PM slightly more rigid. One interpretation is that CD36 drives FA out of the PM thereby 
promoting lipid droplet stores inside cells as was observed by our experiments using 
BODIPY shown in Chapter 4 as well as quantitative analysis of [14C] oleic acid in 
HEK293 cells with and without CD36 expression done recently by our group (Appendix 
and [208]). Initial studies using two-photon microscopy using laurdan (Chapter 4) further 
indicate that some lipid droplets may initiate their formation within the PM when CD36 is 
present .  This lipid droplet formation and FA metabolism are priorities for future directions 
and should be addressed beginning using OA time points in CD36 expressing cells with 
added BODIPY. 
For future directions in the area of FA uptake, the influence of caveolae should be 
investigated. While HEK293 cells do not endogenously express CD36 (Chapter 4), they 
also do not express caveolin-1 (Cav-1) [436]. While we found that CD36 did not enhance 
PM fluidity, our group has previously shown that Cav-1 expressed in HEK293 cells does, 
in fact, sequester OA on the cytoplasmic leaflet of the PM [158].  Combining this previous 
Cav-1 finding with our new CD36 work has led to a new hypothesis for the future that 
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CD36 and Cav-1 work in concert to initiate lipid droplets.  It is important to note that, at 
least in endothelial and adipose cells (cells that also co-express CD36 and Cav-1), Cav-1 
is required for the definitive properties of caveolae [158, 437]. Cav-1 begins caveolae 
formation by binding membrane cholesterol, which is believed to be a highly conserved 
mechanism for membrane bilayer organization [437] and this organization may have 
implications within studies of obesity.  For instance, in Cav-1-/- mice, there is decreased 
caveolae as well as lack of adiposity and resistance to diet-induced obesity [110, 437]. 
These data support the possibility of a physiological role of Cav-1 in FFA accumulation 
and subsequent FA storage in concert with CD36 that will be further discussed below. 
In addition, a high priority for future studies will be to investigate proximity of Cav-
1 and CD36 in the plasma membrane, and their possible direct interactions beginning with 
co-immunoprecipitations and microscopy colocalization experiments including different 
conditions (e.g. with and without FFA).  Preliminary data will be discussed below. 
In future caveolae and CD36 studies, Polymerase I and transcript release factor 
(PTRF/cavin-1) should also be included.  PTRF/cavin-1 is another key caveolar protein, 
required for caveolae formation [194, 201] and found in isolated (immunopurified) 
caveolae together with CD36 and Cav-1 [269, 437].  HEK293 cells also do not 
endogenously express PTRF/cavin-1 [438] and can be used for preliminary transfection 
experiments with and without CD36, Cav-1, and/or PTRF/cavin-1 expression.  While some 
very interesting findings have been published with PTRF/cavin-1 and CD36, PTRF/cavin-
1 expression has been shown to be highly colocalized with Cav-1, with highest expression 
found in lung and adipose tissues.  This expression implies a correlation of caveolar 
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function between these two proteins [195]. Conversely, a lack of PTRF/cavin-1 expression 
was found to correlate with lack of caveolae formation, even with Cav-1 residing on the 
PM surface [195]. Some studies propose a putative mechanism for caveolae biogenesis via 
both Cav-1 and PTRF/cavin-1, where lipid-bound Cav-1 begins as a stabilization scaffold 
and PTRF/cavin-1 replaces Cav-1 in the last caveolae biogenesis steps [194]. With the 
paucity of studies of CD36 with PTRF/cavin-1, our hypothesis for future studies is that 
CD36, Cav-1, and PTRF/cavin-1 all work in concert to enhance lipid droplets upon 
exogenous addition of FFA.  PTRF/cavin-1 should be investigated alongside Cav-1 and 
CD36 future studies of FA metabolism and lipid droplet etiology. 
Single-molecule tracking of CD36 may also begin to elucidate what conditions 
might promote CD36 to localize in caveolae to a greater degree and why CD36 has been 
found in caveolae.  The new and exciting technique of single-molecule tracking has shown 
that CD36 moves along cortical cytoskeleton (F-actin) and responds to oxLDL addition, 
eliciting CD36 clustering in the PM [284].  Because CD36 binds oxLDL in a mechanism 
dependent upon FA binding (using SPR and microscopy; Chapter 5), this method can test 
our hypothesis that CD36 responds to FFA by clustering in caveolae and that perturbation 
of this CD36 clustering will impact oxLDL uptake.  This should be investigated beginning 
with QDot nanoparticle tracking of CD36 in response to FA additions and oxLDL additions 
and preliminary data will be discussed below. 
It will also be important to further investigate the dependence of oxLDL binding to 
CD36 upon FFA using SPR.  Since we have found OA can drastically increase oxLDL 
binding to CD36 in vitro, it will be important to investigate other FA types and oxLDL 
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binding in vitro using SPR, especially with ω-3 versus ω-6 FFA additions, with or without 
oxLDL, and pulsed across CD36 bound to an SPR chip. 
Finally, future studies should be pursued using hydrogen exchange mass 
spectroscopy (HX MS) with recombinant, full-length CD36 embedded into nanodiscs with 
added FA [439, 440].  This should start with purification of full-length CD36 from 
HEK293 cells that are adapted to protein-free / serum-free media and suspension culture 
(293F or FreeStyle 293F cells).  Since our SPR data did not identify specific sites within 
CD36, future structural studies should aim to elucidate and characterize binding sites.  
Structural studies would also address why ω-3 and ω-6 FA bind CD36 but have different 
effects on oxLDL binding to CD36.  Finally, nanodisc embedded CD36 would address 
native structure, since CD36 is PM localized.  All of these areas will also be valuable to 
the diverse field of CD36 and scavenger receptor research as a whole. 
  
6.2. Future Directions 
6.2.1. Confocal Microscopy and Co-Immunoprecipitation of CD36 and Caveolae 
Proteins 
Retrospectively, numerous issues have become apparent with early caveolae 
purification techniques purporting to isolate caveolae, especially those using Triton-
resistant membrane fractions [441].  
The use of highly stringent immunopurification techniques to isolate rat adipocyte 
caveolae has more recently revealed that only a few proteins reside within caveolae [281, 
438].  Along with the important caveolae-forming proteins (i.e. caveolins and cavins), 
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CD36 was present.  While a co-immunoprecipitation (co-IP) has been performed in 2003 
with CD36 and Cav-1 in CHO cells that found no binding association, the same study 
showed no colocalization of CD36 and Cav-1 using microscopy [304].  However, other 
studies and models find localization of CD36 and Cav-1 using microscopy [442].  We have 
begun preliminary studies using confocal microscopy that indicate CD36 and Cav-1 indeed 
colocalize, especially along cell protrusions (Figure 67).  This is especially interesting in 
light of nanoparticle tracking studies (discussed above) that found CD36 moves along F-
actin. 
 
 
Confocal micrograph (60x) of HEK293 cells co-expressing (A) CD36 (green; mouse anti-CD36 antibody, 
JC63.1), (B) Cav-1 (red; rabbit anti-Cav-1 antibody, #2910), and (C) merged images.  CD36 showed high 
background nuclear staining but also strong colocalization with Cav-1 especially along cell protrusions and 
cell junctions.  A protrusion is shown in (D), the enlarged region of the merged micrograph image.   
 
In addition to the potential interactions between CD36 and Cav-1, the cavin family 
of proteins have also been shown to be critical to caveolae biophysics.  Cav-1 is recognized 
to form flat, caveolar, raft domains [194], while the cavin proteins are involved in caveolae 
(i) formation by infolding (PTRF/cavin-1 and SDPR/cavin-2), (ii) enlarged caveolae and 
Figure 67. Confocal micrograph showing colocalization of Cav-1 and CD36 
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caveolar tubes (overexpressed SDPR/cavin-2), and budding caveolar vesicles 
(SRBC/cavin-3) [201].  In future work and along with extensive western blotting 
verifications of protein expression, comprehensive co-IP investigations should be done 
using CD36, Cav-1, and the cavin proteins in HEK293 cells.  Since caveolae contain unique 
lipids and high amounts of cholesterol, careful optimizations should also be done on the 
co-IP detergent conditions to prevent loss of interactions that may be environment-sensitive 
(T20, CHAPS, Big CHAP Deoxy, PPS, and DDM, as discussed in Chapter 3).  With 
discovery of important roles of caveolae and more recently the cavin proteins in a variety 
of diseases, including cancers, lung disease, and glucose and lipid metabolism [443, 444], 
these interactions are important to decipher in their relation to CD36 and FA metabolism. 
Future studies of CD36 and caveolae proteins should also focus on metabolic studies using 
BODIPY and [14C] oleic acid.  This will identify (i) any involvement between these 
proteins that all have been shown to play roles in FA metabolism and (ii) whether this 
involvement leads to metabolic changes, which might determine specific signaling 
pathways to then investigate. 
6.2.2. Quantum Dot Nanoparticle Tracking of Cells Expressing CD36 in Response to 
Fatty Acid and oxLDL Additions 
CD36 has been shown to cluster around P. falciparum (malaria) parasitized 
erythrocytes [445].  This function of CD36 supported intracellular signaling through the 
ERK pathway, which genistein (broad-spectrum tyrosine kinase inhibitor) reduced together 
with a reduction of CD36-dependent parasitized erythrocyte uptake.  It was later shown 
that CD36 receptors move along cytoskeleton-mediated linear tracks, increasing their 
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aggregation probability [446], and CD36 linear motion enhanced CD36 oxLDL uptake 
function [284]. 
Since we found that CD36-mediated oxLDL uptake occurs through a FA-dependent 
mechanism ([41] and Chapter 5), we began studies of single-molecule tracking of CD36 
to investigate real-time responses to fatty acid and oxLDL.  Our hypothesis is that CD36 
clusters in response to exogenous FA, which changes CD36 binding to oxLDL.  With 
preliminary studies, quantum dot (Qdot) nanocrystal fluorophore technology (Qdot 
conjugates are 10-20nm in diameter, similar to a GFP protein) have been selected, based 
on previous CD36 single-molecule tracking studies from another group [284, 446]. 
Our preliminary optimizations utilizing a standard Qdot nanocrystal coupled to a 
secondary antibody (goat anti-mouse), with a mouse CD36 primary antibody, similar to 
[284].  High non-specific binding was observed in empty vector control cells as well as 
some background binding even where no cells were growing (Figure 68), despite 
optimization trials testing a variety of primary and secondary antibody concentrations, 
blocking conditions, and rocking techniques in the 37°C CO2 cell culture incubator. Future 
work should investigate other antibody combinations (e.g. rabbit or other species 
antibodies, different CD36 primary antibody, different Qdot secondary antibody, Qdot 
streptavidin conjugates, etc.) or other detergents and detergent concentrations for washing. 
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(A) Live HeLa cells expressing control empty vector and (B) CD36, incubated first with monoclonal mouse 
anti-CD36 antibody (1:250 in DMEM + 10% BSA) and next with goat anti-mouse Qdot-conjugated 
secondary antibody (1:500 in DMEM + 10% BSA).  High background binding was observed, as well as non-
specific binding to cells expressing control empty vector, despite 1hr of blocking in 10% BSA in DMEM.  
All experiments and microscopy were performed at 37°C with 5% CO2, as described in Chapter 3.  Standard 
phosphate-buffered saline (PBS) was found to induce cell death over the course of this 4+ hour experiment, 
under 5% CO2 conditions. 
 
One difficulty of this investigation compared with published studies, is that we must 
use live cells.  If the cells are fixed with paraformaldehyde, for instance, real-time CD36 
clustering motion will not occur in response to FA or oxLDL.  HeLa cells are more durable 
than HEK293 cells toward antibody washes and FFA additions but this can become an 
issue as more washing is tested.  However, when the experiment is fully optimized, 
different classes of FFA should also be tested (e.g. ω-3 and ω-6) and different doses may 
reveal differing effects. 
Figure 68. Preliminary Qdot single-molecule tracking experiment with and without CD36 expression 
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6.2.3. Additional In Vitro SPR Investigations of CD36 Binding to Fatty Acids and 
Binding to oxLDL in Response to Fatty Acids 
In Chapter 5 (Figure 59), OA added along with oxLDL gave a significant increase 
in CD36 binding that was beyond the expected R.U. of binding from the mass of OA.  
Specifically, when added alone, oxLDL gave about ~30, ~130, and ~250 R.U. of binding 
for 1nM, 4nM, and 8nM oxLDL, respectively. However, when added with about 100 R.U. 
of OA, an additional ~100 R.U. of oxLDL was expected (i.e. ~130, ~230, and ~350 R.U.), 
but instead the R.U. values were ~200, ~400, and ~500 for 1nM, 4nM, and 8nM oxLDL, 
respectively.  This led us to hypothesize that other types of FA that (i) bind CD36 and (ii) 
enhance oxLDL uptake in cells will also enhance oxLDL binding to CD36. 
To begin investigating this hypothesis, preliminary data was collected using doses 
of oxLDL pulsed across an SPR chip surface with either control proteins or CD36.  In 
addition, 100μM of FA was added (Figure 69). Since human-derived oxLDL was used, 
the FA present from human serum is unknown in these types of experiments.  Future work 
should use FA-free oxLDL if possible and run many more replicates, FA types, and doses 
of both oxLDL and FA. 
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Figure 69. Preliminary studies of CD36 binding to oxLDL with fatty acids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panels A. - G. are EDC/NHS activated and ethanolamine quenched lanes from a single 6-well Bio-Rad 
Proteon XPR36 GLM SPR chip. Panels A.– C. contained proteins bound to the SPR chip with only oxLDL 
pulsed across at different doses, n = 5.  Panels D.–G. contained CD36 bound in the same RU amount and 
also had oxLDL doses pulsed but also different FA added at 100μM, n = 1. All wells were normalized to the 
empty well to correct for non-specific binding.  All FA used was complexed to MβCD with 1:3 FA: MβCD, 
except for LA (1:4) and EA (1:6). 
 
 
 
  
224 
 
To enhance SPR experimental rigor and further understand where CD36 is binding 
FA (i.e. FA tail or carboxy head) and understand the importance of double bonds in the FA 
tail, we performed preliminary SPR studies using FA amines covalently linked to various 
SPR chips (GLM, GLC, and GLH) and pulsing recombinant ectodomain CD36 and 
recombinant HSA.  While experiments using18-amino-octadecanoic acid linked to the SPR 
chip with HSA pulsed across were not yet successful using certain conditions, rCD36 
pulsed in 150mM PBS showed good potential for future optimizations (Figure 70). 
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Figure 70. Preliminary studies of CD36 binding to oxLDL with fatty acids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panels A. - F. are EDC/NHS activated and ethanolamine quenched lanes from a single 6-well Bio-Rad 
Proteon XPR36 GLM SPR chip. Panel A. did not contain any 18-amino-octadecanoic acid linked to the 
surface and was used as the empty well.  Panels A.– F. contained 18-amino-octadecanoic acid (Cas #: 17437-
24-0) bound to the SPR chip with rCD36 or HSA pulsed across at different doses, n = 1. Background was 
subtracted from the empty well.  Panel G. illustrates different types of FA amines that may be used. 
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6.2.4. Purification of Full-Length CD36 for Hydrogen Exchange Mass Spectroscopy and 
SPR Studies 
In future studies, full-length human CD36 should be purified from HEK293 cells 
that are grown in serum-free / protein-free media.  This will allow important experimental 
comparisons with ectodomain HEK293 CD36 that has been used in this study for SPR.  In 
addition, purification of large quantities of full-length CD36 will enable important 
structural studies of CD36.  Because of our finding that CD36 binds oxLDL in a 
mechanism dependent upon FA binding, our hypothesis for structural studies is that FA 
binds to CD36 in the same location as oxLDL (the oxLDL binding site on CD36 is well 
characterized [238]). 
Since native CD36 is embedded in the PM, future studies could be done by 
embedding purified CD36 into nanodiscs and collaborating with a nearby hydrogen 
exchange mass spectroscopy (HX MS) research group [447] to gather native structure, with 
and without FA (Figure 5).  These studies would be important not only for research of FA 
uptake, oxLDL binding, and various metabolic disease states, but structural studies of 
CD36 in a membrane bilayer would be useful for the long list of other ligands that the so-
called “scavenger receptor” CD36 binds.  These are listed in Chapter 2 and include: 
thrombospondin, malaria infected red blood cells, advanced glycation end products, 
amyloid beta, and pheromones. 
Full-length CD36 purification experiments were started in our lab but were 
unsuccessful.  The purification steps have been somewhat optimized, as discussed in 
Chapter 3.  It is important to note that transfections of suspension 293-SFA (serum free 
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Figure 71.  A schematic of deuterium exchange 
and a nanodisc 
adapted) cells should be done using antibiotic free media since these cells are especially 
sensitive to transfection death.  In addition, dodecyl maltoside should be used as the 
detergent in every purification step that requires detergent in order to achieve compatibility 
with HX MS of the final rCD36. 
 
(Left Panel) Pulsing proteins into deuterium solvent is 
able to drive hydrogens on the amino acid backbone to 
exchange positions with the surrounding solvent. In 
conjunction with mass spectroscopy, this is a powerful 
technique for identifying exposed surface residues on 
proteins, including plasma membrane proteins such as 
CD36.  Figure modified from [440]. (Below) 
Schematic of a phospholipid bilayer nanodisc model 
membrane consisting of phospholipids encircled by 
two copies of an emphipathic alpha helical scaffold 
protein, apoliprotein A-1. Figure modified from [447]. 
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APPENDIX: ADDITIONAL DATA  
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1. Western blot and fractionation showing CD36 expression level and cellular localization 
(A.) In HEK293 cells, CD36 expression was comparable to that of 3T3-L1 adipocyte cells.  (B.) Cellular 
fractionation shows CD36 is expressed at a molecular weight of both ~53 and ~88kDa in nuclei and high 
density membrane fraction with comparable levels. In the plasma membrane, CD36 is detected mainly with 
the molecular weight of ~88kDa.   
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INHIBITORS CONC. MECHANISM OF ACTION REF. 
PROTEASE 
Pronase 0.25 mg/ml non-specific mixture of proteases [448-450] 
Trypsin 0.25 mg/ml characterized, targeted protease [448, 450-456] 
ANION TRANSPORT 
DIDS 0.2 mM 
irreversible, non-specific / protein 
cross-linker / lysine modifier / removes 
(+) charge 
[448, 449, 453, 
455, 457-459] 
Phloretin 0.2 mM reversible, non-specific / natural biofllavanoid 
[448, 450, 451, 
453, 455, 460-467] 
Quercetin 0.1 mM reversible, non-specific / natural biofllavanoid [450, 468, 469] 
Pentachlorophenol 
 
0.2 mM 
reversible, non-specific / insecticide / 
herbicide [450, 470-472] 
BASIC AMINO ACIDS 
Phenylglyoxal 2.5 mM arginine modifier / removes (+) charge [455, 467, 473-479] 
Diethyl 
Pyrocarbonate 2.0 mM histidine modifier / removes (+) charge 
[467, 474, 477, 
479-481] 
CD36 
Succinimidyl-Oleate 0.2 mM irreversible, “specific” / binds FA and oxLDL binding site of CD36 [449, 453, 458, 
482-489] SulfoSuccinimidyl-
Oleate 0.2 mM 
irreversible, “specific” / binds FA and 
oxLDL binding site of CD36 
 
 
 
 
 
 
 
 
 
 
Table A1. Commonly Used Inhibitors of Long-Chain Fatty Acid Transport/Uptake 
The chemical structures of non-enzymatic inhibitors are shown. Moieties that react covalently with proteins 
and mask the positive charge of Lys, Arg or His amino groups are marked with black arrows on the 
chemical structure. All inhibitors were chosen based on frequency of use in studies of FA uptake into 
different cell or animal models. The concentrations used are comparable to those used elsewhere. Most 
inhibitors are not upheld as specific for putative FA transporters, except SO and SSO.  Cooling to 4°C and 
2-deoxyglucose (not shown) were also used to reduce glycerol substrate for TG synthesis and slow enzyme 
function, respectively. 
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Figure A2. The effect of inhibitors on the binding, transmembrane movement, and metabolism of 
LCFA in rat adipocytes 
Dual-fluorescence measurements of ADIFAB (A-B) and BCECF (C-E) fluorescence were made by adding 
10μM exogenous OA (black arrows) to adipocytes pre-treated with inhibitors.  Inhibitor concentrations are 
found in Table A2. In each, OA binding (ADIFAB fluorescence increase) occurred rapidly (< 2 sec) (A & 
B) and simultaneously with transport to the inner leaflet (BCECF fluorescence decrease) (C & D).  OA was 
then internalized by the adipocyte cells for metabolism, as shown by ADIFAB and BCECF fluorescence 
recovery, with or without inhibitors. In (B) and (D), a similar rapid BCECF fluorescence decrease and 
ADIFAB fluorescence increase was observed compared to (A) and (C) after cooling cells to 4°C or when 
using cells from fasted rats that were suspended in buffer containing 2-deoxyglucose (2-DOG). However, 
(D) did not show the fluorescence recovery seen in (C), indicating that LCFA metabolism was inhibited 
rapidly.  In (E), protein-free SUVs rather than live cells were pre-incubated with inhibitors and OA was added 
(black arrow). 
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Figure A3. SSO and PCPL in SUV and adipocytes generate a pH gradient across the lipid bilayer 
(A) In a suspension of SUVs with addition (black arrow) of 10μM of either OA (control), SSO alone, or 
PCPL alone, the effects of these inhibitors on intravesicular pH was investigated by monitoring BCECF 
fluorescence. SSO produced smaller decreases in BCECF fluorescence and PCPL larger decreases, when 
compared to OA. Similar to OA, the effects of SSO and PCPL were reversed by treatment with nigericin 
(open arrow) suggesting that the observed effect is due to a true pH drop. (B) Direct addition of 200μM SSO 
alone and PCPL alone (with addition of 10μM OA as a control) to a suspension of adipocytes, again resulted 
in acidification of the cytosol. In adipocytes, the rate of the pH drop from SSO is significantly slower than 
that observed with PCPL or OA.  
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Table A2. Quantification of oleic acid esterification products in HEK293 cells with or without 
overexpression of CD36 using [14C]-labeled oleic acid  
Data were expressed as the ratio of pmole per microgram of each class of lipids to the total protein in 
microgram. Data is representative of 4 individual experiments and were represented as means + SD. 
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Figure A4. Quantitative analysis of oleic acid esterification in HEK293 cells with or without CD36 
overexpression 
[14C] Oleic acid (20 μM, 30 pmol/μg of protein) was added to the cell suspension of HEK293 parental and 
HEK293-CD36 stable cell lines. Lipid components were separated by thin layer chromatography and 
quantified by radioactivity counting. The quantities of [14C]-oleic acid esterification products at 0.5, 30, 45, 
and 60 min are plotted in panels A−D (note the expanded vertical scales of panels C and D). Data are 
representative of four individual experiments and are represented as means ± the standard deviation. By a 
Student’s t test, *p < 0.05 and **p < 0.001. 
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Figure A5. Detection of lipid droplets formation in HEK293 cells with or without CD36 overexpression 
using single cell imaging  
BODIPY 500/510: oleic acid was added to HEK293-CD36 cells (A and B) and HEK293 parental cells (C 
and D) and incubated for 24 hours followed by three times washing using PBS. Cells were then imaged under 
a Nikon deconvolution wide-field Epi-fluorescence system and processed using Image J. Image modified 
from [208]. 
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LIST OF ABBREVIATED JOURNAL TITLES 
Acta Biochim Biophys Sin Acta biochimica et biophysica Sinica 
Acta Diabetol Lat Acta diabetologica latina 
Acta Diabetol Acta diabetologica 
Acta Pharmacol Sin Acta pharmacologica Sinica 
Acta Physiol (Oxf) Acta physiologica 
Acta Physiol Scand Acta physiologica Scandinavica 
Adv Drug Deliv Rev Advanced drug delivery reviews 
Adv Exp Med Biol Advances in experimental medicine and biology 
Ageing Res Rev Ageing research reviews 
Alcohol Clin Exp Res Alcoholism, clinical and experimental research 
Am J Cardiol The American journal of cardiology 
Am J Clin Nutr The American journal of clinical nutrition 
Am J Obstet Gynecol American journal of obstetrics and gynecology 
Am J Pathol The American journal of pathology 
Am J Perinatol American journal of perinatology 
Am J Physiol Cell Physiol American journal of physiology. Cell 
physiology 
Am J Physiol Endocrinol Metab American journal of physiology. Endocrinology 
and metabolism 
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Am J Physiol Gastrointest Liver Physiol American journal of physiology. 
Gastrointestinal and liver physiology 
Am J Physiol Lung Cell Mol Physiol  American journal of physiology. Lung cellular 
and molecular physiology 
Am J Physiol Regul Integr Comp 
Physiol 
American journal of physiology. Regulatory, 
integrative and comparative physiology 
Am J Respir Cell Mol Biol American journal of respiratory cell and 
molecular biology 
Anal Biochem Analytical biochemistry 
Anal Chem Analytical chemistry 
Ann Clin Biochem Annals of clinical biochemistry 
Ann Hematol Annals of hematology 
Ann Med Annals of medicine 
Ann N Y Acad Sci Annals of the New York Academy of Sciences 
Ann Oncol Annals of oncology 
Ann Rheum Dis Annals of the rheumatic diseases 
Annu Rev Nutr Annual review of nutrition 
Annu Rev Pharmacol Toxicol Annual review of pharmacology and toxicology 
Antioxid Redox Signal Antioxidants & redox signaling 
APMIS APMIS: acta pathologica, microbiologica, et 
immunologica Scandinavica 
Arch Biochem Biophys Archives of biochemistry and biophysics 
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Arch Cardiovasc Dis Archives of cardiovascular diseases 
Arch Gynecol Obstet Archives of gynecology and obstetrics 
Arch Intern Med Archives of internal medicine 
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